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Abstract
The success of Positron Emmission Tomography (PET) in oncological imaging is
based on the fact that malignancy leads to an alteration in cellular biochemical reactions.
PET tracers, used for detecting malignancies, are synthetic positron emitting analogues of
molecules involved in these metabolic processes. The recent development of the 
18thymidine analogue [ F]3’-deoxy-3’-fluorothymidine (FLT) targets the salvage pathway 
of DNA synthesis and it is thought to have the potential to visualise cellular proliferation.
The aim of this thesis was to investigate the potential clinical use of FLT in 
colorectal cancer (CRC).
FLT pharmacokinetics in patients with CRC were mapped, and methodologies 
for the quantitative analysis of in vivo FLT uptake were defined; subsequently the 
accuracy of semi-quantitative indices (SUVs) was assessed. FLT uptake was compared 
to that of the established glucose analogue radiotracer [18F]fluoro-2-deoxy-D-glucose 
FDG (calculated using SUVs), in patients with primary and/or metastatic disease. Both 
FLT and FDG were compared with Ki67 immunohistochemistry in the same patients to 
determine whether PET can quantify cellular proliferation in vivo. FLT was also used to 
assess response to cytotoxic drug treatment 5-Fluorouracil (5FU) in cultured CRC cells.
Semi-quantitation in the form of SUVs allowed an accurate interpretation of the 
uptake rate of the tracer. FLT PET provides acceptable imaging of primary colorectal 
tumours, but there are inherent difficulties in diagnosing the presence of liver metastases, 
secondary to the hepatic metabolism of the tracer. There was excellent correlation 
between FLT SUVs and Ki67 immunohistochemistry (R=0.8), which can be interpreted 
as a true reflection of the proliferative rate of colorectal cancer tissue. In vitro, cell killing 
caused by exposure to 5FU resulted in increased FLT uptake, with excellent correlation 
(R= 0.9).
FLT PET could in the future contribute to a non-invasive method of in vivo 
grading of malignancy and be used to predict early response to adjuvant chemotherapy.
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CHAPTER 1 
Introduction
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1.1 Colorectal cancer
1.1.1 Impact on deaths in the United Kingdom
Life expectancy at birth in the UK increased during the last century from 48.5yrs to 
75.5yrs for men and 52.4yrs to 80.3yrs for women. When UK government used broadly 
defined causes of death and published the mortality data for the calendar year 1998, the 
leading cause of mortality, accounting for 40.8% of deaths, was circulatory disease, with 
neoplasms accounting for 24.9%, respiratory diseases 16.4%, digestive diseases 3.8% and 
others 14.1%.
More than one in three people in England will develop cancer at some stage in their lives. 
One in four will die of cancer. This means that, every year, over 200,000 people are 
diagnosed with cancer, and around 120,000 people die from the disease (Office of 
National Statistics, Mortality Statistics: cause, England and Wales 2000). In the UK, as 
treatment of ischaemic heart disease improves and the general population ages, trends 
show that cancer will become the leading cause of death within the next 10 years.
The most common cancer for men in terms of mortality is lung cancer followed by 
prostate cancer and colorectal cancer, and for women is lung cancer followed by breast 
cancer and colorectal cancer. Lung cancer is the cancer most commonly associated with 
smoking with over 80% of all lung cancer deaths caused by smoking (The UK Smoking 
Epidemic: Deaths in 1995. Health Education Authority, 1998). It follows that for non- 
smokers, considering both sexes, colorectal cancer (CRC) is the leading cause of cancer 
death in the UK.
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1.1.2 Aetiology
CRC arises following the accumulation o f multiple mutations within the cell, which 
allow it to escape the growth regulatory control mechanisms and acquire characteristics 
which allow invasion. It is well established that a high proportion of CRC arise from pre­
existing benign adenomatous polyps. Work by Muto et al in 1975 first established the 
progression from adenoma to carcinoma and suggested that cancers overtake adenomatous 
tissue as they invade the bowel wall (Muto et al., 1975). A model describing the specific 
genetic changes occurring during the colorectal adenoma carcinoma development was 
originally described by Fearon and Vogelstein (Fearon and Vogelstein, 1990; Vogelstein et 
al., 1988). This model known as the “Vogelgram” is illustrated in figure 1.1. It 
demonstrates the cumulative effect o f either loss o f genes suppressing growth or mutational 
overexpression of genes promoting growth, leading to the development o f cancer.
APC COX-2 K-ras SMA04 / SMAD2 p53 other alterations
Normal
epithelium
\  I
Hy perprol iterative 
epithelium
Early
adenoma
Late
adenoma
Carcinoma Metastasis
APC
DNA mismatch repair genes TGFpRII, BAX 
hMSH2, hMLH1, hPMS1, IGF-IIR, E2F,
HPMS2, hMSH6 & hMSH3 TCF-4
B
Figure 1.1 Diagram of the key genetic events in colorectal cancer tumourigenesis. Two major pathways are 
currently accepted: A and B. The genetic events of the traditional adenoma-carcinoma sequence, which 
85% of tumours follow, are illustrated in A (Vogelgram). The remaining 15% of tumours follow path B and 
exhibit microsatellite instability due to an alteration in a  DNA mismatch repair gene. APC = adenomatous 
polyposis coli, tumour suppressor gene; COX-2 = Cyclo-oxygenase-2; K-ras = oncogene; SMAD 4/2 =
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signaling molecules in the anti-proliferative TGF-f$ pathway; p53 = tumour suppressor gene; TGFfSRII = 
transforming growth factor-^ receptor class II; BAX = apoptosis regulator molecule; IGF-IIR= insulin-like 
growth factor receptor class II; E2F = cell cycle regulated transcription factor, TCF-4 = T-cell factor 4, 
transcription factor.
i) Familial adenomatous polyposis
Earlier work into Familial Adenomatous Polyposis (FAP) an inherited syndrome in 
which hundreds of colorectal adenomas develop and colorectal cancer is inevitable, 
localised a gene on chromosome 5q21-22 responsible for the syndrome (Bodmer et al., 
1987). Vogelstein proposed that alterations in this gene caused hyperproliferation 
preceding adenoma formation. He hypothesised that allelic loss at chromosome 5q was 
enough to produce hyperproliferation which when associated with alteration of a second 
gene is enough to initiate sporadic adenomas. In 1991 this gene became characterised and 
is known as the APC (adenomatous polyposis coli) gene (Kinzler et al., 1991).
The vast majority of sporadic colorectal cancers are thought to be initiated by 
changes in the APC gene and, together with FAP cancers, accumulate the genetic changes 
shown in the Vogelgram which result in the adenoma-carcinoma progression.
ii) Hereditary non -polyposis colorectal cancer and microsatellite instability
Hereditary non-polyposis colorectal cancer (HNPCC) is a syndrome characterised 
by the lack of colonic polyposis. It was identified following work by Lynch into families 
presenting with colonic adenomas at an early age without the presence of multiple colonic 
adenomas (Lynch et al., 1966; Lynch and Krush, 1971). In 1993 colorectal cancers from 
patients with HNPCC and a subset of sporadically occurring disease were noted to have a 
unique type of genetic abnormality, first known as replication errors and subsequently as
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microsatellite instability (MSI). Microsatellites are short segments of repetitive DNA bases 
that are scattered throughout the genome. MSI is defined as “a change of any length due to 
either insertions or deletions of repeating units in a microsatellite within a tumour 
compared to normal tissue” (Boland et al., 1998) and results from a failure of the cell to 
repair errors made during DNA replication. When a group of intranuclear proteins known 
as the mismatch repair system-which is responsible for removing these errors-fails, then 
MSI develops and genes with a lot of microsatellites are particulary susceptable to 
alteration.
Cancers demonstrating MSI develop using an alternative genetic pathway to that 
described by Vogelstein and this is reflected in the clinical presentation of the tumour.
HNPCC and sporadically occurring CRC have similar histological features and 
show a tendency to present on the right hand side of the colon, with approximately two 
thirds of HNPCC being detected proximal to the splenic flexure.
iii) Enviromental factors
External factors are contributory to colorectal tumourigenesis. This is demonstrated 
by migrant studies showing varying incidence of this disease around the world. Wynder et 
al highlighted a higher incidence of colon cancer in second generation Japanese immigrants 
to California and Hawaii than Japanese in Japan (Wynder and Reddy, 1974).
Increseased intake of dietary fibre was previously thought to be associated with 
lower rates of CRC as demonstrated by Howe et al in a meta analysis of 13 studies (Howe 
et al., 1992). Although contradictory evidence is now emerging from recent studies by 
Fuchs, Alberts, Schatzkin and their colleagues, which have shown no benefit or protective
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effect from dietary fibre (Alberts et al., 2000; Fuchs et al., 1999; Schatzkin et al., 2000). 
There is currently no explanation to this discrepancy.
Other contributory factors have been thought to be associated with vitamin intake. 
Dietary supplementation of folic acid has been shown to be associated with the reduction of 
rectal mucosal proliferation indices in patients with adenomas (Khosraviani et al., 2002). 
Evidence also exists that red meat has the potential to be a definite risk factor (Potter, 1999) 
in addition to a high body mass index in the presence of low levels of physical activity 
(Slattery et al., 1997) and increased alcohol intake (summarised in Potter 1999 #462).
Recent developments have highlighted the potential of non-dietary chemo 
protective agents. The findings of polyp regression associated with non-steroidal anti 
inflammatory drug (NSAID) ingestion in patients with FAP (Giardiello et al., 1993; 
Labayle et al., 1991) led to theories regarding an increase in cell death mediated through 
inhibition of the enzyme cyclooxygenase (COX) (Piazza et al., 1995). Further work has 
demonstrated that lack of the COX-2 isoform in mice corresponded to a reduction in 
tumours (Williams et al., 1999). The overexpression of this enzyme in human CRC tissue 
has led to suggestions that the inhibition of COX-2 may lead to the retardation of colon 
cancer development (Sano et al., 1995).
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1.2 Staging of colorectal cancer
1.2.1 Background
Once a tumour becomes invasive, it can extend through the layers of the colonic 
wall and invade adjacent structures. Lymphatic, haematogenous and peritoneal spread 
may also occur. The disease process is staged both clinically and pathologically. The 
stage of the disease at presentation may be a reflection not only of the rate of growth and 
extension of the tumour but also of the type of tumour and the tumour host relationship. 
International agreement on a system of classification is needed in order that groups of 
patients can be compared. It also serves to aid in the selection of primary and adjuvant 
therapy, estimation of prognosis, assistance in the evaluation of the results of treatment, 
facilitation of exchange of information and contribution to the continuing investigation of 
CRC (American Joint Commmittee on Cancer, 2002).
1.2.2 Clinical staging
This assessment is based on a full history and physical examination with either 
sigmoidoscopy or colonoscopy with biopsy. The presence of extra colonic metastases is 
demonstrated using radiological techniques such as chest x-ray, ultrasound, computerised 
tomography (CT), magnetic resonance imaging (MRI), in addition to Positron Emission 
Tomography.
1.2.3 Radiological staging
There has been dramatic evolution in the radiology of CRC over the past twenty 
years. In the 1980’s CRC was diagnosed using Barium enema and its liver metastases
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were visualised with ultrasound and incremental CT. Now there is a definite difference in 
the imaging approach. This section addresses the conventional imaging modalities 
excluding Positron Emission Tomography.
i) Barium enema
The malignant potential of a polyp is estimated using four determinants; size, 
presence or absence of a stalk, architecture and cellular atypia. Barium enema 
examination is capable of determining the first three and therefore detects both adenomas 
and carcinomas. Obviously the fourth cannot be assessed.
Two types of examination exist; single and double contrast barium enema 
(DCBE) the latter being more appropriate in those individuals who are physically able to 
co-operate, and also have a high probability of colonic disease. DCBE has been shown to 
depict polyps less than 1cm in size better than the single contrast technique (Gelfand, 
1997; Smith, 1997). The reported sensitivities for CRC are between 62 -100% (de Zwart 
et al., 2001; Ott, 2000). Barium enema is a technique which examines the entire colon, a 
useful adjunct when it is used as a screening tool considering that 5% of patients have a 
synchronous tumour and more than one third have additional polyps (Levine et al., 2000).
ii) Ultrasound
Transabdominal U/S is generally not used for the detection of primary CRC 
although it has had a role in the detection of colorectal liver metastases. Trans rectal 
ultrasound does have an established role in the staging of rectal cancer as it can 
distinguish between the various layers of the rectal wall (Heriot et al., 1999; Rifkin et al.,
26
1989). This allows attempts at T staging as described in section 1.2.3 with reported 
accuracies of between 67-93% (Beynon, 1989)
iii) Magnetic resonance imaging (MRI)
MRI is most useful in CRC located in the rectosigmoid, because image quality is 
only minimally degraded by respiratory motion and peristalsis in this relatively fixed part 
of the colon.
MRI used to be acquired using a body or external surface coil but more recently 
endoluminal or phased array coils are used. The images created with endoluminal coils 
allow detailed visualisation of both tumour and rectal wall courtesy of the high 
resolution, although because of the limited field of view it is difficult to evaluate the 
mesorectum and surrounding pelvic structures. Phased array coils allow a larger field of 
view to be imaged although spatial resolution is lost.
The superior demonstration of rectal wall layers achieved by endoluminal MRI 
does not improve staging accuracy of rectal cancer compared with phased array MRI 
(Blomqvist et al., 1997). Beets-Tan and colleagues found that the clinically more 
important circumferential resection margin in rectal (section 1.3.2) can be predicted very 
accurately and consistently with phased array MRI (Beets-Tan et al., 2001).
iv) Virtual colonoscopy
Virtual colonoscopy or CT colonography uses helical CT to generate high 
resolution, two dimensional axial images of the abdomen and pelvis. In addition three 
dimensional images can be constmcted from the data obtained. The advantages of virtual
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colonoscopy are its ability to provide a full structural evaluation of the colon with high 
patient acceptance and safety.
The indications for virtual colonoscopy include screening for polyps, incomplete 
or failed colonoscopy and the assessment of the proximal colon in a distal obstructing 
lesion (Pijl et al., 2002).
v) Computerised Tomography
In the 1970s, CT images were acquired by sequentially scanning single slices 
(Hounsfield, 1995). The introduction of spiral scanning in 1989 led to faster volume 
coverage than sequential slice by slice scanning in addition to increased 3D resolution. In 
spiral scanning, the patient is transported continuously through the field of measurement 
while the x-ray tube and the detector rotate continuously. Relative to the patient, the X- 
ray focus travels on a spiral path allowing continuous data sampling along the axis of 
table motion and thus the long axis of the patient (Kalender et al., 1990).
The principles of image reconstruction are similar for both sequential and spiral 
CT although in spiral CT a single slice is reconstructed from the spiral volume data set 
which allows images to be reconstructed from any arbitary position along the long axis of 
the patient.
Since the end of the 1990s, rotation times of 0.5s and multirow detectors have 
become available, making CT a universal imaging modality for all organs.
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CT imaging o f CRC
CT has an established role in the imaging of CRC. It has been successfully 
utilised in the assessment of local infiltration of the tumour with the previously 
encountered problems with lower stage tumours being overcome by the advent of high 
resolution spiral CT (Harvey et al, 1998).
The detection of malignant lymph node metastases is based upon the size criteria 
and the arbitary figure of 1 cm has been given to delineate malignant disease. However, 
this has been shown many times not to be the case. Rodriguez-Bigas demonstrated that 
malignant cells exist in nodes less than 1cm and nodes even greater than 3cm have been 
shown to be benign (Rodriguez-Bigas et al., 1996).
Previously CT has been shown to be inaccurate in the detection of liver 
metastases (Steele, Jr. et al., 1991). Later studies have utilised the different blood supply 
of the metastases and the normal liver parenchyma. The use of intravenous contrast 
coupled with the rapid acquisition times of spiral CT has partially addressed this problem 
and reported sensitivities of 68-79% (Paul et al., 1994; Zerhouni et al., 1996).
CT has performed poorly in the detection of recurrent extrahepatic disease. The 
reason for this is its inability to differentiate between benign, fibrotic tissue resulting 
from surgery and /or radiotherapy and malignant tumour recurrence. The reliance on 
change in tumour morphology without any other tissue characteristics makes dealing with 
indeterminate tissue masses within the abdomen very difficult. Although modem spiral 
CT is more accurate than non-spiral CT (Mendez et al., 1993), MRI is establishing itself 
as the more accurate morphological imaging tool (Brown et al., 2003b; Brown et al., 
2003a; Holzer et al., 2003).
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CT has played a significant role in tumour imaging over the last two decades, as it 
is widely available and clinicians are sufficiently experienced to perform and interpret the 
investigation. The problems of this cross sectional imaging modality in terms of both 
intra and extra hepatic recurrent disease have been highlighted above. In view of this the 
role of functional imaging in CRC is addressed in the following section.
1.2.4 Pathologic staging
Full staging of CRC follows surgical exploration, tumour and regional lymph 
node resection which provides tissue for pathological assessment. In the early 1930’s Sir 
Cuthbert Duke devised a pathological staging system for CRC (Dukes, 1932) (table 1.1) 
which was later modified in 1954 into the modified Astler-Coller classification (Astler 
and Coller, 1954). In the 1980’s following close collaboration between the International 
Union against Cancer (UICC) and the American Joint Committee on Cancer (AJCC), the 
Tumour, Nodes, Metastases (TNM) system of pathological staging was introduced (table 
1.2) the importance of which became internationally accepted in the 1990’s. Today in the 
UK, the AJCC-TNM is used in conjunction with the Dukes and modified Astler-Coller 
classification to pathologically group stage CRC (table 1.3).
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Stage Definition % of C ases 5-Year Survival
A Confined to bowel wall 10 97%
B Extended through bowel wall, but no lymph node 
involvement
35 80%
C1 Lymph node involvement, apical node disease- 
free 30
65%
C2 Apical lymph node involved 35%
D Distant metastases 25 5%
Table 1.1 Dukes staging and classification. Stage D has been added to Dukes’ original classification. % of 
C ases represents the  percentage of cases with that stage at diagnosis at first presentation.
Classification Definition of TNM classification
Primary Tumour (T)
TX Primary tumour cannot be assessed .
TO No evidence of primary tumour.
Tis Carcinoma in situ.
T1 Tumour invades the submucosa.
T2 Tumour invades mucularis mucosa.
T3 Tumour invades through muscularis mucosa into subserosa or into 
nonperitonealised pericolic or perirectal tissues.
T4 Tumour directly invades other organs or structures or perforates 
visceral peritoneum
Lymph Nodes (N)
NX Regional lymph nodes cannot be assessed
NO No regional lymph node metastases
N1 Metastases in 1 -3 regional lymph nodes
N2 Metastases in > 4 regional lymph nodes
Distant M etastases (M)
MX Presence of distant metastases cannot be assessed
MO No distant metastases
M1 Distant metastases
Table 1.2 Modified TNM classification system for the staging of colorectal cancer.
Stage T N M Dukes Modified Astler-Coller
0 T is NO MO - -
I T1 NO MO A A
T2 NO MO A B1
IIA T3 NO MO B B2
MB T 4 NO MO B B3
IIIA T1-T2 N1 MO C C1
NIB T 3-T 4 N1 MO C C2/C3
IIIC Any T N2 MO C C 1/C 2/C 3
IV Any T Any N M1 - D
Table 1.3 Group staging of colorectal cancer.
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1.2.5 Histological grade
The histological grade is the qualitative assessment of the differentiation of the
tumour expressed as the extent with which a tumour resembles the normal tissue and is 
graded as follows:
GX Grade cannot be assessed 
G1 Well differentiated 
G2 Moderately differentiated 
G3 Poorly differentiated 
G4 Undifferentiated
The terms “low7’ and “high” grade are employed for G1-G2 and G3-G4 tumours 
respectively because it has been suggested this may be associated with outcome 
independently of TNM stage group for CRC (Newland et al., 1981).
1.2.6 Other prognostic factors
Currently other independent prognostic factors used in patient management and 
well supported in the literature are histological types, where small cell and signet ring 
cancers have a less favourable outcome (Jass and Sobin, 1989). Extramural venous 
invasion has been shown to be a poor prognostic marker (Talbot et al., 1981) and 
submucosal vascular invasion arising in adenomas is associated with a higher risk of 
regional lymph node involvement (Fenoglio-Preiser and Hutter, 1985).
The intra-tumoural expression of specific molecules like p27 (Belluco et al., 1999; 
Loda et al., 1997), DNA microsatellite instability (Wright et al., 2000) and thymidylate
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synthase (Takenoue et al., 2000) have potential to act as prognostic indicators but need to 
be evaluated further before they are routinely included in the staging process.
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1.3 Treatment
1.3.1 Curative colonic surgery
Curative surgery for cancer of the colon comprises of a segmental resection of the 
primary lesion based on its arterial blood supply. This procedure should also include 
dissection of the regional lymph nodes, which acts as an accurate staging procedure for 
determining whether adjuvunct chemotherapy will be of benefit (1995). Extended 
lymphadenectomy to the para-aortic nodes and initial ligation of the vascular pedicle 
were previously thought to confer survival advantages, but this does not appear to be the 
case (Sugarbaker and Corlew, 1982; Wiggers et al., 1988). In all cases a thorough 
inspection of the peritoneal cavity is carried out looking for synchronous tumours and 
metastatic disease. Synchronous tumours occur in 1.5 -  7.5% of all cases (Davison and 
Stem, 1995) and completion colectomy should be carried out. Based on evidence from 
progression of polyps into invasive cancers a case can also be made for completion 
colectomy once any existing polyps are removed and histopathologically evaluated. 
Usually this information is available pre-operatively, but in certain cases, such as a 
stenosing primary CRC that does not allow the passage of the colonoscope, the finding 
may be intraoperative. It is essential to obtain histological diagnosis before the 
conversion of a segmental resection into a radical colectomy. It has also been suggested 
that these same principles apply to patients with HNPCC, who have a 45% risk of 
developing a metachronous cancer within 10 years (Lynch, 1996). The optimal result of 
surgical treatment should result in tumour free resection margins, both longitudinal and 
circumferential as well as maintenance of intestinal continuity. It is possible to perform 
en bloc resections with curative intent if the tumour is invading adjacent organs.
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1.3.2 Curative rectal surgery
At diagnosis, most rectal tumours have already spread beyond the rectal wall, 
either by direct extension or lymphatic spread, and require radical resection. The 
overwhelming evidence now available regarding the lateral spread of rectal tumours into 
the mesorectal tissues requires an en bloc removal of the cancer with the surrounding 
mesorectal fat habouring the blood vessels and lymphatics (known as the mesorectum) 
(Heald and Ryall, 1986). Involvement of the lateral or circumferential resection margin is 
strongly correlated with the later development of local recurrence. It is now accepted by 
most surgeons that a total mesorectal excision should be attempted in all cases. A margin 
of at least l-2cm of normal rectal tissue distal to the tumour should be included to reduce 
the risk of anastomotic recurrence. As with colon cancer, any adhesion to adjacent organs 
should be resected en bloc with the rectum. Restoration of intestinal continuity is an 
important but secondary consideration. It should only be attempted if a well perfused, 
tension free anastomosis can be performed. When the cancer is so low that the 2cm 
margin cannot be obtained without compromising the sphincter function, the entire 
rectum and anus should be removed. This is known as an abdominal perineal resection 
and in this case a permanent colostomy is created.
1.3.3 Recurrent disease
There is a standard pattern to the presentation of recurrent CRC. The sites include:
i) Liver >30%
ii) Lung and locoregional disease 20-25%
iii) Other intraabdominal sites 15-20%
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iv) Elsewhere 10%
Approximately half of the patients who have undergone surgery for CRC will develop 
recurrent disease within 3 years of initial resection. In up to 30% of cases recurrences 
following treatment of primary CRC is localised and therefore suitable for curative 
resection (Turk, 1993). Ogunbiyi et al has also demonstrated that a significant disease 
free interval can be produced by aggressive therapy on appropriately selected cases of 
recurrent rectal cancer (Ogunbiyi et al., 1997b).
1.3.4 Management of colorectal liver metastases
Metastases localised to the liver alone occur in approximately half of all patients 
presenting with metastatic disease. Liver resection is the only curative option. 
Investigation of patients with liver metastases should determine whether the disease is 
resectable and the criteria usually employed are; lesions confined to a single lobe, no 
extrahepatic metastases, patient fit to undergo major surgery, non-jaundiced with good 
liver function. Five year survival rates following resection now range between 25% and 
39%, with a median survival between 28 and 40 months in most large series. Reported 
ten year actual survival rates have also been documented in a few studies ranging 
between 20 and 26% of patients (Fusai and Davidson, 2003).
Strategies employed for unresectable colorectal liver metastases (CLM) include 
downstaging using neo-adjuvant chemotherapy (most commonly 5FU-leucovorin- 
oxaliplatin) which is delivered either intravenously or via the hepatic artery. Adam et al 
published results of a study of 701 patients with unresectable liver metastases who 
underwent neoadjuvant chemotherapy; of this group 13.5% were found to be resectable
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on reevaluation and underwent potentially curative resection with overall five year 
survival rates of 35% from the time of resection (Adam et al., 2001). Currently the 
European organisation for the research and treatment of cancer (EORTC) is carrying out 
a randomised phase IH trial comparing the effectiveness of surgery with or without 
combination chemotherapy in treating patients who have colorectal liver metastases.
Portal vein embolisation has been used in cases where the liver tumour is 
resectable but surgery is contraindicated, because the anticipated liver remnant is too 
small. This technique produces atrophy of the affected lobe and compensatory 
hypertrophy of the future liver remnant. Azouly et al have showed an increase in 
resectability rate of 19% of such patients (Azoulay et al., 2000). In patients with bilobar 
disease a two staged procedure can be undertaken allowing liver regeneration following 
the initial resection; and the second stage can only be undertaken if clear margins can be 
achieved and there is no evidence of disease progression.
Local ablative techniques like radio frequency ablation act as an alternative to 
systemic chemotherapy. This technique uses heat generated from a radio frequency 
electrode which is inserted into the target hepatic lesion under Ultrasound, CT or MRI 
control. Radiofrequency ablation can be administered at open surgery, laparoscopy or 
percutaneously (Oshowo et al., 2003).
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1.4 Chemotherapy
1.4.1 Background
As discussed above, the primary treatment of CRC is surgical resection, but over 
half of all patients will eventually die of metastatic disease. Approximately 80% of 
patients with colon cancer present with localised disease and are suitable for curative 
resection. However despite attempted curative surgery, patients have a significant 
probability of disease relapse and cancer related death. Over the past few decades there 
has been much interest in adjuvant therapeutic approaches that would eliminate 
microscopic disease and thereby prevent recurrence.
Once CRC has metastasised , the average survival duration without chemotherapy 
is only 3-9 months. Two thirds of patients well enough to participate in clinical trials, and 
randomised to best supportive treatment, die within 1 year (Simmonds, 2000). Systemic 
chemotherapy is rarely curative in such patients except, sometimes, where metastatic 
disease is confined to the liver and potentially resectable after chemotherapy.
The chemotherapeutic drug developments for advanced CRC in chronological 
order are as follows:
1960s 5-Fluorouracil (5FU)
1980s Modulated 5FU 
1990’s Infusional 5FU
Newer cytotoxic agents Oxaliplatin
Raltitrexed
Irinitecan
Oral fluoropyrimidines 
2000 Agents acting on novel targets/molecular markers.
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1.4.2 5-Fluorouracil
For the past 40 years 5-Fluorouracil (5FU) has been the mainstay of drug therapy 
for metastatic CRC. 5FU belongs to the group of anti-cancer drugs known as the 
‘antimetabolites’. These are drugs that interfere with normal cellular function, 
particularly the synthesis of DNA and hence cellular replication (Midgley and Kerr, 
1999).
5FU is a pyrimidine analogue that resembles the bases uracil and thymidine. The 
drug penetrates rapidly into cells, where it is converted intracellularly by the enzymes 
which normally act on uracil and thymidine converting them into nucleoside forms. It 
interferes with the ribonucleotide and deoxynucleotide synthesis pathways after 
phosphorylation which leads to the active fluorinated nucleotides 5-fluorouridine 
triphosphate (5FUTP) and 5-fluorodeoxyuridine monophosphate (5-FdUMP). 5FUTP can 
be incorporated into RNA in place of uridine triphosphate (UTP), leading to inhibition of 
the nuclear processing of ribosomal and messenger RNA and may cause other errors of 
base pairing during transcription of RNA (Glazer and Lloyd, 1982). 5-FdUMP inhibits 
irreversibly the enzyme thymidylate synthase (TS), this leads to depletion of thymidine 
monophosphate (dTMP) which is required for DNA synthesis, thus conferring a degree of 
S phase specificity on the drug. These two mechanisms for the toxicity of 5FU are shown 
in figure 1.2.
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Figure 1.2 Metabolism and activation of 5-fluorouracil. Upon uptake by cells, 5-fluorouracil (5FU) is 
metabolised via two separate pathways: and represents the ribonucleotide synthesis pathway, in
which 5FU is converted to 5- fluorouridine monophosphate, then to 5-fluorouridine triphosphate and finally 
incorporated into RNA. represents the deoxynucleotide synthesis pathway, where 5FU exerts two 
independent effects. It may become metabolised to 5-fluorodeoxyuridine triphosphate and then incorporated 
directly into genomic DNA, with potentially cytotoxic results. Alternatively, 5FU may become metabolised to 
5-fluorodeoxyuridine monophosphate which inhibits thymidylate synthase, an enzyme important in DNA 
synthesis.
The co-administration o f folinic acid potentiates the inhibition of TS by 5FU and 
increases response rate (Piedbois et al., 1992) and is now a component o f most 5FU based 
regimens used in both the adjuvant and metastatic contexts. Data exists supporting the
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use of infusional 5FU where response rate is undoubtedly higher, time to progression 
longer, but survival only minimally extended (Woolmark et al., 1998).
Adjuvant therapy in those patients with Dukes B CRC remains controversial, 
despite two large studies addressing this issue, IMPACT B2 and NSABP (Erlichman et 
al., 1999; Mamounas et al., 1999). The former study pooled results from five trials 
including 1,006 patients with Dukes B2 colon cancer and provided no evidence for the 
routine use of 5FU/Leucovorin as routine adjuvant treatment in this group. Likewise the 
NSABP trial used results from four trials comparing the relative efficacy of adjuvant 
chemotherapy in patients with Dukes B and C disease. Although the results suggested 
that patients with Dukes B disease benefited from adjuvant chemotherapy and should be 
presented with this treatment option, the number of patients with Dukes B was too 
limited to rule out a difference in treatment effect according to staging. In addition this 
trial also collectively looked at the studies by creating two comparison groups; the first 
group consisted of all patients receiving the better of the two treatments in each of the 
four trials, and the second group consisted of patients receiving the inferior treatment. 
This allowed a pooling of the results of 1,565 patients with Dukes B cancer and a 
reduction in mortality and recurrence when adjuvant therapy was used. It must be noted 
however that not all the trials looked at within this study used an observation arm and the 
methodology used in the pooling of results for these separate trials in which the treatment 
received varied widely is unconventional. These results should therefore be interpreted 
with an element of caution. Recently Taal et al published the results of a prospective trial 
on behalf of the Netherlands Adjuvant Colorectal Cancer Project (NACCP) randomising 
1029 patients with Dukes B or C colorectal cancer to receiving twelve months 5FU plus
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levamisole or no further treatment following curative surgery (Taal et al., 2001). This 
showed a 19% reduction in death among those patients with Dukes B CRC.
The large randomised controlled trial conducted by Quasar found that the 
inclusion of levamisole and high dose folinic acid to 5FU and standard dose folinic acid 
did not delay recurrence or improve survival (Gray et al., 2000).
The jury is still out in the value of adjuvant chemotherapy for the treatment of 
Dukes B CRC. In real terms a small treatment difference can only be reliably detected 
with many more patients. To detect an absolute risk reduction of 4% at 5 years with a 
90% power, 4,700 patients are required (Taal et al., 2001). The general consensus in the 
oncological world is that in patients with Dukes B CRC and no other medical 
contraindications, adjuvant treatment with 6 months of 5FU/Leucovorin could be offered 
after careful discussion with the patient, who must be aware that such additional 
treatment is not definitely proven and that any benefit is likely to be small. It must also be 
remembered that that there is a group of patients with high risk characteristics (poorly 
differentiated tumours, venous or lymphatic invasion) to whom adjuvant chemotherapy 
can be reasonably offered.
1.4.3 State-of-the-art chemotherapy
A brief summary of the more recent drugs is offered as a detailed explanation falls 
outside the remit of this thesis.
Irinitecan disrupts cell division and is licensed for first line treatment in patients 
with advanced CRC in combination with 5FU and folinic acid and as a second line 
monotherapy when 5FU based treatment has failed. In randomised controlled trials it has
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increased tumour response rate and extended both progression free and median survival 
when used in combination (Douillard et al., 2000; Saltz et al., 2000). Its role as a second 
line montherapy when 5FU has failed has also shown positive results (Cunningham et al., 
1998).
Oxaliplatin is a platinum compound which inhibits DNA replication by forming 
cross links (Culy et al., 2000). Randomised trials involving the use of oxaliplatin in 
combination with 5FU/folinic acid as first line treatment have shown significant 
improvement in tumour response and progression free survival (de Gramont et al., 2000; 
Giacchetti et al., 2000).
Raltitrexed inhibits TS and is indicated as a montherapy for palliative treatment 
when 5FU is not tolerated or inappropriate and has shown comparable results to 5FU 
regimens (Cocconi et al., 1998; Cunningham et al., 1996).
Two oral fluoropyrimidines are marketed in the UK, Capecitabine and Tegafur, 
these are closely linked to 5FU and are more convenient for patients. Large randomised 
trials have shown that they are effective in the treatment of metastatic CRC (Hoff et al., 
2001; Van Cutsem et al., 2001) with potential pharmacoeconomic advantages (Hoff and 
Pazdur, 1998).
The National Institute for Clinical Excellence (NICE) has recently published 
recommendations on the use in the NHS of irinotecan, oxaliplatin and raltitrexed in 
patients with advanced CRC (NICE 2002). It has advocated the use of irinitecan as a 
second line monotherapy following failure of first line 5FU based treatment and only 
advises the use of combination oxaliplatin plus 5FU in patients with CLM confined to the 
liver where chemotherapeutic shrinkage would allow possible curative resection.
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Interestingly NICE advises against both irinitecan and oxaliplatin being used as first line 
chemotherapeutic agents until further evidence is provided from the Medical Research 
Council FOCUS trial. This has received much criticism amongst UK cancer specialists 
who contest the interpretation of the trial results in addition to the cost analysis (Saunders 
and Valle, 2002).
1.4.4 Future perspectives of chemotherapy
In recent years the options for chemotherapy in CRC have expanded enormously. 
The development of multiple agents with differing mechanisms of action that can be used 
to good effect on their own or in combination with 5FU regimens has made defining the 
ultimate correct schedule for different patients even more of a challenge. Encouragingly 
the new regimens have been shown to be as or more effective than 5FU when used in 
combination or as a monotherapy. The development of prognostic factors and refinement 
of predictive testing will aid in allowing the optimisation of the large range of options 
available and accurately determine how likely a patient is to benefit from specific drug 
treatments.
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1.5 Positron Emission Tomography
1.5.1 Background
Positron emission tomography (PET) is a functional imaging technique, in which 
tracer compounds labelled with positron-emitting radionuclides are injected into the 
subject of the study. There is a fundamental difference between the underlying 
mechanism of image production between clinical radiology and PET. Clinical radiology 
uses instrumentation to induce signal changes and then detects the effects, whereas in the 
case of PET, instrumentation detects the signal but the radioligand used is the source of 
the signal.
PET uses radioligands, also known as tracers to produce images. Positron 
emitting isotopes known as radionuclides (150 , 13N, UC, 18F) are incorporated into a large 
number of biological compounds to create radioligands (or tracer molecules) for studying 
normal and pathophysiological processes. The radionuclide used has an unstable nuclei 
which decays by the emission of a positron. This behaves in a similar way to an electron 
but has a positive charge. The result of this decay is that the emitted positron having 
travelled a short distance in human tissue (~lmm) collides with an electron and 
undergoes mutual annihilation which results in the production of energy in the form of
two 511KeV photons or y  rays travelling in opposite directions . If these y  rays are
emitted at 180° to each other, they are detected simultaneously by the PET scanner, a 
term known as ‘coincidence detection’ and an image of original radionulide distribution 
can be reconstructed.
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For further information regarding the components of a PET facility, including 
cyclotrons and scanner types see appendix A. Also, this appendix covers the physics of 
annihilation coincidence detection and attenuation correction, necessary for image 
processing.
1.5.2 Imaging sequences
i) Whole body image sequences
In the case of CRC the disease has the potential to metastasise to most areas of the 
body, hence whole body PET scans are routinely performed. The axial field of view of 
the majority of PET scanners is 14.5cm, so subsequently larger areas of the body can only 
be imaged by moving the patient couch through the gantry. To complete a wholebody 
scan the patient is moved through the scanner.
ii) Dynamic image sequences
In many studies, one is interested not in the static distribution of the tracer at one 
particular time but in the rate at which the activity enters and leaves a particular region. It 
is in these types of research cases that dynamic imaging is employed and a series of 
images over time are acquired. Factors of clinical interest which can be measured using 
this technique are peak tracer activity within an organ, the time occurrence of peak 
activity, the rate of activity uptake in the organ and the rate of clearance of activity.
In dynamic data sets, each image in the series is acquired over a short space of 
time and so only yields a small number of counts in each serial image. If a single image 
of a dynamic sequence is displayed it invariably contains considerable statistical noise
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which in turn makes the identification of anatomical structures even more difficult. To 
analyse a set of dynamic images, a region of interest (ROI, section 2.4.2) is placed over 
the image with the best anatomical detail and then copied onto the remaining images. 
This enables the computation of a time activity curve (TAC) where uptake of the tracer 
within the ROI can be mapped as a function of time (count rate v. time). In addition, the 
data from the TAC allows further quantitative analysis to be performed.
1.5.3 Biological basis of FDG-PET
“If the carcinoma problem is attacked in its relation to the physiology of 
metabolism, the first question is: In what way does the metabolism of growing tissue 
differ from the metabolism of resting tissue?” Otto Warburg 1924
In 1924 this fundamental question was posed by the German biochemist Otto 
Warburg. From a series of observations based on a rat model and later confirmed on 
human cancer cell lines he concluded that the predominant form of glucose metabolism in 
tumour cells is glycolysis (Warburg, 1931). Tumours have increased demands of ATP 
which is derived from glycolysis. This is due to two factors; cancer cells are by definition 
rapidly replicating cells and secondly these cells are not efficient in the production of 
ATP via the Krebs cycle. This leads to a 19-fold increase in glucose consumption per 
mole of ATP produced. The reason for this is two fold, firstly neoplastic degeneration of 
tumour cells is associated with a loss of efficient production of ATP and secondly there is 
activation of the glucose reliant hexose monophosphate pathway providing the backbone 
for the DNA and RNA synthesis required in growing tumours (Weber, 1977a; Weber,
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1977b). The increased demands of the malignant cell are in some way met by the 
increased number of various membrane glucose transporters (Flier et al., 1987; Hatanaka, 
1974). A major early marker of cellular malignant transformation is the activation of the 
gene coding for the glucose transporter GLUT 1 (Hiraki et al., 1988).
1.5.4 [18F] 2-fluoro-2 deoxy-D-glucose
The application of the above principles led to the development of [18F]2-fluoro-2- 
deoxy-D-glucose (FDG). In this tracer the 18F is substituted for the hydroxyl group in the 
2- position.
FDG is transported into cancer cells by the GLUT1 facilitative glucose 
transporter molecules. Once inside the cell phosphorylation occurs by the enzyme 
hexokinase to form FDG-6-phosphate. This is a polar molecule hence does not cross the 
cell membrane well and becomes metabolically trapped. Although FDG-6-phosphate can 
be converted back to FDG by the enzyme glucose-6-phosphatase, this is a slow reaction 
by an enzyme which is present in very small amounts in cancer cells. Following trapping, 
radioactive decay occurs by positron emission.
In the evaluation of FDG images normal uptake can be seen in the brain, heart, 
kidneys and urinary tract (see figure 1.3). The brain has a high physiological glucose 
metabolism, whilst myocardial uptake is seen as a consequence of insulin sensitive 
glucose transporters (GLUT4). Uptake of FDG by the myocardium is variable although 
generally uptake is decreased in the fasting state and increased in the presence of insulin. 
This is also seen in the skeletal muscle. The effects of fasting on the uptake of FDG has
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led to oncological PET studies being carried out following several hours of fasting to 
reduce insulin levels and hence physiological uptake (Wahl et al., 1991).
Competitive inhibition of FDG uptake by glucose in tumour tissue is an additional 
reason for optimal scanning to be carried out in the fasting state.
PP* bi------
Figure 1.3 Normal physiological uptake of FDG. High uptake is seen in the brain (B), in addition to the 
myocardium (M). Renal excretion can be seen via the kidneys (K) into the bladder (BI).
1.6 PET in colorectal cancer imaging
1.6.1 Primary disease
i) Screening
Other than the study by Yasuda and colleagues (Yasuda et al., 2000) there is little 
substantial published data for the use of FDG-PET in screening for asymptomatic CRC. 
This study of 3165 patients demonstrated an unacceptable false positive and negative 
rate. Further considering the availability of PET and current costs -  two important 
contributory factors - this technique is currently unsuitable for unselected screening 
programmes.
PET’s role in the detection of colonic polyps has been investigated. Drenth et al 
validated pre malignant colonic abnormalities using FDG-PET with endoscopy findings. 
In a cohort of 39 patients, PET had a sensitivity and specificity of 74% and 84% when 
compared with the gold standard of colonoscopy, making it a useful adjunct in the non- 
invasive follow up of patients with CRC (Drenth et al., 2001). Incidental colonic uptake 
of FDG was investigated by Tatlidil et al in a retrospective study of 27 patients without a 
history of CRC referred for FDG-PET studies. In this study high FDG uptake correlated 
with at least a 79% chance of histological analysis at the same site being abnormal, 
making colonoscopy a reasonable next step for those patients displaying abnormal high 
FDG uptake within the colon (Tatlidil et al., 2002).
However, there may be value in detecting polyps on reconstructed CT images 
and matching this data to the metabolic signal using the new imaging modality of 
PET/CT.
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ii) Symptomatic disease
A PET positive rate of over 95% has been reported in the diagnosis of primary 
CRC in symptomatic individuals (Mukai et al., 2000). However, endoscopy and barium 
enema detect over 90% of CRCs while being significantly cheaper and more widely 
available than PET. CT colonography is beginning to make a clinical impact (section 
1.5.4). PET is, therefore, unlikely to play a significant role in diagnosing primary CRC, 
although its use as a targeted screening investigation in high risk groups is yet to be fully 
evaluated.
1.6.2 Pre-operative staging
Pre operative staging investigations allow all foci of cancer to be treated by an 
appropriate combination of surgical excision, chemotherapy and radiotherapy so as to 
minimise the chance of recurrence.
i) Local infiltration
CT is widely used to stage primary CRC and is an accurate method of assessing 
local infiltration especially in advanced tumours (sensitivity 55% - 70%) (Balthazar, 
1991; Zerhouni et al., 1996). Conventional and endoluminal MRI are reportedly more 
accurate for rectal cancers as is endoanal ultrasound (USS) (Hildebrandt and Feifel, 1995; 
Napoleon et al., 1991). Many studies have compared FDG-PET and CT in the staging of 
primary CRC. Abdel-Nabi found in 48 patients that PET had a higher sensitivity and 
specificity than CT (Abdel-Nabi et al., 1998) and similar results were demonstrated in a 
smaller study of 16 patients by Falk et al (Falk et al., 1994). This showed that although
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PET had a increased sensitivity for the pre-operative staging of primary CRC, CT had a 
higher specificity. In addition to detecting malignant lymphadenopathy, synchronous 
tumours can also be detected using FDG-PET as demonstrated in Pin’s case report (Pin et 
al., 2000) FDG-PET does not, however, give accurate information regarding local 
infiltration and it is this which might be a key area in which PET/CT comes into its own.
ii) Involvement of lymph nodes and extrahepatic intraabdominal spread
Standard pre-operative evaluation, using size criteria, lymph node involvement 
and extrahepatic, intraabdominal spread with CT and MR has been shown to be 
inadequate by a number of studies (Freeny et al., 1986; Guinet et al., 1988; Thompson et 
al., 1986). These studies report accuracy for CT ranging between 25-73% (overall 
sensitivity is 45%) with a 40% sensitivity for MRI Laparoscopy with or without USS 
may further improve the accuracy of staging although this is invasive and information is 
not available prior to definitive surgery. Immunoscintigraphy (radiolabelled antibodies) 
is significantly more sensitive for pelvic and intraabdominal disease when compared to 
CT and this technique has potentially useful clinical applications (Veroux et al., 1999). 
Lymphoscintigraphy can also play some role in the detection of the sentinel node.
The studies mentioned earlier in this section also comment on the assessment of lymph 
node involvement and extrahepatic intraabdominal spread. In Falk’s study of 16 patients, 
he demonstrated that FDG-PET was superior to CT for staging (positive predictive value 
(PPV) 93% and negative predictive value (NPV) 50% for FDG-PET versus PPV of 
100% and NPV of 27% for CT. The study by Abdel-Nabi et al is more interesting
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because it showed no difference between the modalities for detection of lymph nodes 
(sensitivity of 29% for both) (Abdel-Nabi et al., 1998). Mukai and colleagues again 
showed the limited value of PET in the detection of metastases to regional lymph nodes 
surrounding the primary lesion by reporting sensitivities of 22.2% (2/9) for lymph node 
detection with specificity of 86.7% (13/15) (Mukai et al., 2000).
Metastases to the liver
Liver metastases are found in 10-25% of patients at the time of operation for 
their primary CRC and 25% are candidates for resection (Adson, 1987). CT is the 
imaging modality most frequently used in the staging of primary CRC and has a reported 
sensitivity of 72% and specificity of 99% with MR having similar results (Freeny et al., 
1986; Rummeny et al., 1992).However, published data also shows that CT failed to 
demonstrate lesions in 7% and underestimated the number of lobes involved in 33% of 
cases (Ferrucci, 1990; Steele, Jr. et al., 1991). Immunoscintigraphy using Indium-111- 
labelled anti-CEA antibodies has shown promise (Patt et al., 1990), but specificity and 
poor spatial resolution can be a problem when compared to FDG-PET. Again in Abdel- 
Nabi’s study the detection of liver metastases by FDG-PET was shown to be superior to 
CT (sensitivities of 88% versus 38%), although this study was not controlled and PET 
reporters were not blinded to CT reports (Abdel-Nabi et al., 1998).
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1.6.3 Recurrent disease
i) Detection of local recurrence
Following treatment of primary CRC, patients undergo surveillance of varying 
intensity in order to detect recurrence. In up to 30% of cases the recurrence is localised 
and therefore suitable for curative resection especially if radical surgery is performed 
(Turk PS, 1993). In order to avoid unnecessary morbidity and mortality appropriate 
selection of patients is essential.
MR remains the optimum morphological imaging modality although there were 
early reports questioning the ability of MR to distinguish recurrent tumour from benign 
fibrotic changes (de Lange et al., 1989). Even so, CT remains the most frequently used 
option when detecting recurrence and suffers similar drawbacks when evaluating “scar” 
tissue. Immunoscintigraphy has been shown to be superior than CT for differentiating 
scar from tumour in the pelvis (Doerr et al., 1991; Lunniss et al., 1999). However, 
Libutti’s recent prospective study of twenty eight patients comparing PET with CEA 
scan and blind second look laparotomy, revealed that FDG-PET scanning is superior to 
anti-CEA immunoscintigraphy and could predict those patients with recurrent disease 
most likely to benefit from laparotomy (Libutti et al., 2001).
Several authors have confirmed the value of measuring the metabolic activity of a 
tissue mass through FDG-PET in order to differentiate between malignant local 
recurrence and scar tissue (Ito et al., 1997; Schlag et al., 1989; Strauss et al., 1989). In a 
study by Schiepers and colleagues (Schatzkin et al., 2000) accuracy for disease in the 
pelvis was 95% with FDG-PET against 65% with CT (Schiepers et al., 1995). Takeuchi 
et al also reported impressive results for the accuracy of PET for diagnosis of pelvic
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recurrence when compared to both CT and MR with 15 of the 16 histologically proven 
recurrences imaged positively (Takeuchi et al., 1999). More recent studies have reported 
similar findings (Flamen et al., 1999; Valk et al., 1999). In fact Valk and colleagues 
demonstrated sensitivity and specificity of 93% and 98% respectively with FDG-PET 
compared to 69% and 96% in the 115 patients with available CT’s. This led to a cost 
saving of approximately US$ 3000 per pre-operaitve study through the avoidance of 
surgical intervention. To date our own prospective experience comparing PET with CT 
in the detection of locally recurrent disease also demonstrated increased accuracy using 
PET with a sensitivity of 100% and specificity of 86% compared to 75% and 100% for 
CT (Arulampalam et al., 2001). Whiteford’s review of 105 patient records of which 70 
had locoregional recurrence also confirmed the superiority of PET when compared to CT 
plus colonoscopy with sensitivities of 90% and 70% respectively (Whiteford et al., 
2000).
ii) Evaluating a rising CEA
Evaluating patients who present with an isolated elevation of CEA with minimal 
symptoms and normal imaging is ideally suited to PET and PET/CT. Flanagan et al 
showed that in 17 out of 22 patients PET was abnormal and recurrence was confirmed by 
tissue sampling and/or follow up. PET had a PPV of 89% and NPV of 100% (Flanagan et 
al., 1998). A PPV of 89% was also demonstrated by Flamen’s group with a sensitivity of 
79% in a cohort of 50 consecutive patients with an elevated CEA with completely normal 
or equivical conventional diagnostic work up (Flamen et al., 2001). The superior 
accuracy of PET over CEA has also been discussed by Simo’s group who looked at 58
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patients referred for FDG PET because of an elevated CEA. PET detected recurrence 
leading to a major management change in 34 (58%) of the cohort. Of this group 18 
underwent curative surgery and 16 were treated with systemic therapy (Simo et al., 
2002). In Zervos’s study, of the 15 patients with an increasing CEA level and normal 
diagnostic imaging, 14 were found to have abnormal PET scans, 9 of these underwent 
surgical exploration with curative intent. This study also looked at 4 patients with 
symptoms of recurrent CRC but a normal CEA level and non diagnostic conventional 
imaging but positive PET scans. Three of the four were found to have no evidence of 
recurrence at surgery, the results of PET scans in these types of patients should therefore 
be interpreted with caution (Zervos et al., 2001).
iii) Evaluation of the extent of disease
The evaluation of patients with suspected recurrent CRC aims to differentiate 
isolated resectable disease from disseminated metastases allowing appropriate patient 
selection for surgical intervention and increasing the chance of disease free survival. 
FDG-PET is more accurate than CT for the purpose of evaluating the extent of recurrent 
CRC as shown by both Ogunbiyi and Vitola (Ogunbiyi et al., 1997a; Vitola et al., 1996). 
The usefulness of PET in diagnosing peritoneal recurrence of CRC has been investigated 
by Tanaka et al in a retrospective review of 23 patients (Tanaka et al., 2002). PET was 
found to have a sensitivity of 88% with a diagnostic accuracy of 78% compared to 38% 
and 44% respectively for CT. In this study a lesion as small as 15mm in diameter was 
diagnosed by PET.
56
iv) Hepatic metastases
Schiepers’ study in 1995 evaluated 76 patients presenting with suspected locally 
recurrent disease or distant CRC. This confirmed a higher sensitivity and accuracy with 
FDG-PET (94% and 98% respectively) compared to CTAJSS (85% and 93%) for the 
detection of hepatic metastases (Schiepers et al., 1995a). Delbeke compared FDG-PET 
with CT and CT portagram in 52 patients treated for CRC and presenting with suspected 
hepatic recurrence. PET demonstrated an accuracy of 92% compared with CT and CT 
portagraphy (78% and 80% respectively) for hepatic disease. In this study PET was also 
more accurate for extrahepatic disease when compared to CT, 92% versus 71% (Delbeke 
et al., 1997). Ogunbiyi s retrospective review also compared PET and CT in the detection 
of hepatic metastases and reported a sensitivity of 95% and specificity of 100% for FDG- 
PET compared to CT (74% and 85% respectively) A higher accuracy for PET compared 
to CT for delineating multiple liver lesions was also reported (Ogunbiyi et al., 1997a)
More recent studies including that of our own unit have systematically confirmed 
the benefits of FDG-PET for the detection of both hepatic and extrahepatic metastases 
from CRC. Zhuang’s direct comparison of PET and CT in 80 patients with CLM again 
highlighted greater sensitivity of PET (100% vs 71.4% for PET and CT respectively) 
(Zhuang et al., 2000). The clinical value of PET in the assessment of potentially curable 
liver metastases has been investigated by Topal et al (Topal, 2001). In this prospectively 
studied group of 91 consecutive patients considered eligible for liver resection after 
conventional imaging, PET provided additional information regarding distant disease in 
11% whilst confirming liver metastases in 99%; although in this study PET also falsely
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upstaged 6.6% and understaged 7.7% (all of which had small intra abdominal lesions). In 
a study by Fong et al PET’s greater accuracy in identifying distant disease is again 
demonstrated (Fong et al., 1999). 40% (16/40) patients had their management influenced 
by the PET findings with 6 of these patients being spared unecessary laparotomy by 
virtue of Pet’s identification of previously undiagnosed extrahepatic disease. This study 
again highlighted a problem with PET and the identification of small lesions. Only 25% 
of hepatic lesions smaller than 1cm were detected by PET, while 85% of lesions larger 
than 1cm were detected.
Our own prospective study currently in press, evaluated 31 patients initially 
staged with spiral CT prior to referral for hepatic resection. These patients then 
underwent FDG PET imaging and the results of the two imaging modalities compared in 
terms of sensitivity and specificity in addition to the effect that PET had on patient 
management. PET detected all the lesions (sensitivity 100%, specificity 91%) whilst CT 
incorrectly diagnosed solitary CLM in 5 patients and failed to detect extrahepatic disease 
in 4 patients (sensitivity 47%, specificity 91%). This resulted in altered management for 
12(39%) of the patients of whom 7 (23%) avoided inappropriate surgery (Arulampalam 
et al., 2004).
The recently published evidence from Kinkel’s meta-analysis of the detection of 
hepatic metastases from cancers of the gastrointestinal tract using US, CT, MRI and PET, 
suggests that FDG PET is the most sensitive non invasive imaging modality for the 
diagnosis of CLM and that the optimal evaluation of patients with CLM should include 
FDG-PET (Kinkel et al., 2002).
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v) Extrahepatic metastases
Lai et al compared FDG-PET with conventional imaging in 34 patients and 
found unsuspected extrahepatic disease in 11 (32%) patients (Lai et al., 1996). Clinical 
management was affected in 10 patients directly as a result of PET. Schiepers also 
reported in his study that a significant number of unexpected extrahepatic metastases 
could be demonstrated using FDG-PET (Schiepers et al., 1995a).
vi) Impact on patient mangement
The advantage that FDG-PET and PET/CT confer to patient management in the context 
of recurrent and/or metastatic disease is that they alter clinical management. This may be 
by avoiding surgery, early commencement of non-surgical treatments or selecting 
patients suitable for surgical re-intervention. FDG-PET is highly accurate for diagnosing 
and staging recurrent CRC as demonstrated in a meta analysis by Huebner and 
colleagues (Huebner et al., 2000). The meta-analysis of eleven studies (349 patients) 
showed a sensitivity of 97%, specificity of 76% and impact on clinical management 
ranging between 25% and 34% of cases. Detection of unsuspected metastases by FDG- 
PET ranges from 13-32% (Schiepers et al., 1995). Large savings could be made if PET 
was incorporated into the routine management algorithm for recurrent CRC on the basis 
of a reduction in unnecessary laparotomies (from 10 to 20%) and the increased number 
of resections with curative intent (Larson, 1994). A recent prospective study where the 
clinical impact of FDG-PET in patients with suspected or confirmed recurrence was 
assessed by comparing the treatment plan assigned by the oncologist in 102 consecutive 
patients. The treatment plan was assigned using conventional staging investigations and
59
compared to the treatment plan based on the incremental information supplied by PET. 
The management plan of 54 of the 102 patients was altered as a direct result of 
unexpected PET findings and in 6 further cases the oncologist would not commit to a 
plan of management without having access to the PET data. Significantly in this study 
planned surgery was abandoned in 26 of 43 patients (60%) because of incremental PET 
findings. Again false negative findings were recorded in 4. patients as a result of the 
metastases being less than 1cm (Kalff et al., 2002).
Table 1.4 summarises some the studies in which PET has changed patient management.
Author No patients Change in management
Beets e t al 35 40% (14/35)
Vitola e t al 24 25% (6/24)
Lai e t al 34 29% (10/34)
Delbeke e t al 52 33% (17/52)
Ogunbiyi e t al 23 44% (10/23)
Valk e t al 78 31% (24/78)
Flamen et al 103 20% (21/103)
Staib e t al 100 61% (61/100)
Fong e t al 40 23% (9/40)
Arulampalam e t al 42 38% (16/42)
Whiteford e t al 101 26% (26/101)
M eta-analysis
Huebner 349 25%-34%
Table 1.4 Summary of the impact PET has m ade on patient m anagem ent
1.6.4 Evaluating subclinical treatment response
Accurate information regarding the response to radiotherapy and/or 
chemotherapy in patients being treated for CRC provides useful guidance in predicting, 
planning and revising ongoing adjuvant therapy, especially in the context of the
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unwanted side effects. Studies assessing the uptake of FDG measured by PET and 
correlation with the anti-tumour effects of chemotherapy have been reported for certain 
tumour types including CRC as discussed below (Nakata et al., 1997; Okada et al., 1991).
i) Response to chemotherapy
The available data suggests highest concentration of fluorine-18 fluorouracil 
([18F]FU) in responsive tumour (Shani et al., 1982). Strauss and Conti demonstrated that 
lesions with low [18F]FU uptake had a significant increase in volume and no response to 
treatment (Strauss and Conti, 1991). Findlay et al evaluated the metabolism of CRC liver 
metastases using FDG-PET before and at intervals after treatment in 18 patients. The 
findings were compared with tumour outcome conventionally assessed using change in 
size on CT. The results were expressed as a ratio of FDG uptake in tumour and normal 
liver (T:L). The T:L ratio 4-5 weeks after treatment was able to discriminate response 
from non-response both in a lesion-by-lesion and overall patient response (sensitivity 
100%, specificity 90% and 75% respectively) (Findlay et al., 1996). There is currently 
speculation that PET/CT may provide a practical solution for evaluating treatment 
response due to faster patient throughput and accurate anatomical/metabolic image 
registration. Debate continues as to whether [18F]FU is superior to FDG in predicting the 
response to treatment on an individual patient basis (Moehler et al., 1998). There is 
uncertainty as to how to obtain the most accurate information on tumour response based 
on morphological imaging (Therasse et al., 2000). There are significant problems 
applying this methodology (Padhani and Husband, 2000) and in this context the EORTC 
has already published guidelines suggesting metabolic criteria should be used for this
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task (Young et al., 1999). The potential role of PET in this aspect of oncology and 
particularly in the management of CRC suggests that its uses will increase.
ii) Response to radiotherapy
Similar promise was thought to be present for PET in the evaluation of RT 
response. There are some problems, most notably demonstrated by Haberkom 
(Haberkom et al., 1991) who evaluated FDG-PET in 21 patients with recurrent CRC 
undergoing pelvic RT. A correlation was made between the palliative benefit and 
reduction in FDG uptake in 50% of patients (this was also more accurate than CEA).
More recently, Guillem (Guillem et al., 2000) has demonstrated that FDG-PET augments 
conventional morphological imaging modalities when used to preoperatively assess 
response to chemo-radiation for rectal carcinoma. This is primarily because information 
is available preoperatively that allows sphincter saving surgery to be accurately planned.
In a study of 40 patients who were imaged both pre and post radiotherapy for low 
rectal cancers, FDG uptake was quantified and found to be a good prognostic indicator in 
terms of long term prognosis (Oku et al., 2002).
A further application of FDG-PET and more recently PET/CT is the potential 
ability to reduce RT treatment fields by restricting the target volume to the metabolically 
active tumour. This is usually smaller than the target volume designated by conventional 
CT (Kiffer et al., 1998; Rosenman, 2001). Such an assessment could possibly reduce 
unwanted side-effects of RT.
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1.6.5 Biological characterisation using PET
The consideration of the biological characteristics of a tumour allows a more 
specific formulation of treatment plans and the possibility of better results in cancer 
therapy (Eary, 1999; Price and Jones, 1995). Currently the analysis of biopsy material is 
the only way of obtaining patient specific information on tumour biology. Although this 
technique provides a method of assessing and characterising cancer, it is both invasive 
and has significant sampling error due to the heterogeneity of tumours and variation 
between metastatic sites. The unique ability of PET to non-invasively image regional 
tumour biology in the form of glucose utilisation using FDG has been discussed in this 
section, in addition to the positive impact that this has had in the management of CRC.
While the success of FDG-PET in CRC has been widely documented, the role of 
PET in the management of cancer in general is not limited to FDG. Other PET tracers 
have been developed and are targeted to areas of tumour biology that include protein and 
membrane biosynthesis, tissue hypoxia and tumour receptor and/or gene product 
expression. Uncontrolled growth is a characteristic of malignant tumours. Techniques 
have been known for some time to measure tumour growth rates in tissue specimens but 
as discussed these have limitations. It has already been demonstrated by Higashi et al that 
FDG uptake is a measure of cell viability and not proliferation (Higashi et al., 1993). 
PET has the potential to offer fully quantitative characterisation of tumour growth 
through the development of these new radiolabelled ligands: A biological process highly 
relevant to CRC and indeed all cancers is the regulation of the cell cycle and cellular 
proliferation.
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The potential use of PET as a tool for imaging cellular proliferation in vivo could open 
new avenues in the understanding and treatment of CRC by bridging in vitro biological 
discovery and clinical medicine.
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1.7 The cell cycle
1.7.1 Background
The cell cycle is defined as the fundamental process by which a cell replicates its 
cellular and genetic material, resulting in the formation of two identical daughter cells. 
This process is essential to the survival and continuing viability of all cells, and various 
regulatory mechanisms inherent in the cell cycle ensure that the transmission of genetic 
material to the resulting daughter cells is performed in an accurate and reliable manner.
i) Early concepts of cell proliferation
As early as 1875, mitotic figures were noted to be present in tissue sections 
examined under the light microscope. From these findings, it was postulated that a cell 
could exist in one of two states, either undergoing mitosis or remaining in interphase, 
which was considered to be an inactive “resting” state. Despite these preliminary 
observations, however, very little progress was made in the understanding of the 
underlying biochemical changes induced in mitosis for the next fifty years.
The first major breakthrough, leading to the initial concept of a cell cycle, was 
based on the work of Alma Howard and Steve Pelc in 1951 (Howard and Pelc, 1951). 
After labelling the roots of Vica faba seedlings with 32P, they performed autoradiography 
to look for the incorporation of this radioisotope in cells manufacturing new strands of 
DNA. Their results showed that the process of DNA synthesis was entirely distinct from 
that of mitosis, and occurred during a discrete period in the middle of the interphase. 
They thus concluded that the cell cycle was composed of four stages, with the presence of
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a long gap phase (Gl) between mitosis and DNA synthesis, and a second shorter gap 
phase (G2) occurring after DNA synthesis.
ii) Localisation of proliferating cells within a tissue
Using high-resolution autoradiography techniques, Hughes performed a similar 
set of experiments aimed at studying the localisation of proliferating cells in different 
tissues (Hughes et al., 1958). After injecting tritiated Thymidine (3H-Tdr) into mouse 
small intestine, he found that 3H-Tdr incorporation was initially observed only in the 
crypt cells of the intestinal epithelium. However, after 24 hours, the presence of 3H-Tdr 
was detected in epithelial cells along the entire surface of the villi, and at 48 hours could 
even be seen in cells shed into the intestinal lumen. He concluded that cell proliferation 
occurred only in a specific population of intestinal epithelial cells, namely the crypt cells, 
but the resulting daughter cells migrated up into the intestinal villi and were eventually 
shed into the lumen. This led to the suggestion that proliferating cells were restricted to a 
specialised compartment of normal epithelial tissues.
1.7.2 Current understanding of the cell cycle
The cell cycle comprises four stages: Gl, S, G2 and M. The cycle is governed by 
extracellular signals such as the availability of nutrients and growth factors and signals 
mediated by cell-cell contact. Transitions from one phase to the next are governed by a 
series of cyclin-dependant kinases (CDKs) that bind to positive effectors, the cyclins, 
whose levels fluctuate during the cell cycle. These complexes phosphorylate certain 
proteins which results in the progression of the cell through the phases. There also exist
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inhibitory cyclin dependant kinases which can cause cell cycle arrest by deactivating the 
complexes and can be triggered by a variety of molecular signals.
i) G l phase
Gl is the first gap phase of the cell cycle and is defined as the period from the end 
of mitosis to the start of DNA synthesis. It usually lasts around 5 hours in mammalian 
cells, but is the most variable stage of the cell cycle and, depending on the physiological 
condition of the cell, may be prolonged to several days or months.
Cells initially begin cycling in the Gl phase, either from the M phase of the 
previous round of replication or from a state of quiescence (GO). The Gl phase allows the 
cell to grow, check the integrity of its DNA and prepare for DNA synthesis, eg, by 
transcribing for necessary enzymes. In order to proceed to the S phase, the cell needs to 
pass an important regulatory checkpoint (Gl/S) ensuring that it has all the necessary 
components to successfully initiate DNA synthesis. If the cell is not allowed to progress 
through the cell cycle it will either enter a state of quiescence (GO) or remain in Gl arrest.
ii) S phase
The S phase lasts around 7 hours in mammalian cells and is the period when the 
DNA of the parent cell is replicated, resulting in the formation of two identical sets of 
chromosomes. The cell has mechanisms to ensure that its DNA is duplicated accurately 
so that the genetic information is transmitted in its entirety between one cell generation 
and the next. The replicative process must also restrict itself from re-duplicating any 
portion of nuclear DNA within a single cell cycle. Failure of these regulatory
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mechanisms can have serious consequences, resulting in cell death or contributing to 
cellular neoplastic transformation.
iii) G2 phase
G2 - the second gap phase - is the period from the end of the S phase to the start 
of the M phase (3 hours). During this stage, the cell ensures that DNA replication has 
been successfully completed, to form two complete diploid sets of chromosomes. Any 
errors that may have occurred in the proceeding S phase are corrected at this stage eg, by 
P53, otherwise the cell will not be allowed to progress past the G2/M check point and 
may be marked for apoptosis. The cell also undergoes replication of its cytoplasmic 
organelles and cellular growth in preparation for the final act of cell division.
iv) M phase
During the M (mitotic) phase the cell divides, resulting in the formation of two 
identical daughter cells. The M phase comprises of four stages: prophase, metaphase, 
anaphase and telophase (Mazia, 1961).
Prophase is characterised by a series of nuclear changes that are visible under the light 
microscope. The initial event is the breakdown of the nuclear envelope, which is under 
the control of specific cyclin/CDK complexes (Gerace and Foisner, 1994). The nucleoli 
are then dispersed and chromosomal DNA is condensed. Finally, the microtubule spindle 
apparatus is formed in order to allow the subsequent redistribution of the cell’s genetic 
material.
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Metaphase is the stage in which the chromosomes attach themselves to the micro tubules 
and eventually become aligned on the spindle equator. The whole spindle apparatus then 
becomes compacted, in readiness for separation of the chromosomal DNA 
Anaphase involves the sister chromatids of each original chromosome beginning to pull 
apart to form two new, independent chromosomes and move towards opposite spindle 
poles. This is facilitated by the formation of anaphase promoting complex (APC) proteins 
which lyse the proteins holding the chromatids together(Glotzer et al., 1991).
In Telophase a nuclear envelope forms around each new set of chromosomes and the cell 
starts to undergo cleavage of its cytoplasmic organelles (cytokinesis). This results in the 
equal division of cellular and genetic material, and formation of two identical daughter 
cells.
1.7.3 Cell cycle and cancer
. Several of the molecular mechanisms that regulate the balance between cell proliferation 
and cell death may be disturbed in tumours. In terms of CRC faults at the check points 
may remove the regulatory checks of repair. Gl/S is governed by the retinoblastoma 
protein. This is phosphorylated and therefore removed from the inhibitory check point by 
cyclins/CDKs influenced by growth factors (eg, EGF). Several of the molecular 
mechanisms that regulate the balance between cell proliferation and cell death, may be 
disturbed in tumours, often resulting in net cell growth. In CRC, the cell cycle 
checkpoints can be overcome and the cell driven to proliferate, in a number of ways 
including:
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(a) APC mutations, in both classical adenoma-carcinomas and MSI cancers. When APC 
is dysfunctional, it cannot contribute to the sequestration and breakdown of P-catenin. 
Therefore p-catenin accumulates and signals for the overexpression of cyclin D. The 
latter complexes with CDKs to drive the cell through the Gl/S checkpoint, therefore 
committing the cell to DNA synthesis.
(b) Mutations in the TGFp pathway molecules, including TGFPRII (in MSI cancers), 
SMADS 2,4 (in adenocarcinomas). Since the TGFP pathway increases the expression of 
inhibitors of cyclins/CDKs, any mutated signalling molecule in this path will result in the 
decrease of inhibitors. This would allow the cell to transverse the cell cycle checkpoints 
and continue proliferating.
(c) P53 promotes the expression of inhibitors of cyclins/CDKs. Therefore when 
dysfunctional, inhibitors are decreased, again allowing the cell to progress throught the 
cell cycle.
A number of other genes also directly affect the balance of the cell cycle, but are 
outside the remit of this thesis.
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1.8 Cell proliferation
1.8.1 Background
“Unfortunately, long lived organisms such as vertebrates need substantial and continuous 
cell proliferation through out their extended lives, both for development and long-term 
maintenance and repair. In teleological terms, the evolutionary imperative of vertebrates 
has been to find a way to allow cell proliferation when needed, while at the same time 
efficiently suppressing the genesis of mutated cells leading to deregulated growth. When 
such measures fail, cancer is the inevitable consequence” (Evan and Vousden, 2001).
Cell proliferation in vitro and vivo has been studied extensively by using 
autoradiography to detect uptake of radioactive thymidine into cellular DNA. 
Autoradiography is a technique used to identify where a radioactive isotope is localised in 
cells or subcellular components. The process involves covering biological material with 
photographic film or emulsion. The radioactivity produced by the isotope then causes 
local exposure of the overlying film or emulsion, which on development can be detected 
as dark grains close to the location of the isotope. By using this technique the cell nuclei 
that have incorporated the isotope during the thymidine exposure can then be identified. 
The proportion of labelled cells at a short interval after administration of tritiated 
thymidine (the labelling index or S phase fraction) is a measure of the proportion of cells 
that were in S phase. All the basic concepts of cellular proliferation have been derived 
from experiments using tritiated thymidine and autoradiography. The study of cell 
proliferation has now largely been superseded by flow cytometry which is an easier 
method to study cell cycle properties. This technique involves tagging cells with a
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fluorescent dye whose binding to the DNA is proportional to the DNA content. The cells 
are then directed in single file through a laser beam. The intensity of fluorescence 
induced by the laser light is detected and the number of cells exhibiting different levels of 
fluorescence is recorded. DNA distributions are then analysed by computer, using 
mathematical models that allow estimation of the proportion of cells in each phase of the 
cell cycle.
Thymidine labelling has been used to estimate the cell cycle time Tc and the 
duration of individual phases of the cell cycle. In many normal tissues of the adult, only a 
small proportion of the cells are actively proliferating. Of the remaining cells, many are 
either differentiated or quiescent. Examples of the latter (quiescent) include, bone marrow 
stem cells, skin cells that participate in wound healing after damage and hepatocytes that 
proliferate after partial hepatectomy. These non cycling cells that retain their capacity for 
proliferation are referred to as a GO population. Most tumours also contain non 
proliferating cells and in 1962 Mendelsohn introduced the concept of a tissue growth 
fraction, which is the proportion of cells within a tumour that are actively proliferating (ie 
progressing through the cell cycle) (Slingerland and Tannock, 1998). He suggested that 
cells could exist in one of three possible growth states (Mendelsohn, 1962).
i) actively dividing (cycling cells)
ii) incapable of further division (terminally differentiated cells)
iii) presently inactive, but could be stimulated to undergo division (quiescent 
cells)
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Although the growth fraction can be estimated by thymidine labelling and 
autoradiography, other specific enzymes exist as proliferation dependent markers which 
can be detected by flow cytometry. The estimate of the growth fraction is useful since 
most chemotherapeutic agents are more toxic to proliferating cells and the growth 
fraction would therefore indicate the proportion of tumour cells that might be sensitive to 
cycle-dependent chemotherapy.
1.S.2 Cell proliferation in normal tissues
The rate of normal cell proliferation varies considerably in different tissues. Table 
1.5 below shows examples of normal tissues with differing proliferative properties.
Tissues which are continuously rapidly proliferating • Bone marrow
• Gastrointestinal mucosa
• Hair follicles
• Testicular germ cells
Tissues which are continuously slowly proliferating • Tracheobronchial epithelium
• Vascular endothelium
Tissues which proliferate in a cyclical fashion • Glandular female breast cells
• Endometrial lining of the 
uterus
Tissues with the capacity to proliferate after injury • Liver
• Bone
Non-proliferating tissues • Skeletal muscle
• Cardiac muscle
• Cartilage
• Neurones
Table 1.5 Proliferative properties of normal tissues.
Some tissues virtually cease replication once the body reaches maturity whilst others 
produce millions of new cells every day up to the time of death. The effects of cytotoxic
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drugs will be most obvious in those normal tissues which are dividing most rapidly, and 
hence it is risk of toxicity to these tissues which limits the usefulness of the 
chemotherapeutic drugs.
1.8.3 Cell proliferation in CRC
In normal colonic mucosa, proliferating cells are predominately located in the 
lower two thirds of the crypts one of the first steps in colonic carcinogenesis is increased 
cell proliferation and an upward shift of the proliferation zone of colonic crypts. This 
expansion of the proliferative compartment has been shown to be a feature at all stages of 
malignant progression (Shpitz et al., 1997).
i) Proliferation as a early marker
One of the earliest events in colorectal carcinogenesis is the alteration of the 
proliferation of epithelial cells in colonic crypts (Srivastava et al., 2001). Bird et al was 
one of the first to describe crypts in mice which were larger, thicker and darker than 
normal (Bird, 1987). Further work postulated that these abnormal crypts might be 
precursors of cancer and they were described as aberrant crypt foci (ACF) (Tudek et al., 
1989). In the early 1990’s ACF were described by Pretlow et al in the human colon 
(Pretlow et al., 1991). Cheng et al looked at crypt production in normal and diseased 
human colonic epithelium and interpreted the results as that the rate of crypt production 
in human colonic epithelium is increased in a number of disease states (Cheng et al., 
1986).
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The idea of abnormal proliferation resulting in ACF in humans was furthered by 
Pretlow when he observed their presence in human colon cancer by staining them with 
carcinoembryonic antigen (Pretlow et al., 1994).
We now understand that larger ACF with altered morphology, dysplastic 
histological findings, altered cell kinetics and mutations in some genes involoved in 
colorectal carcinogenesis, are the most probable candidates for the progression to 
carcinoma. It is also evident that ACF have most of the requisites necessary for use as 
practical early biomarkers of cancer risk.
The importance in identifying this alteration in cellular proliferation is critical in 
the identification of colorectal cancer and seems to be fundamental in the progression of 
the disease.
ii) Proliferation in colorectal adenomas and polyps
The genetic mutations leading to the transition of normal mucosa through to polyp 
formation and eventually carcinoma have been discussed in section 1.1.2 and 1.7.3.
Hyperproliferation is believed to develop in pre-neoplastic epithelium implying 
the involvement of the APC gene. There is currently a lack of understanding into the 
histogenesis of sporadic human colorectal hyperplastic polyps and colorectal adenomas. 
It has also been postulated that sporadic adenomas and polyps grow because of elevated 
rates of crypt fission (Wong et al., 2002). This event involves the basal bifurcation 
followed by longitudinal division of the crypt secondary to deregulation of the cell cycle.
Studies have shown that a high rectal mucosal proliferation indices is associated 
with an increase risk of CRC (Deschner et al., 1988; Gerdes et al., 1993; Lipkin et al.,
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1987; Paganelli et al., 1990; Risio et al., 1988; Risio and Rossini, 1993; Roncucci et al., 
1988; Rozen et al., 1990). In a study attempting to correlate rectal mucosal proliferation 
with the development of adenomas, a cohort of 333 patients who had had at least one 
adenomatous polyp removed underwent rectal biopsy from which a labelling index was 
calculated. No association was found between rectal mucosal proliferation index and 
adenomas (Sandler et al., 2000).
1.8.4 Proliferation as a prognostic marker in colorectal cancer
The role of DNA analysis in the prediction of the outcome of patients with CRC 
has been investigated using flow cytometry in a number of studies. Venkatesh et al 
performed flow cytometry and DNA analysis on 248 patients with CRC and found that 
the combined presence of aneuploidy and an S phase fraction over 20% indicated a 
poorer prognosis (Venkatesh et al., 1994). In a study conducted by the North Central 
Cancer Treatment Group flow cytometry was again used to assess DNA content and cell 
proliferation in 692 patients with stage B2 or C CRC. In this study the proliferation index 
was a significantly strong prognostic factor. In addition those patients with diploid 
tumours had a higher survival rate than those with nondiploid tumours. When these two 
parameters were combined, those patients with both diploid and low proliferative rate 
tumours had a five year survival of 74% compared to 54% five year survival for those 
patients with high proliferative non diploid tumours (Witzig et al., 1991). A Southwest 
Oncology Group study found contradictory evidence in a study using genetic mutational 
status and S phase fraction to try and predict the clinical behaviour of CRC. In this 
randomised trial of 66 patients with stage II and 163 with stage HI disease, where they
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received either surgery and observation or surgery and adjuvant levamisole or 5FU + 
levamisole, no association was seen between a high proliferative rate in the cancer and a 
poor prognosis in either stage of the disease (Ahnen et al., 1998).
The clinical implications that S phase fraction had for the assignment of adjuvant 
chemotherapy has been investigated using flow cytometric DNA analysis on resected 
specimens from 167 patients with stage I or II CRC. In both stages there were groups of 
patients with high and low S phase fractions. Those subgroups with a high S phase 
fraction had significantly worse recurrence rates implying that this biological marker 
might help in identifying which patients may benefit from chemotherapy (Cascinu et al., 
1998).
1.8.5 Quantifying proliferation using Ki-67
The recent use of immunohistochemistry using the MEB-1 antibody, which 
recognises the cell cycle associated Ki-67 protein allows an easier way to assess 
proliferation. The human Ki-67 antigen is a huge protein encoded by a single gene on 
chromosome 10, whose expression is tightly controlled by the cell cycle. It is expressed 
in all proliferating cells during late Gl, S, M and G2 phases but not in the GO phase of the 
cycle. It is known that Ki-67 is vital for cell proliferation, since removal of the antigen 
results in cessation of the process (Schluter et al., 1993). The application of 
immunohistochemical techniques to assess cellular proliferation is preferred as it 
preserves the architecture and cytology of histological material without relying on in vivo 
administration of thymidine analogues (Hall and Levison, 1990; Hall and Woods, 1990)
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The antibody which identifies Ki-67 has been shown to be an excellent indicator 
of proliferation in histological material (Brown and Gatter, 1990; Hall and Woods, 1990), 
but was limited in surgical pathological practice by only being effective on cryostat 
sections. The development of the MIB-1 antibody, has allowed the ki-67 antigen to be 
recognised in formalin fixed and wax embedded material (Cattoretti et al., 1992). It has 
been shown to be a robust marker of cell proliferation easily applicable to archive 
material (McCormick et al., 1993).
1.8.6 Ki-67 and CRC
There have been contradictory reports regarding the potential role of Ki-67 as a 
prognostic indicator in CRC. Ki-67 was selected to assess the proliferation characteristics 
because of its potential value in predicting both prognosis and those individuals who may 
or may not benefit from adjuvant chemotherapy. Palmqvist et al showed that those 
tumours with low Ki-67 expression at the invasive margin had a poor prognosis 
(Palmqvist et al., 1999), whilst Kimura et al concluded that the tumours with high 
expression at the site of deepest invasion had a worse prognosis (Kimura et al., 2000). In 
contrast both Kubota et al who analysed 100 cases of CRC using Ki-67 (Kubota et al., 
1992) and Kyzer et al who examined 30 resected specimens of CRC concluded that Ki-67 
could not be used as a prognostic determinate in CRC (Kyzer and Gordon, 1997).
The prognostic value of Ki-67 in CRC has recently been revisited by the National 
Surgical Adjuvant Breast and Bowel Project Collaborative Study Group in a retrospective 
study of 706 patients with Dukes B and C disease to try and define a marker on which 
therapeutic decisions could be made with greater precision. Significant prognostic value
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was found for patients with Duke’s B and C colonic cancer with respect to recurrence 
free survival as in addition to overall survival. In this study Ki-67 labelling indices were 
unable to differentiate between groups who might benefit from adjuvant chemotherapy 
(Allegra et al., 2003).
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1.9 Thymidine PET tracers
1.9.1 Background
As previously discussed, the incorporation of thymidine nucleotides into DNA 
during the S phase, has allowed the study of cellular proliferation in tumour cells.
The thymidine nucleotides arise from two pathways de novo and salvage (see 
figure 1.4). The salvage pathway involves exogenous thymidine entering the cell by a 
process of facilitated diffusion (Vijayalakshmi and Belt, 1988) which then undergoes 
successive phosphorylations by the enzyme thymidine kinase (section 1.10.3) through 
deoxythymidine monophosphate (dTMP) and deoxythymidine diphosphate (dTDP) to 
eventually form deoxythymidine triphosphate (dTTP). dTTP is then incorporated into the 
DNA following polymerisation by DNA polymerase. The de novo pathway uses 
endogenous thymidine by converting deoxyuridine monophosphate (dUMP) to dTMP by 
the action of the enzyme thymidylate synthase.
Thymidylate synthase
ENDOGENOUS PATHWAY (de novo)
Uridine-P04 (dUMP)
Thymidine dTDP— ► dTTP(dTMP)
^  Thymidine-P04 ^
Thymidine phosphorylase
EXOGENOUS PATHWAY (salvage)
Thymine+dR-1 -phosphate
Figure 1.4 De novo and salvage pathways of DNA synthesis
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Thymidine in the precursor pool is derived by both pathways but mainly by local 
production (de novo), although there is an inverse relationship. The utilisation of the 
endogenous production can be suppressed by exogenous thymidine is supplied in 
sufficient amounts and vice versa. Unless there is a shortage of DNA precursor 
nucleosides the rate of DNA synthesis depends on the “proliferative state” of the tissue 
and not on the concentration of precursors.
The previous mentioned studies in section 1.10.4 have demonstrated the use of thymidine 
in the estimation of the tumour growth fraction or labelling index and the relationship that 
this has with prognosis. The possible implications of how tumours with a higher or lower 
proliferative rate will respond to both chemo and radiotherapy is a field which has 
prompted much investigation in the nuclear medicine world through the conduit of 
thymidine labelled PET tracers.
1.9.2 Thymidine tracers for imaging proliferation
There are three main criteria in choosing a good imaging agent for PET imaging of cell 
proliferation:
i) Proliferating cells should take up the tracer and incorporate it into DNA or 
utilise it in the pathway of DNA synthesis.
ii) Metabolite production which could contribute to images should be kept to 
minimum.
iii) It must be readily labelled with a positron emitter for imaging.
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Radiolabelled thymidine
Since thymidine is not incorporated in the synthesis of RNA, it became the logical 
choice for measuring cell growth by introduction of the labelled thymidine nucleoside 
into the pool of exogenous substrate for growing cells. Labelled thymidine nucleotides 
would not be useful as tracers as they do not cross the cell membrane.
In view of this, the first PET radiotracer developed for the non invasive imaging 
of cellular proliferation was carbon 11 labelled thymidine. It is a short lived tracer with 
minimal radiation burden and the potential to be repeated during a course of therapy. 
[llC]-Thymidine was initially labelled in the methyl position [methyl-llCJthymidine 
(Christman et al., 1972; Sundoro-Wu et al., 1984) but during the 1990s further progress 
led to labelling in the ring 2 position, 2-[llC]thymidine. The difference in labelling 
positions is relevant in terms of metabolite production. Work by Conti and Goethals in 
the 1990s showed that to [methyl-1 lC]thymidine principally metabolises to radiolabelled 
thymine and labelled acidic metabolites (Conti et al., 1994; Goethals et al., 1995). These 
metabolites have access only into those cells that also accumulate thymidine and may not 
contribute to the background image in the same manner as more freely distributed 
metabolites. Shields et al found the main difference in labelling in the ring 2 position is 
that the principle metabolite is labelled CO2 ([11C]C02 ) which is readily transported 
into tissues and therefore ubiquitous (Shields et al., 1992; Shields et al., 1996). When 
compared to the metabolites of the methyl labelled tracer, the likelihood of labelled CO2 
becoming trapped within the cells is much less and hence it is easier to differentiate 
between the metabolites and the thymidine incorporated into the DNA when one is 
attempting quantitative models of thymidine kinetics.
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Both of these carbon 11 labelled tracers have been used in clinical studies. They 
have demonstrated uptake in a wide variety of human tumours. Eary et al studied the 
metabolism of 2-[llC]thymidine using PET in 13 patients with either primary or 
recurrent brain tumours and showed its potential for imaging brain tumour proliferation 
(Eary et al., 1999). Van Eijkeren et al looked at [methyl-llC]thymidine and its role in 
response to therapy in 13 patients with head and neck tumours. High tracer uptake 
specifically in the outer rim of tumour as compared to the central necrotic area was 
demonstrated (van Eijkeren et al., 1992). The role of [methyl-11 C]thymidine in renal cell 
carcinoma was investigated in 11 patients by Edgren and colleagues. They looked at pre 
and post PET scans following treatment with interferon and interleukin-2, and found that 
the images could correctly identify progressive tumours (Edgren M et al., 1995). The 
potential of 2-[llC]thymidine being used to detect response to therapy in small cell lung 
carcinoma and sarcoma was investigated by Shields, who found that tracer uptake 
decreased after successful chemotherapy but, one week following initiation of therapy 
tracer uptake remained unchanged in those patients with progressive disease (Shields et 
al., 1998a). Recently a study by Wells et al assessed proliferation in vivo using 2- 
[llC]thymidine PET in advanced intra-abdominal malignancies. This group found that 
2-[llC]thymidine PET derived parameters correlated with Ki-67 immunohistochemistry 
and that the measurement of 2-[llC]thymidine in tumours using PET can provide a 
surrogate marker of proliferation and also supports its potential as an early assessor of 
response to antiproliferative cancer treatment (Wells et al., 2002).
Although both the 2- and methyl labelled [1 lC]-thymidine show great promise as 
a PET tracer of cellular proliferation, their widespread use is hampered by the poor image
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quality and calculation of proliferation rates due to its rapid in vivo metabolic breakdown 
and the short half life of C-l 1.
These impracticalities of its use in routine clinical PET imaging has led to further 
research in a bid to develop a more stable thymidine analogue which has fewer labelled 
metabolites using longer lived isotopes. Several groups have looked at alternative tracers 
labelled with 18F or 1241 because of their longer half lives involving the investigation of 
18F-labelled 2’-fluoro-5-14C-methyl-l-beta D- arabinofuranosyluracil (FMAU) (Bading 
et al., 2000; Conti et al., 1995) and 1241-labelled-iododeoxyuridine (Blasberg et al., 
2000). This pursuit led to the development of 18F-3 ’-deoxy-3 ’-fluorothymidine (FLT).
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1.10 Development of FLT
1.10.1 Background
3’-deoxy-3’-fluorothymidine (FLT) was originally investigated as an antiviral 
chemotherapeutic agent in the treatment of patients with human immunodeficiency virus 
(HIV) (Flexner et al., 1994). Clinical trials were abandoned secondary to persistent 
haematological toxicity observed in patients treated with FLT. The first description of 
Fluorine -18 labelled FLT was by Wilson et al in 1991 (Wilson et al., 1991). Further 
modifications to the radiosynthesis by Grierson et al (Grierson and Shields, 2000), led to 
Machulla et al developing a simplified approach for the synthesis of FLT which was 
easily reproducible for a clinical application (Machulla et al., 2000).
1.10.2 Transport, metabolism and trapping of FLT
FLT enters the cell by the complex method of equilibrative facilitated diffusion. 
Work by Vijayalaskshmi and Belt found two sodium dependant mechanisms for transport 
of this thymidine nucleoside in mouse intestinal epithelial cells (Vijayalakshmi and Belt, 
1988). Further work involving nucleoside transport in human normal and neoplastic cells 
demonstrated the presence of two transporters, the nitrobenzylmercaptopurine riboside 
(NBMPR) sensitive equilibrative transporter and NBMPR insensitive equilibrative 
transporter (Belt et al., 1993).
It is difficult to conclude that FLT is a substrate of these sodium dependant 
transport mechanisms but from cell line experiments it has been shown that initially there 
is a rapid accumulation of tracer followed by a phase of much slower accumulation (Mier 
et al., 2002).
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1.10.3 Thymidine kinase
The initial rapid accumulation is thought to be associated with the metabolism of 
FLT. Once within the cell FLT undergoes phosphorylation by the cytostolic enzyme 
thymidine kinase-1 (TK1). TK1 is the principle enzyme in the DNA -  salvage pathway. 
TK1 catalyzes the one step ATP-dependant phosphorylation of thymidine to thymidine 
monophosphate which is then incorporated into DNA as decribed in section 1.9.1.
TK1 activity is selectively upregulated in the Gl/S transition phase of the cell 
cycle, reaching its maximum in the late S phase and then declines rapidly in the G2 phase 
(Sherley and Kelly, 1988). The imbalance in the enzymic characteristics of TK in colon 
tumours was first demonstrated by Herzfeld et al in 1978 who noticed that the mean 
activity of TK was several times higher than in non neoplastic colon (Herzfeld et al., 
1978). Further work by Weber et al again demonstrated that in rapidly growing human 
colon carcinoma xenografts the activity of this salvage pathway was again elevated 
(Weber et al., 1981). Increased activities of TK isoenzymes were also investigated by 
Sakamoto et al who found a five fold increase in human colon tumour cells when 
compared to colon polyps (Sakamoto et al., 1985). Following this, he also investigated 
the effects of carcinogenesis on colonic TK activity in FAP (see section 1.1.2) and 
highlighted that this enzyme might have potential acting as a biochemical marker in 
determining the subsequent development of CRC (Sakamoto et al., 1992). In contrast 
FLT is a poor substrate for thymidine kinase-2 (TK2), one of the other 
deoxyribonucleoside kinases (Toyohara et al., 2002).
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As a salvage pathway enzyme, TK1 fluctuates with DNA synthesis, the activity 
being high in proliferating and malignant cells and low or absent in quiescent cells 
(Munch-Petersen et al., 1995). This S phase specific role of the enzyme as a proliferative 
marker has been investigated in 1,692 primary breast cancer patients with high TK1 
values, proving TK1 to be an important risk factor in node negative disease. In addition, 
TK1 was associated with a beneficial effect in those patients receiving anti-metabolite 
chemotherapy, leading to the possibility of it having a role in forming the basis for new 
therapeutic approaches involving DNA salvage pathway inhibition using anti-metabolites 
(Broet et al., 2001).
The phosphorylation of FLT by TKI, leads to the formation of negatively charged 
FLT monophosphate (FLTMP) as shown in figure 1.5.
HO
TKI
FLT
Figure 1.5 Structure of FLT and FLT-MP, following phosphorylation by TK1.
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The negative charge is responsible for the intracellular trapping of FLTMP which, 
in a way analogous to the phosphorylation of FDG to FDG-6-phosphate by hexokinase, 
leads to the accumulation of radioactivity (see figure 1.6).
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Figure 1.6 Phosphorylation pathways of FDG and FLT (from Positron Emission Tomography scanning: 
current and future applications; Czernin J and Phelps ME. Annu. Rev. Med. 2002 53:89-112)
Via this metabolic pathway, FLT acts as a surrogate measure of proliferation by 
reflecting TKI activity in the cell cycle. Work to validate this has been carried out in 
cultured human lung carcinoma cells where FLT uptake was positively correlated with 
cell growth and TKI activity. When cell cycle progression was inhibited, it prevented an 
increase in TKI activity in addition to FLT uptake thus suggesting that FLT images are a 
reflection of TKI activity and the percentage of cells in S phase (Rasey et al., 2002). 
Further work by Toyohara et al, comparing [3H]FLT uptake with [3H]thymidine in 22
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asynchronously growing tumour cell lines showed a correlation between [ H]FLT uptake 
and both %S phase fraction (R=0.76) and [3H]thymidine uptake (R=0.88) again 
demonstrating that FLT uptake reflects tumour cell proliferation. In addition, the authors 
found that after 60 minutes incubation, over 90% of the [ H]thymidine was found to be 
incorporated into the DNA as compared to negligible (0.2%) amounts of [3H]FLT. The 
lack of [3H]FLT incorporation into DNA again highlights that FLT is a marker of cell 
proliferation through the enzyme TKI but is not (as thymidine is) a substrate for DNA 
synthesis (Toyohara et al., 2002).
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1.11 Aims of thesis
Following the success of FDG PET in the imaging of colorectal cancer I aim to 
investigate the new tracer of cellular proliferation 3’-[18F]Fluoro-3’-deoxythymidine 
(FLT) and its potential role in colorectal cancer imaging through conducting both 
clinical and cellular studies.
In chapter 3, the in vivo characteristics of FLT utilisation in colorectal cancer is 
investigated by comparing different analytical methodologies.
The potential use and impact that FLT could have in imaging CRC is addressed in 
Chapter 4, by conducting a comparative study with FDG in patients with proven CRC.
Having established that it can be used as an imaging tool in this disease, Chapter 5 
attempts to assess if it can be used to quantify cellular proliferation in vivo, by correlating 
quantification of in vivo uptake of FLT in CRC with quantification of proliferation using 
immunohistochemistry.
Finally in Chapter 6 the potential role of FLT in assessing response to therapy is 
attempted by conducting in vitro experiments with CRC cell lines and the 
chemotherapeutic agent 5 Fluorouracil.
The conclusions from this work are discussed in chapter 7.
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CHAPTER 2 
Materials and Methods
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2.1 Patients
The protocols for specific laboratory studies are described within the relevant 
chapters. To avoid repetition, this chapter covers the methodology which is common to 
all the clinical studies.
2.1.1 Patient recruitment
The patients who took part in the following studies were all prospectively 
recruited from surgical and oncology outpatient clinics. Inclusion criteria were simply the 
presence of primary or metastatic CRC or a combination of the two. The diagnosis of 
CRC was made on either histology or clinical and radiological follow up. Radiological 
follow up consisted of computerised tomographic colonography (CTC) or virtual 
colonoscopy (VC), see section 2.5 for details. In order for the studies to be conducted, 
approval was obtained from the Ethics Committees of University College London (UCL) 
and University College London Hospital NHS Trust (UCLH) (appendix B). Additionally 
the relevant approval from the Administration of Radioactive Substances Advisory 
Committee (ARS AC) was also obtained (appendix C).
The patient data set were stored within a Dell™ personal computer using 
Microsoft Excell™ software. The data were handled in accordance with the Data 
Protection Act and comprised the patient’s:
i) Name
ii) Age
iii) Date of birth
iv) Disease information
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v) Results of imaging
At no time did investigations relevant to this thesis hinder the routine process of 
clinical investigation and treatment of these patients.
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2.2 Whole body FDG-PET scan
2.2.1 FDG
The FDG used for the studies within this thesis was obtained from 4 centres:
i) Addenbrookes Hospital, Cambridge (Wolfson Brain Imaging Centre)
ii) Hammersmith Hospital (IRSL Cyclotron Unit)
iii) St Thomas’ Hospital (PET Centre)
iv) PET Net Pharmaceuticals (Mount Vernon Hospital)
Arrival of the tracer would be between 9.00 and 9.30am and, prior to injection into a 
patient, notification that it had passed its quality control would be confirmed by fax from 
the producing cyclotron. The dose calibrator in figure 2.1 was used to assay the FDG 
which underwent daily quality control testing before the tracer consignment was assayed 
(see appendix D). The delivery details documented the volume of liquid dispensed into 
the FDG vial, the time at which the FDG was measured prior to dispatch, in addition to 
the assayed activity. This information was recorded on a radiopharmaceutical holding 
patients record sheet (appendix E).
Figure 2.1 Dose calibrator
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FDG is drawn out of the dispensing station using a 23 gauge needle and a 5ml 
syringe in a lead syringe holder. Using the dose calibrator and the decay chart (appendix 
F) a dose of up to 400MBq (although a higher dose can be administered in heavier 
patients) was prepared for patient injection. The guidance for the clinical administration 
of radiopharmaceuticals is in appendix G.
2.2.2 Patient preparation
To achieve normoglycaemia, patients were asked to starve for six hours prior to 
the scan but were allowed to drink water. For tracer quantification purposes a patient 
information sheet was used to record a brief history, the patient’s height (cm), weight 
(Kg) and blood glucose level (mmol/1) (checked on a commercial glucometer 
(Glucometer Elite, Bayer Pharmaceuticals, Newbury, Berkshire, UK). A glucose level 
below 8.5mmol/l was accepted as a cut off for the studies in this thesis, in line with the 
protocol for clinical imaging in the Institute of Nuclear Medicine. The injected dose of 
tracer and the residual left in the syringe post injection were also recorded so an accurate 
administered dose could be calculated.
Prior to injection, the patient was cannulated using a 16 gauge cannula inserted 
into a forearm vein. To aid relaxation and help prevent the uptake of FDG in skeletal 
muscles 5mg of oral diazepam was also administered. Following injection the patient was 
left alone for 45 -  60 mins and asked to lie still before scanning.
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To achieve standardisation of the methodology patients were not routinely 
catheterised or given a diuretic to reduce renal tract accumulation of FDG, but were asked 
to empty their bladder immediately prior to scanning.
The patient was positioned on the scanning bed with feet facing away from the 
gantry with a pillow placed under the knees for comfort and arms placed on either side. 
Strapping was placed around the arms for support and to help keep them still.
Data sets from the base of the skull to the upper third of the lower limb were obtained for 
all whole body scans.
2.2.3 Acquisition of whole body FDG scan
In all patients except for two patients in chapter 3, Whole body FDG-PET 
imaging was performed in 2D mode using the Discovery LS™ (GE medical systems, 
Milwaukee, USA) which is the hybrid PET/CT scanner shown in figure 2.2. These two 
were imaged using the GE Advance™ (GE medical systems, Milwaukee, USA). In 
chapters 4 and 5 the PET emission datasets were attenuation corrected utilising the CT 
capability of the Discovery LS™ (Visvikis et al., 2003). Spiral CT scans were acquired 
using a speed of rotation and couch movement of 0.8s and 22.5mm per rotation, 
respectively, with a slice thickness of 5mm. The CT images were subsequently converted 
to maps of PET attenuation coefficients using a bilinear transformation (Visvikis et al., 
2003). Transaxial emission images of 4.3x4.3x4.25mm3 (matrix size 128x128x35) were 
reconstructed using ordered subsets expectation maximisation (OSEM) with two 
iterations and 28 subsets. These slices were re-orientated to produce whole body coronal 
and sagittal images.
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Figure 2.2 Discovery LS™ hybrid PET/CT scanner (GE medical systems, Milwaukee, USA)
In order to minimise any potential bias introduced by using different attenuation 
correction techniques within the patient group considered in chapter 3, all o f the patients 
included in that group had their PET images corrected for attenuation effects using the 
two rotating 68Ga/68GE rod sources.
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2.3 Whole body FLT- PET scan
2.3.1 Radiosynthesis of FLT
The FLT used for the studies within this thesis was produced by the IRSL 
Cyclotron Unit (Hammersmith Hospital). This was developed by Cleij et al at the IRSL 
(Cleij MC et a l, 2001), using an automated synthesis system, a photograph of the system 
with a corresponding schematic diagram below is shown in figure 2.3 .The complex 
radiochemistry leading up to this method of FLT synthesis is outside the scope of this 
thesis but below is a simplified, brief description of the final production method for
human use with references to the components seen in figure 2.3.
18Enriched H2 0 was irradiated and transferred into a glassy carbon vessel (figure 
2.3). Kryptofix 2.2.2 (15mg, 40pmol) and K2CO3 (30 pmol) in acetonitrile (1ml) was 
added to the [18F]fluoride and the vessel heated to 140°C for 6min under helium. From 
reservoir 2 a second addition of acetonitrile (0.2ml) was made and the vessel heated to 
170°C for 3min. Dimethyl Sulfoxide (DMSO) (1.0ml) was then added from loop 1 over 
30 seconds and the mixture stirred for lOmin at 170°C. A solution of the [18F]FLT 
precursor (20mg) in DMSO (0.2ml) was added from loop 2 over 10s. The vessel was 
sealed and the reaction mixture heated for lOmin at 170 °C. The vessel was then cooled to 
100 °C over 5min. Aqueous 1M Hydrochloric acid (HCL) was added from loop 3 and the 
reaction mixture stirred for lmin. An aqueous solution of (NaOAc) (0.5M, 1.5ml) from 
reservoir 3 was then added and the reaction mixture passed through a neutral alumina 
Sep-pak. From reservoir 4, 2ml of water was transferred via the reaction vessel through 
the Sep-pak. The combined aqueous eluate was loaded onto a semi-prep Cis column
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Figure 2.3 Automated FLT synthesis system (top) with schematic diagram of apparatus (bottom).
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(Phenomenex Luna, 250mm, 5p) and eluted with 10% ethanol at a flow rate of 
7.0ml/min. The eluate was monitored for radioactivity and absorbance at 254nm. 
[18F]FLT was eluted between 10-12min. The radiosynthesis produced between 1.85 -  
3.70 GBq of tracer in 60min using this automated synthesis system.
Prior to dispatch from the IRSL, the FLT would undergo quality control testing; 
received doses were >95% pure.
2.3.2 Dose calibration
On arrival, the FLT was assayed using the dose calibrator in an identical manner 
as previously described for FDG. The same information recording drawing up process 
was also employed (see section 2.2.1).
2.3.3 Patient preparation
For FLT scanning patients were not asked to starve, as glycaemic state has no 
influence on cell proliferation. The rest of the patient preparation was as described for 
FDG in (section 2.2.2).
2.3.4 Acquisition of whole body FLT- scan
The same hardware was utilised to acquire whole body FLT images as has been 
previously described (section 2.2.3). The datasets were also attenuated corrected in the 
same manner.
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2.4 Evaluation of tracer uptake
A number of strategies exist for quantifying tracer uptake. For this thesis the 
following methods in increasing order of complexity were employed:
2.4.1 Visual analysis
Visual qualitative inspection of static images are made after tracer accumulation 
reaches its plateau concentration. This technique is useful for the identification of focal 
areas of high tracer accumulation within metabolically active areas. The advantage of 
visual analysis is that it is simple but the interpretation of subtle changes is difficult.
Whole body data was analysed in terms of the pattern of distribution of labelled 
FDG and also with respect to the measurement of tracer uptake at a specific site. The 
quality of the data obtained depends significantly on the figures of merit of the instrument 
used, software available and amount of tracer administered. Normal and significant FDG 
uptake is always seen in the brain, frequently, but variably, in the myocardium, stomach, 
liver, spleen, muscle and the lumen of the gastrointestinal tract. The bone marrow is seen, 
with variable intensity, often reflecting response to chemotherapy. The FDG tracer is 
eliminated by the kidneys, which are depicted along with the urinary bladder. Since the 
data is recorded in 3D, data sets formatted into any plane (transaxial, coronal, and 
sagittal) can be displayed and inspected.
Consensus reporting was used to analyse and issue a clinical report on each FDG- 
PET scan. This procedure involved visual inspection of coronal, sagittal and transaxial 
images for each patient in addition to the CT data in those scans acquired using the GE 
Discovery LS™. Those present at each reporting session would include at least one
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Nuclear Medicine physician of consultant grade and the physicist and radiographer who 
carried out the injection and imaging.
Direct comparisons were made between the FDG PET scan and the corresponding 
FLT PET scan by a consensus opinion using visual inspection on a lesion by lesion basis.
2.4.2 Regions of interest
With the exception of chapter 6, a region of interest (ROI) approach was used to 
semiquantitate tracer uptake within both normal and malignant tissue.
In the case of the tumours, ROIs were drawn over all identified lesions in the 
images. Since the use of ROIs that encompass the lesions in their entirety, or the use of 
the slice with the maximum count density, may not provide an accurate activity 
concentration in the tumour active region, the method validated by both Lodge et al and 
Eary et al was employed (Eary and Mankoff, 1998; Lodge et al., 1999). Lodge’s study 
used ROIs to look at FDG uptake in soft tissue masses and Eary investigated FDG 
metabolic rates in sarcoma. For each of the ROIs, five consecutive slices were used. The 
slices selected were comprised from the one with the maximum count density over each 
volume of interest and the four immediately adjacent slices.
2.4.3 Semi-quantitative analysis of tracer uptake (Standardised uptake 
values)
In order to obtain more than just qualitative findings in cancer studies semi- 
quantitative evaluations have been adopted. One such evaluation is the standardised 
uptake value (SUV) which is synonymous with the differential uptake ration (DUR) or
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differential absorption ratio (DAR) .These parameters relate to the value of activity 
concentration found in a certain tissue volume of interest to the injected activity per the 
patient’s body weight This allows inter individual differences and varying amounts of 
administered activity to be taken into account. It must be remembered with this technique 
that the amount of activity found in a region is not always static and may change after 
tracer injection by increased uptake of the PET tracer or by washout of the tracer from the 
tissue; this is considered in more fully quantitative methods which are discussed below. 
SUVs are commonly used in PET oncology studies allowing an index of tracer uptake in 
a tumour which may permit differentiation between benign and malignant lesions.
For the studies in this thesis, SUV was defined as:
SUV = ———
Where (A) is the average tumour activity concentration in kBq/ml, (W) the 
patient's body weight in kg and (Ain)  the injected activity in kBq (Graham et al., 2000; 
Takeuchi etal., 1999)
The calculated value relates to the activity concentration found in a certain tissue region 
of interest (ROI) to the activity per the patient’s body weight. In this way inter individual 
differences and varying amounts of administered activity are taken into account The 
amount of activity found in a region is, however, not always static and may change after 
tracer injection by increased uptake of the tracer or by washout of the tracer from the 
tissue.
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2.4.4 Quantitative analysis of tracer uptake
A quantitative measurement of local tracer utilisation can be obtained using a 
kinetic model that closely resembles the movement of the tracer in vivo.
These types of kinetic studies were used in chapter 3 to provide a means of 
obtaining values for physiological parameters for FDG and FLT in absolute units. For 
example using FDG, glucose metabolic rate can be determined in mol/min/g. The 
metabolic rate of a tracer is quantified by using the time course of radioactivity in tissue 
and in blood. This provides a more detailed description of the uptake characteristics and 
the possibility to determine individual rate constants. The explanation of this follows and 
is in terms of rate of glucose metabolism (MRgiuc) using FDG and is given by:
MRgiuc= (CP/LC) . {Ki. K3/(K2+K3)}= (CP/LC)Ki 
CP is the plasma concentration of glucose.
Ki and K2 are rate constants for forward and reverse capillary transport of FDG.
K3 refers to the rate of phosphorylation of FDG.
LC is the lumped constant relating FDG kinetics to that of glucose. Although this 
constant has been evaluated for brain (Lodge et al., 1999), it is not clear what value this 
should take in tumours. For the studies of this thesis the accepted value of 1 was used.
Ki is the net rate of influx of FDG.
For the calculation of this measurement, a dynamic imaging sequence (section 
1.5.2) with simultaneous arterial blood sampling (section 3.3.3) is used and the model 
rate constants are estimated by fitting the tissue and plasma tracer concentrations data to 
the compartmentalised model which is shown schematically below. A fourth parameter 
can be introduced (K4), this represents the rate of dephosporylation of the tracer. The
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three-compartment model of FDG kinetics with the respective rate constants is 
demonstrated in figure 2.4. The same model is shown in relation to FLT metabolism in 
figure 2.5.
Plasm a membrane
Plasma pool Precursor pool Metabolite pool
Figure 2.4 Three compartment model of FDG kinetics
Plasma Tissue
FLT
Pyrim idin^
Thymidine 
Kinase 1
FLT FLT-P
Transport Thymidine
dephosphorylase
Ki
K4:
Figure 2.5 Metabolic pathway of FLT within three compartment kinetic model.
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The two methods used in chapter 3 to fully quantify uptake of FLT were Patlak
graphical analysis and Non linear regression.
i) Patlak graphical analysis
Patlak et al developed a model which can be used for any tracer where uptake in 
the final compartment is irreversible and assumes no dephosphorylation and therefore K* 
to be zero. Although it must be realised that if K4 is not zero then there will be an 
underestimation of the metabolic rate of the tracer. This method does not allow for the 
calculation of the individual rate constants Ki and K3 (Patlak et al., 1983).
This is based on the assumption that the ratio of the tracer concentration in tissue 
to that in plasma is linearly increasing when plotted as a function of normalised time, and 
is given by the following expression:
where, Ci(t) and Cp(t) is the tracer concentration in tissue and plasma at a particular time 
point t respectively, Ki is the tracer blood-tissue transfer constant or influx rate constant, 
V is a constant related to the blood volume.
plots the time point where the linear behaviour commenced. Ki as the net influx constant 
was subsequently obtained from the slope of this linear part of the plot in units of 
ml/g/min.
? V / _ 0_____
C p(t)  '  Cp(t)
+ v
For chapter 3, visual inspection was used to determine from the Patlak
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ii) Non linear regression
The most straight forward method used to estimate the metabolic rate of a tracer is 
by fitting tissue time activity curves to a two-tissue compartment model using an arterial 
input function and non-linear regression routines by means of a mathematical model 
(Huang et al., 1980). This method has the advantage of not only obtaining the Ki but also 
the enzyme (K3) activities.
There is debate regarding whether the hydrolysis of FDG-6-PO4 to FDG (K4) by 
phosphatase should be taken into account when estimating the metabolic rate of glucose. 
Original work by Sokoloff et al and furthered by Reivich et al (Reivich et al., 1979; 
SokolofF et al., 1977) demonstrated negligible hydrolysis in the brain and therefore did 
not take K4 into account. The opposite was found by Okazumi et al in hepatocellular 
carcinoma, where K4 values were found to be similar or greater than K3 this can be partly 
explained by the high level of glucose-6-phosphatase activity.
It is now accepted that for each tumour the presence and possible effect of K4 
should be investigated in order to establish its inclusion.
Dynamic imaging sequences as discussed in section 1.5.2 are required in order to 
establish time-activity curves. In addition arterial sampling as described in chapter 3 is 
also needed for the determination of an input function as well as blood time activity 
curves.
A three compartment (4K) model was used in Conjunction with non-linear 
regression analysis. The kinetic constants describing the tracer pharmacokinetics for the 
three compartment model used were: Ki and K2 as the influx and efflux constants
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respectively between the plasma to the free tracer compartment, while K3 and K4 are the 
rates of phosphorylation and dephosphorylation respectively.
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2.5 Computerised Tomography
2.5.1 Patient preparation
i) CT abdomen, pelvis, liver and chest
Patients are asked to not eat anything for four hours prior to the scan and can drink non- 
fizzy drinks upto one hour before the scan. No other special preparation is required. Oral 
contrast may be given just prior to CT of the abdomen and pelvis.
ii) CTC (CT pneumocolon)
Bowel preparation in order to clean the colon was required and this took place the day 
before the examination. Preparation involved ingestion of one sachet of oral picolax the 
day before the CTC (between 7.30 and 9 am for a morning appointment and before 7pm 
for an afternoon appointment). Patients were encouraged to drink clear fluids 
(approximately 500ml per hour) continuously and a low residue diet was allowed until 
approximately 18 hours prior to the scan. Immediately before the scan, patients were 
required to drink two glasses of water.
2.5.2 Image acquisition
i) Abdomen, pelvis and liver
CT scans of the abdomen and pelvis were contrast enhanced and performed in either a 
Somatom Plus 4 or a Somatom Plus 4 Volume Zoom (both Siemens AG Medical 
Engineering Group, Forchheim, Germany). The contrast used was Omnipaque 350 
(Nycomed Amersham pic, Amersham Place, Little Chalfont, Bucks, UK.). Scanning 
protocol with the Somatom Plus 4 for the abdomen and pelvis involved 5mm contiguous
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slices after giving 100ml intravenous contrast at 4ml per second with a 45-second delay. 
For bi- or triphasic liver imaging patients were scanned at 20s, 50s, 180s with slices being 
5mm thick at 2.5mm intervals. For the Plus 4 Volume Zoom CT scanner, abdomen and 
pelvis imaging involved dynamic multislice imaging with 3 mm contiguous 
reconstructions after giving 100ml intravenous contrast at 4ml/s with a 45 second delay. 
For bi- or triphasic liver imaging patients were scanned at 35s, 50s, 180s with slices being 
3mm thick at 1.5mm intervals.
ii) Chest
Standard, non-contrast enhanced scans were performed as detailed above.
iii) CTC (CT pneumocolon)
Patients were given 120ml of Omnipaque 350 intravenously at a rate of 5ml/s and 
scanned after a 25s delay. Scanning took place in the prone and supine positions (in order 
to reduce faecal artefact that may obscure mucosal lesions) after an initial scanogram was 
taken.
2.5.3 Image reconstruction and analysis
All data was processed on the CT scanner Siemens workstation where images 
were reconstructed accordingly. Images were usually formatted into the transaxial plane, 
but when necessary coronal and sagittal prints were produced on a SUN microsystems 
workstation.
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A Radiologist of specialist registrar or consultant grade evaluated all images. In 
addition, all CT scans were presented at a weekly CRC MDT meeting where they were 
re-evaluated by a Radiologist of consultant grade. All films were visually analysed.
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2.6 Confirmation of diagnosis and follow up
In line with guidelines issued by the government on optimal individualised care 
for patients with a confirmed diagnosis of CRC, a multi d isc ip lin a ry  team (MDT) 
managed all those patients presented in this thesis. This group consisted of both medical 
and allied healthcare professionals. Included in the group were radiologists, nuclear 
medicine physicians, surgeons, medical and clinical oncologists as well as nursing staff. 
The objective of the MDT is to offer the CRC patient the optimal care by harnessing the 
expertise of a variety of medical specialities, rapid referral between the specialists and 
maintenance of high standards through audit.
This group made consensus decisions regarding the clinical management of 
complex cases and therefore formed an ideal forum to present both PET and CT data in 
order to decide management based on this and relevant clinical information.
All diagnoses in the studies related to this thesis were confirmed either on 
histological evidence following biopsy or surgery or by careful clinical and radiological 
follow-up within the CRC MDT.
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CHAPTER 3
Characterisation of in vivo FLT 
uptake in colorectal cancer
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3.1 Background
PET allows the quantitative measurement of the concentration of positron- 
emitting tracers within a three-dimensional object in vivo. By using different 
radioligands, specific types of regional tumour metabolism can be measured. In the case 
of FDG the final aim has been the quantitative determination of glucose uptake. Since 
tumours exhibit a variety of different histological characteristics, the measurement of the 
rate constants within a “compartmentalised system” discussed in section 2.4.4 has to be 
independent, in order that values for physiological parameters in absolute units can be 
obtained. This will lead to a quantitative measurement of local tumour utilisation with 
regard to that tracer.
In this situation individual rate constants may be determined with the help of a 
dynamic PET measurement. This requires arterial blood sampling simultaneously with 
the PET image measurement. The resulting time activity curves can be evaluated by 
fitting the measured data to the dynamics of the tracer model so that the rate constants 
may be obtained.
The dynamic approach to determine individual rate constants is not readily 
compatible with the whole body PET protocols described in section 2.2.3. Dynamic rate 
constant measurements require additional imaging time, therefore this is not practical for 
routine clinical use and for the most part is limited to scientific investigations into new 
tracers. The acquisition of this dynamic data is described in the methodology of this 
chapter.
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3.2 Aims
The aim of this chapter is to study the in vivo metabolism and pharmacokinetics 
of FLT in patients with primary and metastatic CRC. The objectives are to
i) compare uptake patterns of FDG and FLT.
ii) investigate potential methods for the quantitative assessment of in-vivo FLT 
utilisation.
iii) compare semi-quantitative with fully quantitative measures of FLT uptake.
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3.3 Methods
3.3.1 Patient recruitment
All patients recruited for this study presented with either primary of metastatic 
CRC. This cohort was made up of patients referred internally to the UCLH NHS trust 
multidisciplinary team in addition to those referred from peripheral district general 
hospitals.
All patients were asked to give written consent following a full explanation of the 
procedure (appendix H).
Pre-scanning preparation details for both FDG and FLT imaging can be found in 
chapter 2.
3.3.2 Dynamic data acquisition
A total of eleven patients with a total of 20 malignant lesions (4 primary, 6 liver 
metastases, 5 lung metastases, and 5 extrahepatic metastases) were included in this 
investigation. All patients underwent FDG scanning followed by an FLT investigation 
with a median intervening period of 4 days (range 1 -7). Imaging comprised of a 60min 
dynamic acquisition which commenced immediately following bolus tracer 
administration. The location for the dynamic acquisition was such that wherever 
available, multiple lesions were included in the field of view. That location was 
determined in conjunction with the CT scans available.
All data was acquired in 2D mode using the GE Advance in the case of 2 patients 
and the GE Discovery LS in the remaining 9. For the latter cases the CT facility was used 
to aid in the exact localisation of lesions. In order to keep all parameters during data
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acquisition consistent within the group of patients included in this study, the CT 
attenuation correction capability of the GE Discovery LS was not employed. All emission 
datasets were corrected for attenuation using data acquired with two rotating 68Ga/68Ge 
rod sources.
The dynamic acquisition comprised of the following frame durations: 15 x 5 
seconds, 3 x 15s, 6 x 20s, 11 x 60s, 9 x 300s. The time of transmission acquisition was 3 
mins per axial field of view, which has been shown in the past by Visvikis et al to be 
reliable in reducing the overall data aquistion time without compromising the accuracy of 
SUV measurements (Visvikis et al., 2001). Transmission data was corrected for post­
injection emission contamination and processed using an unsupervised segmentation 
algorithm prior to its utilisation for the attenuation correction of the emission data as 
described by Bettinardi et al (Bettinardi et al., 1999).
Transaxial emission images of 4.3 x 4.3 x 4.25mm3 (matrix size 128 x 128 x 35 
slices per axial field of view) were reconstructed using Ordered Subsets Expectation 
Maximisation (OSEM) with 2 iterations and 28 subsets. All images were decay corrected 
to the time of the first frame of the dynamic series and both scatter and random 
corrections were applied.
Following the end of the dynamic acquisition a whole body scan was performed 
with emission frames of 5min per bed position as described in section 2.2.3.
3.3.3 Acquisition of blood sampling data
Both arterial and venous blood was analysed in each FLT study. No blood 
sampling was undertaken during the FDG scans. Arterial blood was drawn from an
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arterial line inserted into the patient’s radial artery. Prior to this, bilateral arterial supply 
to the hand was confirmed and documented with hand held Doppler (Huntleigh 
Healthcare). Any doubt in the detectable presence of both a patent radial and ulnar artery 
excluded the patient from the study. The local anaesthetic lignocaine (2%, 0.5-1 ml) was 
infiltrated subcutaneously followed by insertion of a 20 gauge cannula into the radial 
artery. The cannula was connected to a 3-way tap to aid rapid blood letting. Intermittent 
flushing of the line with heparinised saline prevented the arterial line from clotting off.
Venous sampling was carried out through a designated line, on the opposite side 
to the arterial line. This was via a 16 -  18gauge cannula which was inserted into a large 
forearm vein or into a vein in the ante-cubital fossa. Again a 3-way tap was attached and 
the line was regularly flushed.
In order to allow access to both the arterial and venous lines during the dynamic 
acquisition phase of the scan, the patient was positioned with arms above the head, 
supported by both arm and head rests. Figure 3.1 demonstrates the patient position used 
including the sites of both sampling cannulas. In addition, the venous line used for tracer 
injection is also shown.
A series of manual blood samples were taken from the arterial and venous lines 
during acquisition of the dynamic scan. A stop watch was started which coincided with 
the start of the scan enabling sampling at specific time points. A sample was taken every 
7s for the first 2min post injection, followed by 30s intervals for the next 2min. Between 
5-10min, a sample was drawn every minute, followed by 5min sampling up to 30 
minutes. Thereafter blood samples were taken in lOmin intervals until the end of the 
scan.
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Figure 3.1 Patient positioning for arterial and venous blood sampling. The arterial and venous sampling 
cannulas are shown (a) and (v) in addition to the injection cannula (i).
The blood samples were collected in labelled 2ml syringes and a portion of each 
sample was centrifuged in the Eppendorf Minispin (Eppendorf AG, Hamburg, Germany) 
to obtain plasma information (figure 3.2). Activity concentration in both the blood from 
the original sample and plasma from the centrifuged sample for both the arterial and 
venous blood was measured using a Gamma counter (1282 Compugamma, Universal 
Gamma Counter, Wallac, Crownhill, Milton Keynes, UK.) shown in figure 3.3. The 
counter had previously been cross calibrated with the scanner.
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Figure 3.2 Eppendorf minispin centrifuge (Eppendorf AG, Hamburg, Germany)
Figure 3.3 Gamma counter (1282 Compugamma, Universal Gamma counter, Wallac, Crownhill, Milton 
Keynes, UK.)
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3.3.4 FLT metabolite analysis
At certain time points 10ml volumes of blood were withdrawn for FLT metabolite 
analysis. These time points were at 5min, 15min, 30min, 60min and 90min post injection. 
After the blood was centrifuged, cell -  free plasma was prepared by mixing plasma (1ml) 
with methanol (9ml). Following centrifugation (3000rpm, lOminutes) the supernatant 
was concentrated in vacuo and the residue reconstituted in mobile phase [MeCN- 0.1M 
KH2PO4 (15 : 85 v/v)]; 1.5ml. The reconstituted sample was filtered (Millipore MV 
Syringe filter, 0.4pm, Waters, Elstree, Herts, UK.) before injection on a Waters p- 
Bondapak C l8 column (300 X 7.8mm; Waters, Elstree, Herts, UK.) and eluted with 0.1M 
potassium dihydrogen phosphate-acetonitrile (85: 15v/v) at 3ml/min. The HPLC eluate 
was monitored sequentially for absorbance at 286nm and radioactivity. The fraction of 
unchanged FLT was determined by integrating the areas under the radioactive curve for 
each sample. FLT eluted on this system had a retention time of 9min.
3.3.5 Data analysis
i) Regions of interest and time activity curves
Regions of interest approach as described in section 2.4.2 was used to analyse the 
reconstructed FDG and FLT images in order to obtain time activity curves (TACs) for 
malignant lesions in addition to the normal liver. Since bone marrow has been another 
organ identified as having high physiological uptake of FLT (Shields et al., 1998b), 
TACs were also obtained for normal bone marrow.
To construct a TAC, ROIs were identified in an image created from the sum of 
the last three frames of the dynamic acquisition series and then placed over the complete
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series. In the normal liver, ten 20mm diameter regions were drawn in the late summed 
image and projected to the whole of the dynamic series. The mean of these ten average 
activity concentrations was subsequently calculated for each image in order to yield the 
normal liver TAC. For the normal bone marrow, three ROIs were placed in consecutive 
slices over the same vertebra.
ii) Image derived input function
The image derived, input function utilises the measured activity in the abdominal 
aorta of human subjects to non-invasively estimate blood-pool input function in 
abdominal PET scans.
To calculate the image derived input function ROIs were placed over the 
abdominal or thoracic aorta (AA and TA), depending on the body location where the 
dynamic images had been acquired. These ROIs were drawn over six consecutive 
transaxial slices on the summed image of the frames acquired between 30s and 60s post 
injection. These same ROIs were then projected onto the complete dynamic datasets and 
TACs were subsequently derived.
iii) Standardised uptake value
Standardised uptake values were calculated using the method described in section
2.4.3.
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iv) Patlak analysis
The linearised model for irreversible tracer uptake developed by Patlak was used 
(Patlak et al., 1983) and has been described in detail in section 2.4.4(i).
iv) Non linear regression and three compartment model
A weighted non-linear regression algorithm was used to fit the plasma or image 
derived input function and the tissue TACs to this model. All the plasma and image 
derived input functions were corrected for the presence of metabolites prior to their use in 
the model fitting. In both models all kinetic constants were estimated by minimising the 
sum of square differences between the tissue TACs and the model output values. The data 
was also fitted with a K4 set equal to zero and described forthwith as the three 
compartment model (3K). This 3K model was derived in order to further determine the 
effect of dephosphorylation in the first 60 minute dataset used in this analysis as 
previously explained in section 2.4.4 .
A combination of the individual kinetic parameters was determined from both the 
4K and 3K model. The Kj by non linear regression analysis was calculated using the 
following expression in order to provide a direct comparison to the Ki (patlak) determined 
using Patlak analysis.
K x*k3Kj (NLR) =
k2 +k3
The kinetic modelling described in this section was performed using JAVA based 
software called PMOD (Biomedical Image Quantification & Kinetic Modelling Software, 
www.PMOD. com) (Burger and Buck, 1997).
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3.3.6 Statistical analysis.
A paired two-sided t test and correlation analysis was used (Microsoft Excell™ 
software) in order to assess the significance of any differences in the kinetic constants 
obtained using the quantitative methods (Patlak, NLR(4K) and NLR(3K)) for deriving in 
vivo measures of FLT utilization evaluated in this study. The correlation between the 
SUVs and these quantitative indices was also assessed. In addition, the statistical 
significance of any differences in the Ki values obtained as a result of using image 
derived compared to measured plasma input functions was evaluated. All statistically 
significant levels were set at 5% (p<0.05).
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3.4 Results
3.4.1 T im e activity  curves
The time course of SUVs for both FDG and FLT is shown in figures 3.4 and 3.5 
respectively.
These figures demonstrate TACs for two liver metastases and two lung metastases 
present in one of the eleven patients who underwent dynamic scanning using both tracers. 
In the case of the FLT there is rapid accumulation up to lOmin post injection, which is 
subsequently followed by a much slower rate of SUV increase when compared to the 
TAC seen with FDG.
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Figure 3.4 FDG time activity curve for two liver and two lung m etastases from the sam e patient
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Figure 3.5 FLT time activity curve for two liver and two lung m etastases from the sam e patient.
The temporal response of the uptake of FDG and FLT in normal liver and a 
solitary liver metastasis from the same patient is shown in figures 3.6 and 3.7 
respectively. In addition figure 3.7 demonstrates the high physiological uptake of FLT 
which is expected to be seen in the rapidly proliferating bone marrow.
The areas of high physiological uptake seen graphically in these figures are 
demonstrated in figure 3 .8 , which displays the normal uptake pattern of FLT.
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Figure 3.6 FDG time activity curve comparing uptake in normal liver and a liver metastasis.
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Figure 3.7 FLT time activity curve comparing uptake in normal liver and bone marrow with that of a liver 
metastasis.
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Figure 3.8 Normal FLT uptake demonstrated in coronal whole body images. Increased physiological activity 
is seen in the liver, bone marrow, right ureter and bladder.
3.4.2 M etabolite  analysis
Deproteinisation of plasma with 9 equivalents o f acetonitrile before HPLC analysis
18consistently recovered greater than 85% of the total FLT radioactivity in plasma. The 
percentage of radioactivity that precipitated with proteins showed no relationship with 
sampling time.
Metabolite analysis on HPLC of samples, revealed that 2 radioactive metabolites of FLT 
were eluted off of the column before the unchanged parent with retention times of 4.2 and
5.5 min (figure 3.9) The parent compound eluted l lmin  after the sample was placed on 
the HPLC column. By this time 90-100% of the injected radioactivity was
recovered.
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Figure 3.9 Chromatogram demonstrating the temporal relationship of the different radioactive components 
in arterial plasma. The chromatogram shown is of a plasma sample taken at60m ins post FLT injection. The 
two polar metabolites are shown by peak (a) and peak (b). The parent compound is seen in the third peak
(c).
The time course (15min - 90min) of the parent compound and the metabolites is 
shown as a percentage fraction of the total plasma activity in figure 3.10. The fraction of 
radioactivity in the plasma attributed to unchanged 18FLT, 60min after injection ranged 
from 55-80% (mean 68.9%, SD 7.8%). Although the amount of metabolites in the 
plasma increased steadily from <4% at 5 min p.i,. to <30% at 60 min p.i., the rate of 
increase after 60min was greatly reduced.
For the arterial input function, the ratio of tracer concentration between blood and 
plasma was ~1.05-1.15, while in the case of the venous blood this difference was <10%. 
Although on the fraction of unchanged parent obtained from venous and arterial plasma, 
there was a tendency for venous plasma to slightly overestimate the fraction of plasma 
radioactivity attributed to FLT.
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Figure 3.10 Plot demonstrating the average time course of the parent compound and the metabolites as a 
percentage fraction of the total plasma activity (error bars demonstrate the range of values obtained for the 
11 patients).
3.4.3 P a tlak  analysis
The input function obtained using the abdominal or the thoracic aorta was in 
excellent agreement with the plasma input function as shown in figure 3.11. There is an 
inevitable slight time delay demonstrated between the input function derived from the 
arterial sampling and the one derived from images o f the abdominal aorta.
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Figure 3.11 Plot demonstrating for the sam e patient the relationship between a blood input function derived 
using arterial blood samples and that derived using ROI analysis over the arterial aorta in a series of 
dynamic FLT images.
The mean time between injection and the start of the linear phase in the Patlak 
plot was found to be 250sec ranging between of 3-7 minutes. Using the data from the 
start of the linear phase an accurate fit was observed up to the 60min data used in the 
analysis. An example of a Patlak plot for one of the liver lesions is shown in figure 3.12. 
The mean K; values obtained for the bone marrow and the lesions, using the plasma input 
function in the fitting of the model are shown in table 3.1.
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Figure 3.12 Example of a Patlak plot for a liver metastasis.
Patlak Mean Kj Standard Range
(ml/gr/min) Deviation (ml/gr/min)
BONE MARROW 0.125 0.064 0.095 -0 .219
LESIONS 0.092 0.036 0.035 -0.143
Table 3.1 Mean Kj values for normal bone marrow and lesions (primary / liver / lung / extrahepatic) using 
Patlak analysis with arterial blood derived input function.
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In comparison, the use of the image derived input function, including both the 
abdominal and thoracic aorta resulted in a mean difference of <4.5% in the estimation of
Ki.
No statistically significant differences were obtained between the two 
methodologies.
The correction for the presence of metabolites in the plasma input function again 
did not result in a statistically significant difference in the K; values (p>0.01).
Very good correlation (R2 = 0.8551) between the proliferation rate expressed by 
the influx rate constant K; values and the corresponding SUVs measured from the same 
lesions using the last frame of the dynamic dataset acquired is shown in figure 3.13.
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Figure 3.13 Plot of proliferation rate ( K j )  using Patlak analysis and the SUVs measured from the sam e 
lesions.
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3.4.4 Non-linear regression
Mean Kj for both 3K and 4K values for the malignant lesions (primary, 
liver, lung and extrahepatic) and the bone marrow are shown in the tables 3.2 and 3.3 
below.
3K Mean K; Standard Range
(ml/gr/min) Deviation (ml/gr/min)
BONE MARROW 0.102 0.054 0.068-0.179
LESIONS 0.079 0.029 0.031-0.135
T able 3.2 Mean Ki values using NLR analysis and 3K model.
4K Mean Ki Standard Range
(ml/gr/min) Deviation (ml/gr/min)
BONE MARROW 0.092 0.058 0.052-0.144
LESIONS 0.085 0.0 0.039 -  0.141
Table 3.3 Mean Ki values using NLR analysis and 4K model.
Again no statistically significant differences were found between the utilisation of 
the plasma or the image derived input functions.
The average value of K4 was not significantly different than zero in both lesions 
and bone marrow, although it was slightly higher in the case of the lesions as shown in 
table 3.4.
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k 4 Mean K4 Standard Range
(ml/gr/min) Deviation (ml/gr/min)
BONE MARROW 0.001
LESIONS 0.004 0.002 0.0015-0.009
Figure 3.4 Average value of KU in lesions (primary, liver, lung and extrahepatic) and bone marrow.
Additionally a worse correlation was demonstrated between the SUVs and the 
corresponding Kj(4K) (R2=0.49) in comparison to Ki (3K) (R2=0.85).
0.16
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Figure 3.14 Correlation between Ki determined using (4K) model and the corresponding SUVs.
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Figure 3.15 Correlation between Kj determined using (3K) model and the corresponding SUVs.
Finally figure 3.16 shows that the K; derived from the linear part of the Patlak 
analysis correlated highly (R2 = 0.9362) with the equivalent parameter derived from 
Kj(3K).
136
0.16
FT = 0.93620.14 -
0.12 -
0.10 -
0.08 -
0.06 -
0.04 -
0.02 -
0.00
0.00 0.02 0.04 0.16
NLR Kj(3k) (ml/gr/min)
Figure 3.16 Correlation between Kj derived from Patlak analysis and that derived using NLR (3K) model.
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3.5 Discussion
Previous metabolite analysis carried out in dogs has shown 90-97% of activity in 
late blood sample as unmetabolised 18FLT (Shields et al., 2002). In the same animals, this 
limited metabolism was also associated with low liver uptake. However, the results of our 
study in relation to FLT metabolism in humans demonstrate the presence of 
approximately 70% of the activity as unmetabolised tracer at 60min p.i. This is in 
addition to the presence of significant uptake and retention in the liver. The slower rate of 
increase of the metabolites in plasma observed after 60min p.i is in agreement with 
previous work (Shields et al., 2000) that has suggested a preferential clearance of the 
glucuronide compared to the parent compound in urine after 60min p.i.
The methodology employed for the metabolite analysis in our study was chosen 
for its high level of reliability and it can be used in a routine clinical setup. In this study 
two metabolites have been observed, which is in contrast with the work carried out 
previously by Shields et al (Shields et al., 2002) where only the presence of glucuronide 
was reported. In view of these findings and the fact that further characterisation of the 
two metabolites was not carried out due to unavailability of technical resources, I have 
hypothesised that these metabolites are free F I8 in addition to glucuronide. One possible 
reason behind this could be that the method of analysis used in this work, with the use of 
online detection of the radioactivity and deproteinisation of a large volume of plasma (1 
ml) followed by concentration prior to HPLC analysis, is more sensitive.
The time activity curves demonstrate a rapid tracer accumulation followed by a 
slow increase in the rate of uptake. At the same time there is persistent activity in the 
normal liver (see figure 6) even at 60min p.i. On the other hand, the corresponding FDG
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investigations demonstrate a higher increase in the rate of uptake following the initial 
tracer accumulation. These observations may have significant impact in optimizing the 
time of acquisition for FLT scans in CRC, suggesting that there may be no significant 
improvement in lesion detectability by delaying imaging protocols.
The Patlak model is based on the assumption that although there may be number 
of tissue compartments which reversibly communicate with the plasma, there must be at 
least one tissue compartment in which the trace is irreversibly trapped. An additional 
requirement for the linear behaviour to be observed is that there must be sufficient time 
passed such that the arterial plasma and the free tissue compartment have reached an 
equilibrium state. This is the reason for an initial period of curvature expected in the 
Patlak plots which corresponds to the period prior to the equilibrium being achieved 
between the plasma and free tissue compartments. The excellent linear fit observed 
following the initial period of equilibrium in the tracer concentration between the plasma 
and the free tissue compartment, suggests that no significant dephosphorylation takes 
place within the first 60min p.i. In addition, this hypothesis is further supported by the 
better NLR fits obtained with the 3K model in comparison to including a non-zero K4. A 
high correlation was also observed between the net influx constants obtained using the 
Patlak analysis and the NLR 3K model.
This work has not targeted the quantitative modelling of FLT in normal liver as 
the study was not designed to measure a double input function which would take into 
account the dual blood supply of the liver. However this does not prevent quantitative 
evaluation of the lesions since malignant lesions of the liver are supplied by the hepatic 
artery only (Kemeny and Ron, 1999).
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Shields et al were the first to explore the kinetics of FLT clearance from the 
blood and uptake into tissues by again studying normal and tumour bearing dogs, 
additionally bone marrow biopsies were obtained to validate the in vivo results. In this 
study a three compartment model was used to investigate the retention of FLT by 
intracellular phosphorylation. The dephosphorylation rate (K4) was found to be 
approximately zero and was not significant during a 60min study. There was reasonable 
agreement between the phosphorylated FLT fraction and the unmetabolised FLT fraction 
using this theoretical dog model and the experimental data obtained from the DNA 
extraction (Shields et al., 2002).
The potential of non-invasive methodology for the quantitative assessment of 
18FLT in vivo has been also assessed in this chapter. Firstly, the results show that the use 
of venous plasma samples in monitoring the presence of metabolites as a function of time 
leads to no significant differences compared to the use of arterial plasma. Secondly, the 
use of an image derived input function, using either the abdominal or the thoracic aorta, 
does not introduce statistically significant differences in the calculation of the influx rate 
constant. Ohtake et al, Germano et al and van der Weerdt et al, have all previously 
investigated the validity of using an image derived input function for FDG quantitation 
and demonstrated that non-invasive, accurate measurements of the arterial input function 
by dynamic PET imaging are possible and represent a clinically viable alternative to 
arterial blood sampling (Germano et al., 1992; Ohtake et al.; 1991; van der Weerdt et al., 
2001). Similar such work has never been carried out in the case of FLT.
Both these results support the use of non-invasive methodology for the 
quantitative assessment of FLT uptake in vivo using Patlak analysis. Finally in this
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tumour population a good correlation was found between the SUVs and the influx rate 
constant obtained using either the Patlak analysis or the NLR(3K).
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3.6 Conclusion
In conclusion, various techniques for the characterization of FLT uptake in vivo in 
patients with primary and metastatic colorectal cancer were investigated. When TACs 
were compared to FDG TACs, there was lower uptake as a function of time. In terms of 
quantitative analysis our study has demonstrated that the behaviour of FLT in-vivo 
utilization can be well characterized by a 3k model for data up to 60min p.i. In addition, a 
high correlation was demonstrated between the NLR(3K) and the simplified Patlak 
analysis with either measured or image derived input functions. The good correlation 
seen between SUVs and the quantitative measures of FLT utilization in terms of the net 
influx constant Ki suggests that non-invasive methodology may be used to assess the 
proliferation rates of CRC tumours with FLT.
In view of these findings, in the subsequent chapters of this thesis SUVs have 
been used to quantify the uptake of FLT.
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CHAPTER 4
Potential clinical role of FLT in 
imaging colorectal cancer.
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4.1 Background
FDG has without doubt gained a clinical role in the diagnosis and staging of 
patients with CRC. On the cellular level, FDG, which is a glucose analogue, measures the 
metabolic activity, hence reflects cell viability within a given tumour. Whether cells are 
actively dividing or are quiescent is not distinguishable. Therefore it is recognised that 
FDG is not, and cannot be, a specific tumour marker, hence the efforts to develop new 
18F-labelled tracers which may become clinically useful in the molecular characterisation 
of disease.
The production of the thymidine analogue FLT has provided us with the 
opportunity to study cancer cell proliferation in a routine clinical environment. Although 
the potential role of FLT PET is to image cellular proliferation, it is as yet unknown 
whether it is sensitive enough to be used to image CRC.
There are no studies in the published literature investigating the role that this new 
tracer could have in CRC. Therefore in this chapter a comparison is made, in the same 
patients on a lesion by lesion basis, between glucose utilisation/cell viability using FDG 
and cellular proliferation using FLT, in primary and metastatic CRC. The aim of this 
work is to investigate the potential role of FLT PET as an imaging modality in CRC by 
comparing its accumulation with that of FDG in malignant and normal tissue.
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4.2 Aims
i) Establish if FLT PET can be used to image CRC in a clinical setting.
ii) Directly compare uptake of FDG and FLT on a lesion by lesion basis using 
SUVs.
iii) Directly compare uptake of FDG and FLT in normal liver and bone marrow 
using SUVs.
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4.3 Methods
4.3.1 Patient selection
All patients were prospectively recruited from among routine surgical and 
oncology outpatients. Inclusion criteria were the presence of primary CRC, metastatic 
CRC or a combination of the two. Lesions were identified by conventional imaging 
modalities including the use of multi-phase enhancement patterns with multi-slice 
computed tomography (CT), as described in section 2.5. All patients gave written 
informed consent, and the study was approved by the Hospital Ethics Committee 
(appendix B) and the Administration of Radioactive Substances Advisory Committee 
(ARSAC) (appendix C).
A total of 23 patients with 61 malignant lesions were recruited. These comprised 
15 males and 8 females with a median age of 69 years (range 50-87years). Four patients 
had solitary primary lesions, six had both primary tumours and liver metastases, six 
presented with just liver metastases and three had malignant lung lesions in addition to 
liver metastases. The remaining four patients had peritoneal lesions (table 4.1) 
Malignancy was confirmed histologically in 18 lesions, by laparotomy findings in 14 and 
by clinical and radiological follow-up using conventional techniques in the remaining 29 
lesions.
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D istribu tion  o f lesions
Patient Primary tumour Liver metastases Lung m etastases Peritoneal metastases
1 1 3 - -
2 - 3 1 -
3 1 4 - -
4 1 - - -
5 - 2 3 -
6 - 1 2 -
7 - 1 - 2
8 - 2 - -
9 1 - - -
10 - 3 - -
11 - - - 3
12 1 1 - -
13 - 2 - -
14 - 5 - -
15 - 4 - -
16 - - - 1
17 1 1 - -
18 1 - - -
19 1 1 - -
20 1 - - -
21 - 1 - -
22 1 4 - -
23 - - - 1
Total number 
of lesions
10 38 6 7
Table 4.1 Distribution of lesions (n=61) within the patients in the study.
4.3.2 Im aging
Patients underwent whole body FDG and FLT PET scans as per the protocols in 
chapter 2 within a median period of 6 days (range 1-22 days). FDG and FLT tracers were 
prepared as described in chapter 2 with a mean administered dose of 377MBq (SD 21) 
and 360MBq (SD 53) respectively. All patients underwent whole body scanning at mean
of 59min p.i (SD 8) for FDG and a mean of 63min p.i (SD 6) for FLT. This timing of the 
data acquisition for FLT was determined from the TACs studied in chapter 3.
Standardised uptake values (SUVs) were obtained for each lesion. For each 
patient, regions of interest (ROI) were drawn over the tumour and normal tissue images 
(normal bone marrow and normal liver). As described in section 2.4.1, five consecutive 
slices were used and consisted of the slice with the maximum count density and the four 
immediately adjacent slices. In the case of the normal bone marrow and liver, the ROI 
was placed over the same vertebra and the same area of normal liver for both the FDG 
and FLT scans. SUVs were subsequently calculated using the methodology described in 
sections 2.4.2 and 2.4.3.
4.3.3 Statistical analysis
A two sided paired t test and correlation analysis was used to assess the 
significance of differences between the uptake of the two tracers on a lesion by lesion 
basis (Microsoft Excell™ software).
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4.4 Results
The whole-body study in figure 4.1 shows a comparison between the normal 
physiological uptake of FDG and FLT. There is prominent uptake by bone marrow, a 
highly proliferating tissue, in addition to significant accumulation within normal liver. As 
with FDG, excretion is via the kidneys and urinary bladder. In contrast to FDG, FLT does 
not cross the intact blood-brain barrier and hence exhibits no cerebral uptake.
(1111
Figure 4.1 Comparison of normal physiological uptake of FDG and FLT. There is increased accumulation of 
FLT within the normal liver and bone marrow. Excretion via the urinary bladder is noted with both tracers, 
whilst only FDG is seen to cross the blood brain barrier.
Of the 61 malignant lesions, 60 (99%) were imaged with FDG-PET. Lesions were 
grouped together as primary tumours and liver metastases, while extrahepatic metastases
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were subdivided into lung and peritoneal lesions. Findings are described below for the 
different groups.
All ten (100%) of the primary tumours (six rectal and one each in the sigmoid 
colon, transverse colon, ascending colon and caecum) were successfully imaged using 
both FDG and FLT. Although on visual inspection all o f these primary lesions showed 
increased uptake as compared to their surrounding structures, the avidity of these tumours 
for FDG was far greater than that of FLT. When this difference was semi-qauntitated 
using SUVs, FDG showed an approximate two fold increase in uptake when compared to 
FLT. Figure 4.2 shows this difference in a primary adenocarcinoma of the rectum which 
demonstrates how primary CRC is seen as avid for FLT but to a lesser extent than with 
FDG
FDG FLT
Figure 4.2 Primary carcinoma of the rectum showing avidity for both FDG and FLT.
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FLT showed avidity for five of the six (83%) lung lesions which were imaged 
successfully with FDG. The thorax showed very little uptake of either tracer. Those 
lesions visualised using FLT demonstrated similar SUVs when compared to FDG (mean
4.5 and 5.5 respectively). One of the patients with a primary rectal tumour, who was 
originally included in the primary group, underwent a staging scan and appeared to have 
diffuse bilateral areas of avid FDG uptake within the lung fields. The symmetry of these 
lesions raised the suspicion of sarcoidosis and this was confirmed on biopsy. Interestingly 
these lesions were not seen as avid for FLT.
All six (100%) peritoneal tumour deposits showed increased uptake of both 
tracers. Once again there was an obvious increase in the intensity of FDG as that of FLT 
which was also reflected in the SUVs. In one case, FDG exhibited significantly increased 
uptake in a peritoneal lesion, which was also thought to be malignant in nature during 
resection. Subsequent full histological examination found this lesion to be made up of 
inflammatory cells secondary to fat necrosis. This same lesion had displayed no avidity 
for FLT during pre operative scanning. This case is shown in figure 4.3 and at 14 month 
post operative follow up there is still no evidence for malignant disease at that site using 
both metabolic and cross sectional imaging methods.
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Image 1 Image 2
A
Figure 4.3 Image 1 shows increased uptake of FDG by peritoneal tumour recurrence marked by the cross in 
addition to abnormal uptake by an inflammatory lesion (A). Image 2 again shows increased activity from the 
peritoneal tumour recurrence using FLT but no abnormal focus in the area of inflammatory activity.
O f the 38 liver metastases, 37 (97%) showed accumulation of FDG. The false 
negative liver lesion was a 1cm metastasis lying inferior to a larger lesion. This smaller 
metastasis was not visualised using either tracer but became evident during liver 
resection. In contrast only 12 of the 38 liver lesions (32%) were visualised using 18FLT. 
An example of multiple liver metastases seen with FLT is demonstrated in figure 4.4; it is
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interesting to note that the pattern of FLT distribution within the lesions differs from the 
pattern seen with FDG. More of a doughnut appearance is seen with FLT indicating that 
perhaps there is less true tumour in the outer rim and more central necrotic tissue than is 
demonstrated by the FDG uptake.
FDG FLT
Figure 4.4 Multiple liver m etastases seen with both FDG and FLT.
The lack of visualisation of the majority of liver lesions (n=26, 68%) using FLT is 
highlighted in a case of a patient with a solitary liver metastasis shown in figure 4.5. The 
intense uptake of FDG can be seen against the relatively low liver background uptake. In
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comparison, the corresponding area in the FLT image in fact displays lower uptake as 
compared to the high FLT liver background.
Figure 4.5 Liver metastasis (M) displaying high uptake of FDG. The corresponding area in the FLT image 
displays lower activity in comparison to the background normal liver.
All means, standard deviations and ranges of SUVs are shown for each tissue type 
in table 4.2. In summary, in primary CRC, the almost two fold increase in SUVs is 
evident. The mean uptake values for the tracers in colorectal lung metastases were similar 
for the 2 tracers, whereas uptake of FDG in malignant peritoneal disease was on average 
1.7 times higher than that of FLT. The 32% of liver metastases visualised with FLT 
demonstrated comparable SUVs to FDG (mean SUV 6.3 vs 6.5 respectively).
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Tissue SUVs
™FDG iaFLT
Malignant Mean (SD) Range Mean (SD) Range
Primary 7.6 (2) 3 .9 -13 .4 3.9(1.7) 2.1 -7 .3
Liver 6.3 (2.6) 2 .9 -11 .7 6.5(16) 4.2-9.1
Lung 5.5(1.3) 3 .5 -7 .0 4.5(15) 2 .5 -6 .8
Peritoneal 6.5 (2.4) 4 .4 -10 .2 3.9(13) 2.8 -  6.1
Non malignant
Liver 2.1 (0.4) h-OvjI00d 4 .5(12) 2 .7 -7 .9
Bone marrow 1.5 (0.4) 0 .8 -2 .4 7.2(13) 4 .5 -9 .7
Table 4.2 Summary of SUVs for malignant and non malignant tissue
For those lesions visualised with both tracers («=34), there is no correlation 
(R2=0.03) of SUVs (figure 4.6). A lesion by lesion avidity of the respective is shown in 
table 4.3
R2 = 0.0309
♦  ♦
_ i
LL
S U V s-F D G
Figure 4.6 In the lesions visualised by both tracers (n=28) no correlation w as seen as measured by SUVs.
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Avidity
Patient Lesions 1#FDG FLT
1 Primary (sigmoid colon) 4 V
Liver metastases 1 4 V
2 4 4
3 4 V
2 Lung metastases 4 V
Liver metastases 1 4 X
2 4 X
3 4 X
3 Primary (transverse colon) 4 V
Liver metastases 1 4 V
2 4 V
3 4 V
4 4 V
4 Primary (caecum) 4 V
5 Lung metastases 1 4 4
2 4 4
3 3 4
Liver metastases 1 4 4
2 4 X
6 Liver metastases 4 X
Lung metastases 1 4 X
2 4 4
7 Peritoneal metastases 1 4 4
2 4 4
Liver metastases 4 X
8 Liver metastases 1 4 4
2 X X
9 Primary (ascending colon) 4 4
10 Liver metastases 1 4 X
2 4 X
3 4 X
11 Peritoneal 1 4 4
2 4 4
3 4 4
12 Primary (rectal) V 4
Liver metastases V 4
13 Liver metastases 1 V X
2 V X
14 Liver metastases 1 V X
2 V X
3 V X
4 V X
5 V X
15 Liver metastases 1 V X
2 V X
3 V X
4 V X
16 Peritoneal metastases 1 V 4
2* V X
17 Primary (sigmoid) V 4
Liver metastases V 4
18 Primary (rectal) V 4
19 Primary (rectal) V 4
Liver metastases V X
20 Primary (rectal) V 4
Lung (lesions)t V X
21 Liver metastases V 4
22 Primary (rectal) V 4
Liver metastases 1 V X
Liver metastases 2 V X
Liver metastases 3 V X
Liver metastases 4 V X
23 Peritoneal metastases V 4
Table 4 .3  Avidity of th e  respective tra ce rs  for tum our tissu e  on a  lesion by lesion basis. P eritoneal lesion avid for FDG but found to be  
inflammatory on histology (see fig4.3). f  lung lesion avid for FDG but sarcoidosis on histology.
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4.5 Discussion
This is the first study to compare and contrast uptake of the two tracers FDG and 
FLT in CRC. Results from this work have found no significant correlation between the 
uptake of FDG and FLT in malignant CRC lesions (R2=0.03). This lack of correlation 
provides further evidence that FDG uptake, which depends on glucose metabolism and 
reflects cell viability (Higashi et al., 1993) does not correlate with cellular proliferation as 
depicted by FLT.
Both tracers displayed 100% sensitivity when imaging primary CRC. For 
visualisation of extrahepatic lesions, FDG and FLT demonstrated sensitivities of 100% 
and 92%, respectively, however false positives and false negatives were encountered.
The specific cases of the inflammatory peritoneal lesion thought to be malignant 
owing to the increased uptake of FDG and the sarcoid lung lesions showing intense 
uptake of FDG, highlight the potential pitfall of false positives secondaiy to increased 
tracer uptake by macrophages. It is interesting to note that none of these lesions showed 
avidity for FLT. This demonstrates a specificity which may be useful for further 
characterisation of equivocal lesions.
One false negative lung lesion was encountered when using FLT. This type of 
false negative lung metastasis secondary to CRC has previously been reported when 
imaging with FLT (Buck et al., 2002). The reasons for such findings are unclear and need 
to be elucidated by further work. Histological analysis, in addition to a quantitative 
assessment of the proliferative activity of these lesions, is imperative to ascertain why the 
tumour is not visualised against such a low background as that seen in the thorax with 
FLT.
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False negative liver lesions pose a significant problem in the field of CRC as 30% 
of patients ultimately develop liver metastases (section 1.3.4). A wide range of treatment 
options are now available, but selection of the most appropriate depends on accurate 
staging. Of the 38 liver lesions presented, only 12 were visualised with FLT unlike FDG 
which correctly identified 37 of the 38 lesions. A possible explanation for this is the high 
background activity due to the metabolism of FLT.
High hepatic uptake of FLT was first described by Shields et al in 1998 (Shields 
et al., 1998b). This work was conducted using canine subjects and a pilot study involving 
one human with non-small cell carcinoma of the lung was included. Using the canine 
model quantitative analysis of intravenous blood sampling and dynamic PET imaging 
was performed (as has been carried out in human subjects in chapter 3 of this thesis). 
Selective uptake in the bone marrow was demonstrated with a mean SUV of 4.6 and low 
uptake in the brain was observed. FLT was excreted by the kidneys and HPLC analysis 
of the dog urine revealed over 95% of the activity was present as unchanged parent 
compound with late blood sampling also showing 90-97% remaining unchanged. In the 
human subject similar uptake patterns as those found in this study were demonstrated in 
the bone marrow and kidneys. The most interesting finding was the unexpectedly high 
uptake which was observed in the liver (SUV 7.6 at 64min) compared to the low uptake 
in canine hepatocytes. This high SUV value for liver uptake in the one human study 
compares well to what was found in the cohort of patients studied in this chapter.
The divergent liver uptake finding is explained by the difference between dogs 
and humans in the hepatic glucuronidation of 3’-azido-3’-deoxythymidine (AZT) related 
compounds, where the biotransformation rate was shown to be much lower in dog
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hepatocytes than human ones (Nicolas et al., 1995). The process of FLT glucuronidation 
within the liver leading to this high background uptake is best explained by examining 
the hepatic metabolism of the drug from which it was developed AZT. Prior to exerting 
its antiviral effect AZT undergoes sequential intracellular phosphorylation in a way 
analogous to FLT. In addition to this phosphorylation pathway, the alternative pathway of 
AZT metabolism is the formation of AZT glucuronide within the liver (Good et al., 1990; 
Moore et al., 1995). This reaction is catalysed by the enzyme UDP- 
glucuronosyltrtansferase resulting in compounds which are more water soluble, less 
toxic, and easier to excrete in the bile and the urine (Barbier et al., 2000; Veal and Back, 
1995). This theory is supported by the significantly higher normal liver SUV (mean 4.5) 
in FLT scans as compared with FDG (mean 2.1). Accordingly, the detected hepatic 
lesions were those with SUVs higher (mean 6.5) than those recorded for the normal liver. 
This suggests the existence of a minimum ‘uptake threshold’ which has to be exceeded to 
allow the detection of hepatic lesions with FLT. On the other hand, the lack of FLT 
uptake in colorectal liver metastases may be a good prognostic sign. The lack of 
visualisation of lesions may reflect the less aggressive nature of these tumours by virtue 
of them having a lower proliferative rate (Slingerland and Tannock, 1998). This is 
investigated in the following chapter.
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4.6 Conclusion
FLT generally demonstrates lower cellular trapping and hence lower SUVs in 
comparison with FDG. The demonstration of no correlation between the retention of the 
two tracers further confirms that there is no direct relationship between glucose utilisation 
and the uptake of FLT in tumour cells. The poor sensitivity which FLT displays in the 
detection of colorectal liver metastases makes it a poor candidate as a staging tool for 
CRC. Although lacking in sensitivity, FLT does have the potential to improve the 
specificity for the detection of CRC. The prognostic implications of the uptake of this 
novel tracer need to be assessed in terms of response to chemoradiotherapy and 
ultimately survival.
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CHAPTER 5
Quantifying cellular proliferation in 
colorectal cancer: a comparison of 
FDG and FLT PET with 
immunohistochemistry
161
5.1 Background
The only reliable methods dictating what, if any, adjuvant therapy patients with CRC will 
receive, are the Duke’s grading system(Dukes., 1932), and the TNM staging system 
introduced by the American Joint Committee on Cancer (Compton et al., 2000). These in 
addition to the histological grade of the tumour are reviewed in section 1.2.3. Seventy 
years since the introduction of Duke’s staging coupled with the more recent TNM system 
and the histological grade of the tumour remain the only reliable methods dictating what, 
if any adjuvant therapy patients with CRC will receive.
Unfortunately under current guidelines, which have been set up in light of the 
above prognostic indicators, there is still a cohort of patients who unnecessarily receive 
toxic chemotherapy whilst others who could potentially benefit from it are not 
recommended to receive it.
This has led to the attempt to try and define a marker on which therapeutic 
decisions could be made with greater precision. The potential value of quantifying 
cellular proliferation using the Ki-67 antigen present in the cycling cell, has led to an 
effort to predict populations of individuals with CRC who may or may not benefit from 
adjuvant chemotherapy. This has been highlighted in section 1.10.6.
However present methods to assess tumour proliferation require a tissue sample 
and are therefore limited by potential morbidity and sampling problems. A non invasive 
method to assess proliferation might avoid unnecessary biopsies and permit serial 
assessments during cancer therapy. Having established thatFLT-PET can be used for the 
imaging of CRC in vivo, I now move on to ascertain whether the images produced are 
indeed those of cellular proliferation and their potential value.
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5.2 Aims
The aims of this chapter are to
i) Compare the uptake of FDG with cellular proliferation as quantified using 
MIB-1 (anti-Ki67 antibody) immunohistochemistry.
ii) Compare the uptake of FLT with cellular proliferation as quantified using 
MIB-1 (anti-Ki67 antibody) immunohistochemistry.
iii) Evaluate the role of PET in quantifying in vivo cellular proliferation in CRC.
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5.3 Methods
5.3.1 Patient selection
Ten patients (5 male, 5 female), median age 68 years (range 54-87), with 13 
resectable primary or recurrent CRC were recruited at diagnosis from local surgical 
clinics. Patient demographics can be seen in table 5.1. Written informed consent was 
obtained following approval from the Local Ethical Committee and the ARSAC 
committee (appendix B and C). All patients underwent whole body FDG scanning 
followed by an FLT scan with a median intervening period of 5 days (range 1-19).
Following surgical resection, the lesions were sent for routine histopathological 
assessment in addition to immunohistochemical analysis.
5.3.2 Imaging
Acquisition of the whole body scans in addition to tracer and patient preparation is 
covered in the general materials and methods in Chapter 2.
Scanning data was acquired at a mean time of 57mins (SD 10) p.i and 62mins (SD
12) p.i for FDG and FLT respectively. Post injection image acquisition time for FLT was 
determined through the work carried out in chapter 3 with respect to the time activity 
curves. Specifically the images were acquired at a significant time after the initial lOmin 
rapid accumulation phase, thus allowing for the tracer uptake to plateau. Mean injected 
activity was 371MBq (SD 24) for FDG and 351MBq (SD 52) for FLT.
A ROI approach as described in Chapter 2, was used to obtain SUVs in order that 
the uptake of the respective tracers could be quantified and compared.
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5.3.3 Immunohistochemistry
Routine histological examination was performed on 4pm thick haematoxylin and 
eosin (H&E) stained sections. Immunohistochemistry was performed by using 3jim thick 
sections cut from paraffin blocks and dried overnight at 60°C. Sections were taken from 
xylene (2 changes), through graded alcohols (100% and 70%) to water. Antigen retrieval 
was performed by pressure cooking for 2 minutes in a conventional 151b pressure cooker. 
The slides were cooked for 2mins, then flushed with running tap water.
The slides were then rinsed in 0.05% Tween 20 in Tris buffered saline 
(TBS/Tween) in an incubation tray. Endogenous peroxidase activity was blocked for 10 
minutes using a commercially available peroxidase blocking solution (DAKO, Ely, 
Cambridgeshire, UK.). The sections were rinsed in TBS/Tween and then primary mouse 
monoclonal antibody (MIB-1 (DAKO, Ely, Cambridgeshire, UK.) diluted 1/50 in TBS 
pH7.4) was applied for 60 minutes at room temperature.
The sections were rinsed in TBS/Tween and secondary antibody (goat anti-rabbit/mouse), 
(DAKO, Ely, Camdridgeshire, UK.) was applied for 30 minutes. The sections were again 
rinsed in TBS/Tween and streptavidin-horseradish peroxidase was applied for 30 
minutes. After rinsing in TBS/Tween, diaminobenzidene, used as a chromogen, was 
applied for 7mins. A haematoxylin counter stain was applied for 2mins.
Sections were dehydrated through graded alcohols (70% and 100%), cleared in 
xylene (2 changes) and mounted with DPX.
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5.3.4 Examination of sections
Sections of tumour were identified on the H&E slides and the corresponding 
MEB-1 sections were examined independently by 2 experienced observers A and B, 
blinded to the results of the scans.
Three MIB-1 stained sections of tumour were used for each lesion in order to 
account for tumour heterogeneity. Thirty high power fields (x40 objectile lens) were 
examined and 50 tumour cells were assessed per field using a graticule, making a total of 
1500 cells per case. A labelling index (LI) was calculated as the percentage of positive 
staining nuclei out of all nuclei examined. ‘Positive’ nuclear staining was regarded as 
staining of the entire nucleus. Nuclei with no staining or nucleolar staining only were 
regarded as negative.
5.3.5 Statistical analysis
Inter-observer reliability was assessed using Pearsons correlation coefficient, linear 
Regression analysis using the SPSS 10.0.7 statistical software package (SPSS, 
Inc.,Chicago, IL, USA) was employed to correlate uptake of both FLT and FDG with 
MIB-1.
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5.4 Results
Histopathology of the lesions (n=13; 5 primary cancers, 5 liver metastases 
and 3 peritoneal deposits) confirmed adenocarcinoma in 12 of the 13 cases. The 
remaining case was thought to be a malignant peritoneal recurrence by pre-operative CT, 
18FDG PET imaging and at intraoperative evaluation, but on microscopic histological 
examination it was found to be an inflammatory lesion secondary to fat necrosis.
There was excellent inter-rater reliability between the two observers responsible 
for quantifying proliferation using MIB-1 immunohistochemistry, with a Pearson’s 
correlation coefficient of 0.9 (figure 5.1).
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Figure 5.1 Inter rater correlation between observer A and B (Pearsons correlation coefficient of 0.9)
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Patient demographics in addition to quantification of tracer uptake and the 
corresponding Li’s can be seen in table 5.1. All five primary tumours and both malignant 
peritoneal lesions were visualised with increased focal uptake as compared to the 
surrounding tissue using both FLT and FDG. The SUVs of these primary lesions ranged 
between 5.9 and 5.7 for FDG and 1.4 and 5.5 for FLT. The corresponding Lis of these 
lesions ranged between 67% and 77%.
Patient Gender Age
(yrs)
Weight
(Kg)
Resected lesion s FDG
(SUV)
FLT
(SUV)
Labelling 
Index 
(% MIB-1)
1 M 87 72 Primary (asc colon) 9.2 3.5 69
2 M 66 82 Peritoneal recurrence 7.6 3.3 60
Peritoneal lesionf 7.8 - 23
3 F 78 54 Liver m etastases 1* 5.5 - 19
Liver m etastases 2* 11 - 26
4 F 75 63 Primary (rectal) 9.6 4.8 70
Liver metastases 3.7 9.1 87
5 M 62 85 Primary (caecal) 9.7 5.5 77
6 F 60 58 Liver metastases 3.7 4.8 73
7 M 59 70 Primary (trans colon) 8.5 2.9 67
8 F 54 55 Primary (rectal) 5.9 1.4 69
9 F 67 95 Peritoneal recurrence 4.5 2.6 75
10 M 71 65 Liver metastases 4.7 6.1 87
Table 5.1 Summary of patient dermographics, SUVs and labelling indices.
All of the five liver metastases were shown to be avid for FDG but only three of 
these lesions were clearly seen to be avid for FLT. All three FLT avid metastases showed 
a corresponding high proliferation labelling index (73%, 87% and 87%).
The three lesions (peritoneal inflammatory lesion and 2 liver metastases) which 
did not show increased uptake of FLT and were therefore not visualised using this tracer 
had corresponding low proliferation rates as determined by the Lis, ranging from 19-26.
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The SUVs for all thirteen lesions seen with FDG ranged between 3.7 and 11
compared to a range of 1.4 -  9.1 for the 10 lesions visualised using FLT .
There was statistically significant correlation (R=0.8, p<0.01) between the SUVs
of the 10 tumours visualised with FLT and the corresponding Lis (figure 5.2).
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Figure 5.2 Correlation between SUVs of the 10 tumours visualised with FLT and the corresponding Lis. 
(R=0.8).
No such correlation (R=0.4) was demonstrated in the case of the FDG avid lesions 
and Lis (figure 5.3).
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Figure 5.3 Correlation between SUVs and those lesions seen avid for FDG (R=0.4).
Three specific cases demonstrating the differences between uptake of both tracers 
and the corresponding Lis are shown in figure 5.4. The resected tumour specimens 
represented are a primary caecal carcinoma (a) and two colorectal liver metastases from 
separate patients (b) and (c). The macroscopic histology is compared to how the 
distribution of the tracer is seen in the PET images using both FDG and FLT. The lower 
cellular trapping of FLT as compared to FDG is clearly seen. In addition the high liver 
background secondary to the glucuronidation of the FLT within human hepatocytes is 
demonstrated. The liver metastases shown in (b) which can be seen against the high 
background also shows a very high LI of 87% as demonstrated in the MIB-1 microscopic 
slide section shown. The LI of the liver metastases from the second patient (c) is 
significantly lower and therefore is not seen against the background liver in the FLT PET 
image.
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Figure 5.4 Specific cases demonstrating differences between FDG, FLT and corresponding labelling indices.
5.5 Discussion
There is no previously published data comparing FLT-PET and 
immunohistochemistry in the quantification of proliferation in CRC. The results from this 
chapter suggest that FLT reflects proliferative activity in CRC as determined by MIB-1 
staining, with a strong correlation (R=0.8). Therefore, it is possible to non-invasively 
acquire an in vivo measurement of proliferation equivalent to an immunohistochemical 
marker. The lesions successfully imaged with FLT demonstrated higher SUVs in addition 
to higher Lis when compared to those lesions not visualised by FLT which were shown 
to have correspondingly lower SUVs and Lis.
The lack of correlation between the Lis and FDG in this study supports previous 
in vivo and in vitro evidence that FDG is not a specific marker of proliferation. Higashi et 
al has demonstrated in ovarian cell lines that the utilisation of glucose by tumour cells 
represented by FDG uptake is not a reflection of cell proliferation as measured by DNA 
flow cytometry and 3H-Thymidine incorporation, but is strongly related to the number of 
viable tumour cells (Higashi et al., 1993). Buck et al attempted to use FDG-PET in vivo 
in order to estimate proliferative activity as a means of differentiating pancreatic cancer 
from chronic active pancreatitis. In this study, again no correlation was found between 
FDG uptake and cellular proliferation using MIB-1 immunostaining (Buck et al., 2001). 
Although it is generally accepted that a highly proliferating cell would need proportional 
amounts of energy, supplied by glucose metabolism, metabolic activity is also needed for 
other cell functions, therefore the two processes of glucose metabolism and proliferation 
would not necessarily correlate.
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It is known that the glucuronidation of FLT within the liver leads to high hepatic 
background activity which may inhibit its diagnostic utility as demonstrated in Chapter 4. 
This was again exemplified by the failure of FLT-PET to identify 2 of the 5 liver 
metastases against this high liver background. However, both these lesions displayed low 
proliferation Lis (19% and 26%) suggesting relatively slow growth compared to the 
remaining 3 liver metastases (Lis of 87%, 87% and 73%). The fact that certain liver 
lesions are not seen with FLT may have prognostic implications in terms of 
aggressiveness of these tumours.
Unfortunately it was not possible to carry out surgical resection and subsequent 
histology on the “metabolically silent” lung metastasis described in chapter 4. Such an 
investigation might have yielded valuable information which would have contributed to 
our understanding as to why certain colorectal lung metastases do not show avid for FLT 
despite the very low thoracic background. Proliferation indices tend to correlate well with 
aggressiveness of some tumour types, eg, lymphoma and breast adenocarcinomas. In 
terms of colorectal carcinomas, clear evidence does not as yet exist, with conflicting 
results from different trials detailed in section 1.10.6. The most recent report, a 
retrospective analysis of 706 patients by the National Surgical Adjuvant Breast and 
Bowel Project Collaborative Study Group, does suggest that proliferation has prognostic 
implications (Allegra et al., 2003). The relationship between proliferation and tumour 
behaviour for liver metastases is as yet unknown.
The only published work to date using FLT-PET to quantify proliferation in 
humans in vivo, has been in studies investigating lung lesions. In a prospective study of 
thirty patients with solitary pulmonary nodules in which all the cases had histological
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assessment, FLT uptake using SUVs was compared to proliferative activity as quantified 
with Ki-67 immunohistochemistry. This showed that FLT PET had a sensitivity of 
detecting malignant lesions of 86% on qualitative review and agreed with the results of 
this chapter in that uptake correlated significantly with proliferation rate (correlation 
coefficient 0.87) (Buck et al., 2002b). Further work, investigated ten patients with either 
histologically proven or clinically suspected non-small cell lung cancer. In this study, as 
in chapter 3 of this thesis, arterial and venous blood sampling with dynamic PET imaging 
was carried out in order that both the SUVs and the FLT flux determined by Patlak 
analysis could be utilised. These were compared to determine any correlation with Ki-67 
proliferation indices. Excellent correlations were found between S U V aVerage measures of 
FLT uptake (R=0.84) and Ki-67 scores with even stronger correlations using Patlak 
derived FLT influx (R=0.94) (Vesselle et al., 2002). These two studies have shown that 
FLT uptake can be used to image lung tumours and can be used to asses proliferation 
rates. Both authors of these respective studies felt that it might have a role to play in the 
further characterisation of lung lesions as well as the determination of prognosis and 
therapy.
In addition to malignant lung lesions, the role of FLT as an imaging agent of 
proliferation has been investigated in vitro, in a murine model using SCDD mice and in 
human disease in B-cell lymphoma (Wagner et al., 2003). The findings of this work again 
found good correlation between SUVs and the Ki-67 labelling index of the tissue biopsies 
in the human cohort (R=0.95). The mouse lymphoma model showed that the injected 
dose per gram of FLT correlated with the in vivo Bromodeoxyuridine (a uracil analogue) 
labelling index. Following a 240min incubation period the in vitro studies revealed that
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12.5% of the total FLT applied was trapped within the cell and approximately 1% was 
recovered from the DNA. The incorporation of FLT into DNA has also been investigated 
using a rat model and asynchronously growing tumour cell lines. In the former samples of 
rat spleen and intestine were removed for DNA analysis and separation following 
administration of FLT, where DNA incorporation was found to be only 2% (Lu et al., 
2002). A second study used asynchronous human cell lines to which [ H]FLT was added 
and following incubation both cell cycle measurements and DNA extraction was 
performed (Toyohara et al., 2002). FLT uptake correlated well with %S-phase fraction 
(R=0.76) in addition to [3H] thymidine uptake (R=0.88). Although [3H]FLT incorporation 
into the DNA fraction was again negligible (0.2%). The results from these studies show 
FLT correlates with proliferation markers, in fact it is an extremely accurate surrogate 
measure of cellular proliferation although its lack of incorporation into DNA does not, at 
present allow it to be a direct marker.
The very nature of PET allows the metabolic assessment of the whole tumour in 
its heterogeneic entirety overcoming inherent problems with tissue sampling. The 
excellent correlation in terms of CRC, shown by the work in this chapter coupled with 
the lung tumour studies (Buck et al., 2002; Vesselle et al., 2002), have demonstrated that 
PET’s unique ability to quantitate the uptake of the tracers used, non-invasively and in 
vivo, can open new avenues in the assessment of malignancy by functional imaging.
This has the potential to offer the clinician a further prognostic marker with which 
to assess the aggressiveness of the disease and perhaps allow a more precise method for 
therapeutic decisions to be made. In real terms, a decision regarding response to 
chemotherapy in CRC is usually judged 6 weeks into a 12 week treatment cycle. The
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potential of avoiding 6 weeks of unnecessary toxic chemotherapy by establishing the 
non-responders from the responders at a pre-treatment stage is a prospect which cannot 
be ignored.
Future work will help in validating FLT-PET as a potential tool for the non- 
invasive in vivo assessment of CRC and may enable more accurate evaluation of the 
antitumoural effects of new as well as established anticancer drug treatments aimed at 
competing with DNA synthesis.
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5.6 Conclusion
This chapter has demonstrated that FLT PET may be used as a non-invasive 
method of quantitating cellular proliferation in CRC. The tracer FDG, on the other hand, 
does not offer this. This might allow CRC to be imaged at a pre-treatment stage and 
define the population of patients who might benefit from neo-adjuvant therapy. In 
addition, it may also help in identifying a group of patients with recurrent disease who 
would not benefit from first line chemotherapy as a result of the low proliferation rate of 
the tumour as demonstrated by the low SUV on FLT-PET imaging.
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CHAPTER 6
Monitoring 5-FluorouraciI 
chemotherapy response in 
colorectal cancer using FLT in
vitro.
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6.1 Background
5-Fluorouracil (5FU) has been the mainstay of chemotherapy for CRC. The 
metabolic pathways and current evidence supporting its clinical role are covered in detail 
in section 1.4.2.
Briefly, the rapid metabolism of 5FU produces by one pathway, 5-fluorouridine 
triphosphate (5FUTP) which is incorporated directly into RNA A second 
deoxynucleotide synthesis pathway enables 5FU to exert two independent effects. The 
metabolism of 5FU to 5FUTP allows incorporation directly into genomic DNA with 
potentially cytotoxic results. Alternatively the production of 5-fluorodeoxyuridine 
monophosphate (5-dFUMP) inhibits thymidylate synthase thus depleting the production 
of thymidine monophosphate, which is an indispensable precursor of de novo DNA 
synthesis. When this occurs, the thymidine necessary for DNA synthesis has to be 
acquired through the salvage pathway.
FLT is phosphorylated to FLTMP by the S phase specific enzyme TK (section 
1.12.3). This leads to the intracellular trapping of the tracer via the salvage pathway of 
DNA synthesis. The cytotoxic effect of 5FU chemotherapy necessitates that cells employ 
this pathway in order to obtain thymidine for DNA synthesis.
Current knowledge of tumour biology has allowed greater opportunities for 
cancer treatment. Much interest has been shown in the development of molecules which 
have the potential to interfere with cell cycle control. As for all clinical trials 
pharmacodynamic endpoints need to be defined for anti-cancer agents. Non-invasive 
imaging using PET is a particularly attractive option to assess these end points in terms Of
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tumour response to therapy. Its proven value using FDG has already been discussed in 
section 1.6.4.
In this chapter the impact on FLT uptake that the administration of 5FU has on 
CRC cells in vitro is assesssed. CRC cell lines are employed to create a model to look at 
the potential role of FLT PET in monitoring response to therapy in 5FU treated CRC.
6.2 Aims
The aims of this chapter are to:
i) Optimise growth over time for two CRC cell lines to mimic actively 
growing in vivo CRC tumours.
ii) Quantify the dose response cytotoxicity of 5FU in the two CRC cell lines.
iii) Establish the uptake of FLT over time in the CRC cell lines.
iv) Investigate the impact that 5FU has on the uptake of FLT in CRC cell 
lines to establish its role in monitoring treatment response in vitro.
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6.3 Methods
6.3.1 Materials and cell lines
i) Materials: Plastic consumable items were bought from Nunc (VWR, Poole, Dorset, 
UK), while chemicals were obtained from Cambrex Biowhittaker (Woking, Berks, UK), 
unless otherwise stated.
ii) Cell lines: The human colorectal cancer cell lines used were: HT29, derived from a 
primary colorectal cancer and SW620, derived from a colorectal lymph node metastasis 
(both from the European Collection of Animal Cell Cultures, Porton Down, Wilts, UK).
6.3.2 Routine maintenance
HT29 and SW620 cells were routinely grown in 75cm2 flasks in Dulbecco’s 
Modified Eagle’s Medium (DMEM) containing 2mM glutamine, supplemented with 
foetal calf serum (FCS, 10% v/v) and penicillin & streptomycin antibiotic mixture (100 
IU/ml and 100 pg/ml respectively), at 37°C. All work described below was carried out 
within 15 cell passage numbers for each cell line to avoid differences due to phenotypic 
drift.
To propagate the rolling stock of cells and also obtain cells for carrying out the proposed 
experiments, cells were allowed to grow to near confluence levels (approximately 90%), 
washed in phosphate buffered saline (PBS) followed by washing in 0.02% 
Ethylenediamine tetracetate (EDTA) in PBS and enzymatically disaggregated using 
trypsin (lmg/ml in EDTA/PBS). PBS removes any serum (FCS) while EDTA chelates 
(and therefore “removes”) calcium; the latter, like FCS, is inhibitory for trypsin action. 
Disaggregated cells were harvested in medium supplemented with FCS to partially
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neutralise trypsin, centrifuged (400g, 5min) to separate cells from trypsin-containing 
supernatant and again resuspended in fully supplemented medium. Cells were either (i) 
passaged into flasks (at between 1:3 to 1:8 ratios), gassed using 10% CO2 and grown at 
37°C, in a dry incubator for stock, or (ii) counted using a haemocytometer and 
resuspended at appropriated dilutions for further experiments as described below.
6.3.3 Basic experimental protocol
To determine the pattern of uptake of radioactive tracer early after chemotherapy, 
experiments were designed as follows: Cells were seeded and allowed to settle and grow 
for 48 hours (2 days). At this time point, 5FU was added for 2 hours and then removed 
from the cells. Radiotracer uptake was investigated immediately after 5FU removal (day 
0 of 5FU treatment), and 1 and 2 days later, ie, day 1 and day 2 post 5FU treatment The 
total time cells were in culture was 4 days; 2 for cells to settle down and grow and 2 for 
experiments. From this point onwards in the text, days 0, 1 and 2 refer to time post 5FU 
treatment. Specific experimental conditions were defined from pilot studies described 
below.
6.3.4 Optimisation of seeding densities
Six-well plates (growth area of 9.5cm2 per well) were chosen to carry out 
investigations in 5FU cytotoxicity and subsequent radiotracer uptake, so that end-of- 
experiment harvesting would result in cell numbers sufficient for counting under a light 
microscope (5FU effects) and volumes large enough (2ml) for scintigraphy (radiotracer 
uptake).
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The purpose of this pilot study was to determine appropriate seeding densities - for 6-well 
plates - for the two cell lines which would result in actively growing cell populations 
(mimicking actively growing in vivo tumours) without reaching confluence. Cell 
concentrations from 100,000 cells per well to 500,000 cells per well (volume of 2ml) 
were seeded and left to adhere and grow for 48, 72 or 96 hours, ie times which 
correspond to days 0, 1 and 2 post 5FU treatment Cells were washed and disaggregated 
with trypsin/EDTA (200pl) as described previously, centrifuged and resuspended in fully 
supplemented medium, before counting cell numbers using a heamocytometer.
The seeding densities which gave appropriate growth without reaching confluence for all 
time points was 200,000 cells per well for HT29 and 200,000 cells per well for SW620. 
These plating concentrations were used for all experiments described below.
6.3.5 Dose response cytotoxicity of 5FU
HT29 and SW620 cells were seeded in 6-well plates and allowed to grow for 48 
hours. 5FU (2jig/ml to 150pg/ml) was placed in the wells (2 ml per well) and cells were 
incubated (37°C, CO2 incubator) in the dark for 2 hours (because 5FU is photosensitive). 
Drug containing medium was removed from the wells, cells were washed twice in PBS 
and fully supplemented medium was replaced. Parallel experiments were stopped at day 
0, immediately after 5FU removal, or days 1 or 2. Cells were trypsinized and then 
counted on a haemocytometre as described. Tryphan blue dye (Sigma, Poole, Dorset, 
UK.) was added to the cell mixture before counting to identify dead cells -  which take up 
the dye (Tryphan Blue exclusion method); Every 6-well plate had at least one untreated 
well as internal control. This study determined the dose for treating cells as 50pg/ml,
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which resulted in non-significant killing on day 0 (up to 10%), with killing on days 1 and 
2 significant at 50% and 75% respectively.
6.3.6 Uptake over time of radiotracers
HT29 and SW620 cells were seeded in 6-well plates and allowed to grow for 48 
hours, as described previously. FLT (lOOKBeq per well) was placed on the cells for 5 to 
180 minutes. The experiment was stopped at the different time points using ice-cold PBS 
(3x 2ml washes) and the cells were rapidly trypsinised. All washes and final cell aliquots 
were placed in the gamma counter (figure 3.3) to obtain a measure of the activity present 
in each cell sample.
6.3.7 Radioactive tracer uptake in 5FU treated cells
SW620 cells (200,000 per well) were seeded in 6-well plates and allowed to grow for 48 
hours, as described previously. Cells received 5FU (2 ml of 50jjg/ml per well) and were 
incubated in the dark for 2 hours (37°C, CO2 incubator). At that time, 5FU was removed, 
cells were washed twice with PBS and given fully supplemented medium. Cultures were 
given FLT (lOOKBeq per well, 90 min) on days 0, 1 or 2 post 5FU treatment. The 
experiment was stopped with ice-cold PBS (3 washes) and cells were trypsinised and 
counted on the gamma counter. Wells on each plate were given no radiotracer but were 
used for counting cell numbers from both 5FU treated and untreated cultures. Results are 
expressed as radioactivity present per viable cells. Only SW620 cells were used for this 
experiment, since a persistent infection at that point, made HT29 cell growth and FLT 
uptake suspect.
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6.3.8 Statistical analysis
To establish the significance of the effect of 5FU on cell growth, the Mann 
Whitney test was used with a p<0.05 as significant (SPSS 10.0.7 statistical software 
package, Inc, Chicago,IL).
To correlate change in FLT uptake with cell killing, non linear regression analysis 
was used.
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6.4 Results
6.4.1 Optimisation of seeding densities
Cells were seeded at different concentrations in 6-well plates and allowed to 
grow for 48, 72 or 96 hours. Results are shown for concentrations between 100,000 and 
300,000 (figure 6.1).
Cell growth curves HT29
HT29-100
HT29-200
HT29-300
Day 2 Day 3 Day 4
(a)
Cell growth curves SW620
SW620-100
SW620-200
SW620-300
-  10
Day 2 Day 3 Day 4
(b)
Figure 6.1 Cell growth curves at seeding densities between 100, 000 and 300,000 for HT29 (a) and SW620 
(b). In the colour key, 100, 200 and 300 refers to 100,000, 200,000 and 300,000 cells respectively. Results 
are shown as mean and standard deviation of 4 experiments.
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The highest seeding concentration for both cell lines (300,000 cells per well) 
usually resulted in maximum growth by 72 hours. Visual inspection under the light 
microscope confirmed confluence in these wells, at this time point. Thereafter, the 
number of cells in the well either stayed stationary or started decreasing, due to contact 
inhibition. A confluent state for the cells would not mimic an actively growing in vivo 
tumour. The smaller concentrations of 100,000 gave a small number of cells at 48 hours 
which rarely exceeded 40% confluence by eye. Therefore, 200,000 was considered more 
appropriate for the experiments. Furthermore, this level of growth would allow for a 
enough cells to survive and counted after 5FU exposure.
6.4.2 5FU cytotoxicity
Cells were exposed to various concentrations of 5FU and resultant cytotoxicity 
was quantified immediately after 5FU removal (day 0), or at days 1 and 2 post 5FU 
treatment. Growth of cells (expressed as percent of control) immediately after exposure to 
the drug (day 0) was not significantly different from control untreated celis, for any of the 
concentrations tested. This was evident for both cell lines as is demonstrated in figure 6.2. 
On day 1 post treatment, a dose-dependent decrease in %cell number was noted. This was 
maximal at doses equal or greater than 25pg/ml and produced approximately 50-55% 
drop in cell number compared to controls, for both cell lines. A further decrease in cell 
numbers (70-83% of controls) was seen on day 2 with all concentrations tested, with 
significant killing shown for 50 and 75pg/ml 5FU.
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Effect of 5-Fluorouracil on HT29 Colorectal Cancer Cell Number
% of control 
of that day
Dose of 5-Fluorouracil (ng/ml)
□  Day 0 
■  Day 1
□  Day 2
Effect o f 5-Fluorouracil on SW620 Colorectal Cancer Cell Number
% of control 
of that day
(b)
100 i
I
25
I
f i
50
Dose of 5-Fluorouracil (ng/ml)
■
75 100
□  Day 0 
■  Day 1
□  Day 2
Figure 6.2 Effect of 5FU on cell number for both cell lines, HT29 (a) and SW620 (b). Results are shown as 
medians and ranges of 4 experiments; apart from the dose 100pg/ml.
* significantly less growth than control was observed by 2 days post treatment at 50 & 75 pg/ml (p<0.05, 
Mann Whitney)
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FigureJk^Tshows absolute cell numbers over the time period of the experiment.
HT29 cells (figure 6.4(a)) which received no 5FU always grew well. However, the effect 
of even the smallest dose of 5FU on the absolute cell number was quite profound, with 
cells hardly growing after 5FU administration on day 0. Similarly to HT29 cells, SW620 
cells which were not treated with 5FU grew well over the course of the experiment 
(figure 6.4(b)). Unlike HT29, SW620 cells still grew after 5 and 10pg/ml 5FU 
administration, but to a lesser extend than control untreated cells. However, at 
concentrations greater than 25fig/ml, growth was stunted. The 5FU concentration chosen 
for contacting further experiments was 50 pg/ml.
HT29
20
Cell Number
x 10|5 10
15
5
—• — 75 ug/ml 5-FU
■ 5 ug/ml 5-FU
10 ug/ml 5-FU 
25 ug/ml 5-FU 
50 ug/ml 5-FU
Control
o
Day 0 Day 1 Day 2
Time
(a)
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Cell Number 
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25
20
15
Control 
5 ug/ml 5-FU 
10 ug/ml 5-FU 
25 ug/ml 5-FU 
50 ug/ml 5-FU 
75 ug/ml 5-FU
Day 0 Day 1 Day 2
Time
(b)
Figure 6.3 Absolute cell numbers over time following exposure to 5FU (5 - 75|jg/ml) at days 0,1,2 post - 
treatment for HT29 (a) and SW620 (b). Examples of one experiment per cell line shown.
6.4.3 FLT uptake over time
To determine a time when the uptake o f FLT by cells would reach saturation, the 
radiotracer was administered from 5 to 180 minutes. A steadily increasing uptake of 
cellular FLT was seen over the first 45-60min o f exposure, with saturation observed by 
90 minutes, for both cells lines (figure 6.4) Therefore, 90 minutes was chosen as exposure 
time to FLT for subsequent experiments.
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(b)
Figure 6.4 FLT uptake overtime seen for both cell linesHT29 (a) and SW620 (b). Results are shown as 
m eans and SD of 5 experiments.
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Before counting cell radioactivity, the wells had been washed three times to 
remove excess (figure 6.5). The largest percentage of radioactivity was present in the 
supernatant and of the remaining excess radiotracer, most was removed with subsequent 
washes.
Sequential washes SW620
600000
500000
400000 -
5 min incubation 
15 min incubation 
30 minute incubation 
45 min incubation 
60 minute incubation
300000 h
200000 -I
100000
Supernatant 1st wash 2nd wash 3rd wash cells
(a)
Sequential washes HT29
600000
500000
400000
5min incubation 
15 min incubation 
30 minute incubation 
45 minute incubation 
60 minute incubation
300000
200000
100000
Supem aten 1st wash 2nd wash 3rd wash cells
(b)
Figure 6.5 Example of amounts of radiotracer (counts per minute, CPM) present in supernatant, w ashes 
and cells, at 5 -  60 minutes of incubation, (a) HT29, (b) SW620.
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6.4.4 FLT uptake in 5FU treated cells
Cells (SW620) were treated with 5FU (50pg/ml, 2 hours) and were given FLT 
either immediately after 5FU removal (day 0), or after 1 or 2 days. For meaningful 
comparisons, the radioactivity taken up by specific test and experimental cell populations 
was corrected for cell number. Although 5FU treated cell numbers compared to controls 
were unchanged on day 0, a median 4.7- fold increase in FLT uptake was observed (table 
6 .1).
% cell killing Fold increase in FLT uptake
Median Range Median Range
Day 0 5 0 - 1 6 4.8 3 .6 - 6.9
Day 1 47 2 6 - 5 4 8.3 6 .5 - 10.2
Day 2 76 73-82 14.7 12.7 - 17.8
Table 6.1 % cell killing with corresponding increase in FLT uptake for days 0 - 2 .
On day 1, 5FU produced 47% (26-54) killing, with a corresponding 8.3 fold 
increase in FLT uptake. On day 2, the drug killed 76% of cells and FLT uptake increased 
14.7-fold. Therefore, as cell kill increased, there was a corresponding increase in FLT 
uptake which correlated well (R= 0.9) (figure 6.6)
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Figure 6.6 Correlation between cell killing and FLT uptake in the SW620 cell line.
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6.4 Discussion
The study in this chapter represents the first in vitro work carried out assessing the 
effect on FLT uptake of 5FU, when administered to CRC cell lines. 5FU belongs to a 
group of anti-cancer drugs known as the “anti metabolites” which exert lethal toxicity 
only for cells that are synthesising DNA and is therefore an S phase specific drug. After 
killing all vulnerable cells, an increase in concentration of 5FU will have systemic 
deleterious effects.
The doses of 5FU chosen for the experiments described result in approximately 
50% and 75% reduction in viable cell numbers at 1 and 2 days post treatment. The effect 
of 5FU seen here is comparable to previous research which found cells derived from the 
HT29 cell line to be most sensitive to 5FU from a total of six human epithelial cancer cell 
lines, including two colonic adenocarcinoma cell lines (Calabro-Jones et al., 1982).
In assessing response to chemotherapy using FDG-PET a decrease in the uptake 
of the tracer is taken as a indicator of a positive response (Young et al., 1999)The results 
of this study have demonstrated that in vitro, a dramatic increase in FLT uptake by CRC 
cells is seen, which corresponds to a positive response to 5FU therapy in terms of cell 
kill. This indicates that although increasing 5FU doses resulted in decreased absolute 
numbers of viable cells, the ability of these cells to take up FLT increased.
Dittmann et al have conducted the only in vitro study to date investigating the 
potential of FLT in monitoring the early response to chemotherapy (Dittmann et al.,
2002). Oesphageal cell lines were used and the early changes in FLT uptake following 
chemotherapy were assessed. The effects of 5FU, methotrexate, cisplatin and gemcitabine 
on FLT accumulation 4, 24 and 72 hours following exposure were recorded. FLT uptake
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was shown to increase 7-10 fold 24 hours following treatment with 5FU or methotrexate. 
A more moderate 5 fold increase in FLT accumulation was observed with gemcitabine. 
For the above drugs the total FLT uptake exceeded that of controls despite considerable 
reduction in cell counts due to cytostasis up to 72hr after treatment. In contrast, 
accumulation of FLT decreased in a dose related manner following exposure to cisplatin. 
This study suggests that tumour cell uptake of FLT reflects changes specific to the 
cytostatic drug used for treatment.
Both the study presented here and the results published by Dittmann et al 
highlight the significant increase in FLT uptake early after 5FU therapy. The implications 
of this dramatic increase can be partly explained by the mechanism by which FLT is 
sequestered by the cells. As has been previously discussed in section 1.10.3 FLT trapping 
is dependant on the S-phase specific enzyme thymidine kinase 1 (TK1). Recent in vitro 
work using pancreatic cell lines evaluated the expression of the pyrimidine metabolising 
enzymes in addition to the uptake of FLT (Seitz et al., 2002). TK activity was measured 
by Western blot analysis, immunofluoresence staining and flow cytometry. Quantitative 
DNA recovery was performed to assess FLT incorporation into DNA in addition to 
HPLC analysis of the FLT metabolites in cells. This study demonstrated the uptake, 
trapping and a 1.28% incorporation of FLT into the DNA TK1 was validated as the rate 
limiting enzyme of FLT metabolism and its over expression in pancreatic cell lines and 
human pancreatic cancer led to it being thought of as a promising tracer in this disease. 
Furthermore in a recent study by Barthel et al, TK1 levels were significantly increased 
compared to controls 2 days post 5FU treatment. This is consistent with the possibility
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arising from this study that increased FLT uptake may be partly the result of altered TK1 
catalytic activity (Barthel et al., 2003).
Like any in vitro study, the present study is a simplified version of the in vivo 
situation. It does not account for important parameters like vascularisation and 
oxygenation, which often vary in different tumour regions and may also be modulated by 
treatment. Furthermore, tumours regularly contain non-uniform cell populations of which 
a proportion are not tumour cells but supporting stroma cells, endothelial cells and 
inflammatory cells. PET imaging of in vivo tumours represents a reflection of the average 
behaviour of the cell types present in the tumour mass. This needs to be taken into 
account when interpreting the results of this study.
If the 5FU mediated increase in FLT accumulation demonstrated in this study is 
also seen in vivo then persistent uptake after treatment of CRC with this agent would be 
non-diagnostic, since a drug induced increase might obscure effective proliferation 
inhibition by the drug. Barthel’s study demonstrated FLT uptake by fibrosarcomas grown 
in mice was actually reduced following 5FU treatment. This corresponded to a decrease 
in tumour cell proliferation, detected by staining histological sections (Barthel et al.,
2003). It would be interesting to carry out similar investigations in the clinical setting to 
determine the uses of FLT in mapping treatment response in CRC.
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6.5 Conclusion
In response to the treatment of CRC cell lines to 5FU chemotherapy, FLT 
surprisingly demonstrated a dramatic increase in uptake. A likely explanation of this is 
through an increased activation of the salvage pathway of DNA synthesis and the 
cytostolic enzyme TK1. If a similar pattern is observed in vivo then the problem will be 
determining whether the drug has caused effective proliferative inhibition or indeed one 
is simply observing a drug induced increase in tracer accumulation.
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CHAPTER 7 
Conclusion
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7.1 Summary of findings
The success of PET in oncological imaging is based on the knowledge that 
malignancy leads to an alteration in cellular biochemical reactions. Synthesis of positron- 
emitting analogues from molecules of organic matter can demonstrate these biochemical 
processes. The combination of PET and the glucose tracer FDG is an established imaging 
tool which has made a significant impact in CRC.
The recent development of the biologically stable thymidine analogue FLT has 
allowed PET to visualise a different biological process. This is achieved by targeting the 
salvage pathway of DNA synthesis, and hence the images are related to cellular 
proliferation.
This thesis has investigated various techniques for the characterization of FLT 
uptake in vivo in patients with primary and metastatic CRC. In chapter 3 when time 
activity curves were acquired using the gold standard oncological PET tracer FDG and 
compared to those acquired using FLT, there was lower uptake by FLT as a function of 
time. In terms of quantitative analysis the behaviour of FLT in vivo utilization was 
characterized by a 3k model for data up to 60 minutes p.i. In addition, a high correlation 
was demonstrated between the NLR(3k) and the simplified Patlak analysis with either 
measured or image derived input functions. The good correlation seen between SUVs and 
the quantitative measures of FLT utilization in terms of the net influx constant Ki 
suggests that non-invasive methodology may be used to assess the proliferation rates of 
CRC tumours with FLT. In view of these findings the quantification of the uptake of this
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new tracer using SUVs represents a true reflection of rate of uptake of the tracer. It was 
therefore justified to use SUVs.
In chapter 4, FLT was shown to demonstrate considerably lower cellular trapping 
and hence lower SUVs in comparison with FDG. This lack of correlation between the 
retention of the two tracers gave further evidence to there being no direct relationship 
between glucose utilisation and the uptake of FLT in tumour cells. Unfortunately poor 
sensitivity was demonstrated in the detection of liver metastases which is a common site 
for metastatic spread. This makes FLT a poor candidate as a staging tool for CRC. 
Although lacking in sensitivity, FLT did display potential in improving the specificity for 
the detection of CRC, as in this study no FLT uptake was seen in the inflammatory 
lesions which displayed high avidity for FDG.
Chapter 5 demonstrated that FLT PET may be used as a non-invasive method of 
quantitating cellular proliferation in CRC. The tracer FDG, on the other hand, does not 
offer this. This might allow CRC to be imaged at a pre-treatment stage and define the 
population of patients who might benefit from neo-adjuvant therapy. In addition, it may 
also help in identifying a group of patients with recurrent disease who would not benefit 
from first line anti proliferative chemotherapy as a result of the low proliferation rate of 
the tumour as demonstrated by the low SUV on FLT PET imaging. The prognostic 
implications of the uptake of this new PET probe warrant further investigation in terms of 
response to chemoradiotherapy and ultimately survival.
The final results chapter of this thesis (chapter 6) attempted to assess the effect on 
FLT uptake of the most commonly used chemotherapeutic agent for CRC. The dramatic 
increase in FLT uptake demonstrated in vitro following 5FU administration most
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probably reflected the activated salvage pathway of DNA synthesis, overshadowing the 
inhibition of proliferation caused by 5FU. This of course presents a potential problem 
trying to determine whether the drug has caused effective proliferative inhibition. 
However it was encouraging to see excellent correlation between the increase in FLT 
uptake and cell kill induced by the 5FU.
202
7.2 Future perspectives
'The development of FLT has raised the hope of a PET probe whose specific 
biological action has the potential to (a) determine tumour proliferation rates and 
therefore aggressiveness and (b) monitor response to chemoradiation therapy.
Work in this thesis demonstrated that FLT may be used as a non-invasive in vivo 
assessment of proliferation within CRC. Its potential to act as an indicator of tumour 
aggressiveness through this biological parameter has to be followed up in terms of 
patient outcome and ultimately survival. This would enable us to see if uptake of FLT 
indeed gave a true reflection of the future pathological disease process.
The effect on tracer uptake that 5FU chemotherapy has on CRC cell lines was 
also investigated in this thesis. This work has to be taken from the bench and assessed in 
vivo. If meaningful results are obtained FLT-PET might allow the clinician to overcome 
the inherent problems of tumour heterogeneity and tissue sampling in assessing a 
tumour’s response to therapy.
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Appendix A
PET components and image 
generation
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i) Components of a PET facility 
Cyclotron
1 < |  1 1 1 Q
The positron emitting radionuclides 0, N, C and F are all produced by nuclear 
bombardment in a cyclotron. The cyclotron consists of two ‘dee electrodes’, which are 
about lm  in diameter. An ion source is located at the centre of the dees and produces 
negative ions. The application of an alternating voltage causes the ions to move from one 
dee to another. The ions are forced to travel in a circular orbit by a strong magnetic field 
at right angles to the plane of the dees. The diameter of orbit increases as the ions pick up 
energy from the electric field. As they approach the outer edge of the dees, the ions are 
passed through a thin carbon stripping foil which where electrons are stripped and the 
resulting ions move out of the magnetic field and directed towards a target to undergo 
a nuclear reaction with a specific target material needed to produce the radionuclide 
required.
The short half lives of the radionuclides 150  {Tm = 2.07min), 13N (Ti/2=9.96min) 
andu C (Ti/2 = 20.4min) necessitate that the scanner be sited close to the cyclotron. The 
most widely used clinical PET tracer is [18F]Fluoro-2-Deoxy-D-glucose (FDG) which 
uses the radionuclide 18F incorporated into the biological compound FDG. This synthesis 
occurs in a radiochemistry laboratory. The T\n of 109.8min allows for several hours 
transport time, therefore for centres without their own on-site cyclotron, a radiotracer 
distribution facility is used which supplies [18F]FDG once or twice daily. Prior to use or 
dispatch the PET tracer undergoes strict quality control and quality assurance eg, high 
performance liquid chromatography (HPLC) is employed to ensure adequate chemical, 
radiochemical and radionuclide purity.
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FDG is the most commonly used PET tracer for CRC imaging and is described in
detail in section 1.7.2. Another tracer which has been used with effect is 
18 • • •[ F]Fluorouracil. This is a ligand which is identical to the non- labelled fluorouracil 
chemotherapeutic agent used in CRC, has also been used in the assessment of CLM. A
18 15double tracer study usmg [ FJFluorouracil and [ 0]water identified the transport system 
of fluorouracil in the liver metastases and showed potential for the selection of those 
patients more likely to profit from intra-arterial chemotherapy (Dimitrakopoulou-Strauss 
etal., 1998).
PET scanners
There are a variety of detectors capable of imaging positron-emitting tracers. 
They can be broadly divided into four classes:
i) thallium doped sodium iodide gamma camera with lead collimators
ii) dual-head rotating sodium iodide camera with modified electronics for 
coincidence detection
iii) dedicated sodium iodide PET camera with ring detection system
iv) dedicated bismuth germinate oxide (BGO) PET camera with either a full or
partial ring detection system.
It is not in the realms of this thesis to discuss the technology of each of these detectors as 
current dedicated PET scanners are high performance multi-slice devices usually 
employing discrete BGO scintillation crystals. The PET scanner used in this thesis is the 
Advance Scanner (Advance, General Electric Medical Systems, Milwaukee, Wl). This 
consists of 12,096 bismuth germinate crystals constructed into a ring which surrounds the
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patient. This is considered to be the gold standard because the BGO crystals are better 
suited to the 51 IKeV photons produced. Much higher count rate performance is achieved 
due to the multicrystal layout, allowing a higher injected dose and improved image 
quality.
ii) Annihilation coincidence detection
The average range of a positron in soft tissue is only a few millimetres following 
this journey it combines with a electron to produce two 51 IKeV J  rays which are emitted
at almost 180° to each other. If these are detected within a certain time of each other (this 
is known as the coincidence time window) then it is assumed that they both originated 
from the same annihilation event, and the original disintegration occurred along a line 
joining the two detection positions and coincidence detection occurs. The BGO ring 
surrounding the patient is arranged in such a way that pairs of detectors are placed on 
opposite sides of the ring to allow them to operate in coincidence with each other and 
data can be reconstructed without the use of a collimator.
iii) Attenuation correction
The definition of “attenuation” is the process by which a beam of radiation is 
reduced in energy when passed through tissue or other material (Dorland.,1988).
The ability to directly measure and correct for photon attenuation makes PET an 
inherently quantitative procedure, enabling the rates of biochemical processes to be 
measured in vivo. Attenuation correction can be performed using an external 
(transmission) source. PET allows the fraction of the photon flux attenuated by tissue to
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be independent of where along the line joining the detectors the radionuclide lies. 
Therefore accurate attenuation correction can be made. The correction factors are 
obtained by the calculation of the ratio between two additional scans, a blank scan and a 
transmission scan, which are performed with external positron emitting sources 
(Germanium rod sources). The introduction of the state of the art Discovery LS PET/CT 
scanner used in this thesis, utilises CT images for PET attenuation correction (CTAC). 
The advantages of this are that it produces less noisy transmission maps with shorter 
times of acquisition. Recent work by Visvikis et al has demonstrated that with FDG, 
CTAC is a viable alternative to rod sources for AC, reducing overall time of wholebody 
transmission acquisition from 15-20 min to 0.5-1.5 min (Visvikis D et al., 2002).
iv) Image reconstruction
The theory of reconstruction is very mathematical and is outside the scope of this 
thesis. Briefly two methods are commonly used. Filtered back projection (FBP) is the 
most common technique in use with gamma cameras as it is quick and provides 
acceptable results. The theory is that the acquired planar images are projections of the 
distribution of activity. These projections can subsequently be backprojected onto a 
matrix placed at the centre of the camera’s field of view to produce an image. Simple 
back projection creates a very blurred image and a filter is applied to the data to remove 
this blurring and to control noise and artefacts at high spatial frequencies hence the term 
FBP.
Ordered Subsets Expectation Maximisation (OSEM) method is the most widely applied 
iterative reconstmction technique, which modifies the reconstructed data set until
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projections formed from the reconstructed dataset match those measured from the patient. 
This type of reconstruction used to be much slower but courtesy of modem improved 
computer technology is in common use and able to include corrections for scattering, AC 
and variation in response with depth.
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Study No: 00/0295
Title: A comparison of 2-F18 fluoro-2-deoxy-D-glucose (FDG) with F18-fluorothymidine
PET for imaging patients with colorectal cancer.
Thankyou for considering the amendments to our study. W e have addressed the four issues raised as 
follows:
1. The information sheet now contains details o f the risks associated with arterial line insertion.
Pain, haemorrhage and thrombosis. (Please see highlighted section on the amended information 
sheet attached)
2. Local anaesthetic will be used for arterial cannulation.
3. The gauge o f  the cannula will be 20 gauge (1mm diameter).
4. Bilateral arterial supply to the hand will be confirmed and documented with hand held doppler and
if  there is any doubt o f the presence o f  an Ulnar artery then the patient would be excluded from the
f  study.
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fluorodeoxyglucose (FDG) PET imaging in patients with metastatic or locally 
advanced cancer: A phase I pilot study.
Thank you for letting us s e e  the above application which was reviewed by the Chairman and agreed  
by Chairman’s  Action. There are no objections on ethical grounds to this study going ahead on 
condition that the radiation dose is explained in the patient information sheet. P lease supply a copy  
of an am ended information sheet for com pleteness of our records.
Please ensure that you have obtained final approval from the Trust (via the R&D office) before 
proceeding with your research.
Please note that it is important that you notify the Committee of any adverse events or changes (name 
of investigator etc) relating to this project. You should also notify the Committee on completion of the  
project, or indeed if the project is abandoned. Please remember to quote the above number in any 
correspondence.
Yours sincerely
Professor Andre McLean, BM BCh PhD FRC Path 
Chairman
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Dear Mr Francis
Study No: 00/0295 (Please quote in any correspondence)
Title: A comparison of 2-F18 fluoro-2-deoxy-D-glucose (FDG) with F18-
fluorothymidine PET for imaging patients with colorectal cancer.
Your amendment to the study w as considered by Ethics Committee A and the following points 
raised:
1. The information sheet should contain details of the risks associated with arterial cannulation 
(pain, haemorrhage, thrombosis).
2. Local anaesthetic should be used for arterial cannulation.
3. What is the gauge of the cannula to be used?
4. Do you intend to confirm bilateral arterial supply to the hand via the ulnar artery prior to
cannulation? If so, do you intend to cannulate the radial artery in patients who do not have
an ulnar artery?
If you can address th ese  issues then your study may proceed.
Yours sincerely
Dr R MacAllister 
Chairman
Francis3oct/rm ac/03/10/01
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4C O N F ID E N T IA L  
Patient Information Sheet 
A comparison of F18 -fluorothvmidine (FLT) PET with routine 
PET in patients with colorectal cancer
* You are invited to take part in a research project. You do not have to take part in this study if  you do not want 
| to. If you do decide to take part you may withdraw at any time without having to give any reason. Your 
] decision whether to take part or not will not affect your care and management in any way. All proposals for 
| research using human subjects are reviewed by an ethics committee before they can proceed. This proposal was 
reviewed by the joint UCL/UCLH Committees on Ethics o f Human Research.
1. This study aims to establish if  positron emission tomography (PET) scans using an alternative 
radioactive tracer, FLT, is more accurate than the conventional radioactive tracer, FDG for im aging 
bowel cancer.
2. It has been shown that FDG-PET is an accurate and safe means o f imaging patients with bowel cancer. 
This allows the most appropriate treatment to deal with an individual patient’s cancer to be chosen. The 
information, therefore, influences the extent o f surgery performed and possibly the use o f  other 
treatments such as chemotherapy or radiotherapy.
3. The accuracy o f FDG-PET, although extremely good, is not perfect. One method o f improving this 
situation is to use an alternative radioactive substance to pinpoint the site of cancer cells in the body. 
FLT is such an alternative and it can be safely substituted for FDG for PET scanning.
Description o f the research study :
In addition to a routine FDG-PET scan that patients with bowel cancer undergo at this hospital, you will have
an FLT-PET scan. PET scans take place in the Institute of Nuclear Medicine at the Middlesex hospital, usually
on separate days. The procedure will entail you having to fast for a period o f four hours (so that glucose that
you consume in your diet will not interfere with the FDG-PET scan). Once you are in the Institute o f Nuclear
Medicine you will be given an injection of FDG (chemically similar to glucose, but which has been labelled
with a radioactive substance) through a cannula (plastic tube) in a vein. The radioactivity lasts approximately
90 minutes, therefore you do not have to wait for the scan. You will have to lie on a platform that moves you
into the scanner. The scan itself takes one hour and you will need to lie still with minimum interaction with
staff, as this interferes with the scan quality. The whole process takes between 2 to 4 hours. The procedure for
the FLT scan is similar to that described above, but you will receive an injection of FLT instead o f FDG. Most
importantly, you will have a cannula inserted into an artery and a vein in your arm so that we can take blood
(about 50 ml in total -  1/6 o f the volume of a standard fizzy drinks can) in order to analyse it. Before inserting
the arterial cannula the blood supply to your hand will be evaluated to assess i f  it is OK for you to take part in
the study. We undertake this so that in the highly unlikely event that the artery should become damaged o t
clotted (thrombosed) there would be no adverse affects/ Local anaesthetic w ill be used prior to inserting the
arterial cannula to minimise any pain or discomfort. After removal o f  the cannula we will press on the artery so
as to stop it bleeding, This all helps to increase the accuracy o f the scan report we can give to the doctors
looking after you. It will also help us develop a way o f working out the distribution of FLT in the blood so that
patients in the future may avoid the blood tests. The cannulae will remain in your arm for an hour. If  you
proceed to have an operation, the surgeon will make a thorough examination and document the findings. A tiny
fragment of the cancer and surrounding tissue will be taken for examination by one of the doctors involved in
the study. Cancers need growth promoting agents as well as a blood supply therefore particular attention will be
? 1  A
paid to the presence o f these factors. The main part o f  the tissue, which is removed, will be sent for analysis b> 
apathologist, as is the usual practise. A comparison will be made between both types o f  PET scan to see i f  
there is in fact any difference in the information gained. Both scan findings will then be related to the analysis 
of the tissue removed.
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FOR THE
ADMINISTRATION OF RADIOACTIVE MEDICINAL PRODUCTS 
Certificate Reference Number RPC 141-790 (15381)
It is hereby certified for the purposes of the Medicines (Administration 
of Radioactive Substances) Regulations 1978, amended by the Medicines 
(Administration of Radioactive Substances) Amendment Regulations 1995, 
that
Peter Josef ELL
The Middlesex Hospital
Institute of Nuclear Medicine
Mortimer Street
London
WIT 3AA
may administer until 8 Jul 2003 the radioactive medicinal products 
specified in the Schedule to this certificate for the purpose (s) there 
specified.
for The Secretary of State for Health
Health Care Directorate 9-Jul-2001
Specialist Clinical Services Division 
Department of Health
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MEDICINES CONTROL AGENCY
Market Towers 1 Nine Elms Lane London SW8 5NQ 
Telephone 020 1212 0220 
Facsimile 020 1213 0443
Professor P J Ell 
Institute o f Nuclear Medicine 
Mortimer Street 
LONDON W IT  3AA
Dear Professor Ell
THE MEDICINES (EXEMPTION FROM LICENCES) (SPECIAL CASES AND 
MISCELLANEOUS PROVISIONS) ORDER 1972 
PRODUCT: (F-18) Fluorothymidine
I am writing in connection with your notification under the M edicines (Exemption from 
Licences) (Special Cases and M iscellaneous Provisions) Order 1972 which relates to a 
proposed trial using (F-18) Fluorothymidine supplied by Imaging Research Solutions Ltd.
This exemption is effective from 6 June 2001; the above-named supplier may lawfully supply 
the product for the purpose outlined in your notification: the Licensing Authority have 
decided not to issue a direction under article 4(2)(v) o f the Order. There is no need for a 
marketing authorisation or for a clinical trial certificate for the purpose o f the trial.
Please note that all serious unexpected adverse reactions occurring during the trial should be 
notified to the Licensing Authority.
In coming to its decision the Licensing Authority has not evaluated the safety, quality and 
efficacy o f  the product, and this notice should not be taken to imply approval o f  the product 
in terms o f  safety, quality or efficacy.
Remark:
* It is assumed that approval fo r  this trial will be sought from  the Administration o f  
Radioactive Substances Advisory Committee.
We shall be pleased to see a copy o f any report which is produced as a result o f this trial.
Yours sincerely
i t t -  ( 5 3  Y  '
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Our Ref: M F8000/11079 
6 June 2001
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Institute of Nuclear Medicine -  SOP Dose Calibrator QC in PET
SOP: PET_9 TITLE: Dose Calibrator QC in PET
R ev: 1.0 D ate: 22/10/2001 R eview : Oct 2002
G ro u p : PET A uthor: CET / WW A u th o rise d : PJE
OVERVIEW
T he d o se  calibrator in the PET Suite n e e d s  to be calibrated every  day th a t d o se s  a re  m easu red  in the 
calibrator. T he calibration n ee d s  to be done before any d o se s  a re  m easu red .
RELEVANT STAFF
INM practitioners and  operators working in the PET Suite.
BACKGROUND
This SO P details how to perform daily QC testing on the PET Unit V eenstra  V D C -404 Radioisotope 
D ose  Calibrator. For further information regarding the  calib rators’ correct operation, refer to the  
O w ner's M anual (copies a re  kept in the D ose Calibrator QC record file in the  PET Unit and  in the 
P hysics Office).
T he te s ts  a re  designed  to a) check the operation of the calibrator and  b) its re sp o n se  to a  standard  
137C s sou rce  to elim inate the possibility of sudden  equipm ent failure and incorrect readings. 
Additionally, a s  each  radioisotope setting links to specific softw are and /o r electronic circuitry, a 
reading m ust be obtained for the 137Cs source for each  radioisotope setting to be u sed  that day. This 
policy is in line with current guidelines for the daily testing of d o se  calibrators, developed by the  NPL 
and  IPEM. The following te s ts  m ust be perform ed each  day  for e a c h  calibrator to be used  to  a s sa y  
d o se  preparations, and m ust be perform ed before tha t calibrator is u se d  for the first time that day.
PROCEDURE
• E nsure that the LCD show s ‘BGD O n’. With no activity in th e  ch am ber or in the vicinity se lec t 
MODE and  then se lec t ZERO  ADJUST. P re ss  ENTER, wait while th e  cycle com pletes (abou t 30- 
60 seco n d s) and  then hit ENTER to continue.
• S elect BATTERY TEST. P re ss  ENTER, wait while the  cycle com ple tes (about 10 seconds). 
C heck that the reading is g rea ter than 135 volts, and en ter th is reading on the  record sh e e t for 
Daily QC and  C onsistency  Checking (see  Appendix).
NB If th e  b a tte ry  re a d in g  is le s s  th a n  135 v o lts  it m u s t b e  re p la c e d .
• Hit ENTER to continue, and se lec t MODE to return to the m e asu rem en t sc reen .
• Now u se  the C s-137 standard  source  to record the  activity m e asu red  in the Cs-137 channel and
the F-18 channel. The sou rce  is kept in the locked isotope sa fe  store, with the key is kept under
the calibrator control panel. R em ove the  s tandard  sou rce  and p lace  it centrally in the  dipper.
• To se lec t the 137-Cs channel, hit the SELECT ISOTOPE key and  u se  the  arrow  keys to locate 
CS-137. P re ss  ENTER to m easure . To se lec t 18-F, locate F-18 using the arrow s.
• Note the  m easu red  activity for both channels on the  record s h e e t for Daily QC and  C onsistency  
Checking. If th e  m e a su re d  ac tiv ity  fo r e i th e r  c h a n n e l is o u ts id e  th e  p r in te d  ± 5%  lim its 
sh o w n  o n  th e  rec o rd  s h e e t ,  no tify  th e  D uty  P h y s ic is t  im m ed ia te ly .
• Return the C s-137 source  to the safe  and  lock it.
NB Do n o t fo rg e t to  s e le c t  F-18 p rio r to  m e a su r in g  th e  p a t ie n t’s  d o s e .
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Institute of Nuclear Medicine -  SOP Dose Calibrator QC in PET
APPENDIX
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In s titu te  of N uclear M edicine, UCL H o sp ita ls  NHS T rust
PET Unit V eenstra  VDC ■ 404 D o se  C alib rato r
I ! i i i
Oailv QC Check for C orrect Operation and C o n s is te n t of Res ponse
I I I I I i
137C aesium  D ose C alib rato r S ta n d a rd  R e fe ren ce  S o u rc e  : Month beginning : Nov-01
Calibration Data 8.77 MBq on 23 Aug 2001
Serial No. HT 778 | I
M anufacturer AEA Technology /  QSA GmbH
............
117Caesium Setting 1*Flourlne Setting
Operator 3kg Activity Ion Chamber Calculated Measured Calculated 1 Measured
Data Initials (MBq) Voltage (V) -5% Activity ♦ 5% Activity -5% Activity +5% Activity
01-Nov-01 8.295 8.731 9.168 4.958 5.217 5.478
02-Nov-01 8.294 8.731 9.187 4.956 5.216 5.477
03-Nov-Ol 8.294 6.730 9.167 4.955 5.216 5.477
04-Nov-Ol 8.263 8.730 9 188 4.955 5.216 5.477
05-NOV-01 8.293 8.729 9 165 4 955 5.216 5.478
06-Nov-01 8.292 8.728 9.165 4.954 5.215 5.476
07-Nov-01 8.2B2 8.728 9.104 4.954 8.215 5.476
08-Nov-OI 8.291 8.727 8.164 4.954 5.215 5.475
OS-Nov-01 8.290 8.727 9.163 4.953 5.214 5.475
10-Nov-01 8.290 8.726 9.163 4.953 5.214 5.475
11 Klov-01 8.289 8.726 9.162 4.953 5.214 5.474
12-Nov-Ot 8.289 8.725 9.161 4.953 5.213 5.474
13-Nov-01 8 288 8.725 9.161 4.952 5213 5.474
14-Nov-OI 8 288 8.724 9.160 4.952 5.213 5.473
IS-Nov-01 8.287 8.724 9.160 4.952 5.212 5.473
16- Nov-01 8.267 8 723 9.159 4.951 5.212 5.472
IT-Nov-01 6.286 8.722 9.159 4.951 5.212 5.472
IB-Nov-01 8 286 8.722 9.158 4.951 5.211 5.472 i
19-Nov-OI 9.285 8.721 . 9.157 4.950 5.211 5.471
20-NOV-01 . 8 285 8.721 9.157
1--------
4.950 5.211 5.471
21-Nov-OI 8.284 8.720 9.156 4.950 5.210 5.471
22-Nov-01 8.284 8.720 9.156 4.949 5.210 5.470
23-Nov-01 8.283 8.716 9.155 4.94B 5.210 5.470
24-Nov-OI 8.283 8.719 i1 9.154 4.949 5.209 5.470
25-NOV-01 0 282 8.718 9.154 j_ 4.946 5.209 5.469
26- Nov-01 8.282 8.717 9.153 4.948 5.209 5.469
27-NOV-01 8.281 8.717 9.153 4.948 5.208 5.469
28-Nov-OI 8.281 8.716 9.152 4.948 5.208 5.468
29-Nov-OI 8.280 8.718 9 152 4.947 5.208 5.468
30-NOV-01 8.279 8.715 9.151 4.947 5.207 5.468
01-Oac-OI 1 8.279 8.715 9 150 4.947 5.207 5.467 ! '
S O P  No: PE T_9 V ersion P a g e  of P a g e s
D ate  of Issue: 22/10/2001 1.0 2 2
222
Appendix E
Record sheet of 
radiopharmaceutical holdings
223
SOP 
No: 
PET_7 
Version 
Page 
of Pages 
Date 
of Issue: 
22/10/2001 
1.0 
2 
2
>
INM PET Facility - Record Sheet of Current Radiopharmaceutical Holdings -o
m
Date : ______________  Radiopharm aceutical Form :   Radiopharmaceutical QA Status (circle and in itia l) :  P a ss  Fail ZD
C onsignor ( tick ) :  University of Cambridge UMDS (Guy’s and St. Thom as’) MRC Cyclotron Unit, H am m ersm ith X
Activity A ssay  - Entire Shipm ent
Stock Volume (mis) Time of Assay Assayed Activity (MBq) Two A ssays in A greem ent ? j
Consignor Activity Assay (i.e. both agree within ± 10%)
Decay-Corrected Consignor Assay - circle below as appropriate
INM PET Unit Activity Assay Yes /  No
Activity A ssay  - S ub -d ispensed  Preparations
Time of A ssay O perator
Initials
Stock Volume 
Diluted ?
Volume 
Removed (mis)
Assayed Activity 
(MBq)
Volume 
Remaining (mis)
Activity
Remaining
P urpose  I
........r
r I
C onsignm ent of Current H oldings to W aste
j Time O perator Initials Volume Remaining (mis) Estimated Max. Remaining Activity (MBq) P urpose
r WASTEt WASTE
Institute 
of 
Nuclear M
edicine 
- 
SOP 
M
easuring 
FDG 
upon 
arrival in 
the 
PET 
suite
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1
18
J  _ .1........
Flourine - Decay Factors relative to Calibration Time
minutes d ecay  factor minutes decay  factor
0 .070
0 .070
0.069
0.069
0.068
0 .068
decay  factordecay  factordecay factor decay factordecay  factor decay factor m in u tesm in u tesminutes minutes m in u tes m in u tes
1.000
0 .994
0 .987
0.981
0 .975
0 .969
0 .963
0.149
0.148
0.148
0.147
0.146
0.145
0.102
0.102
0.101
0.100
0.100
0 .099
0.218 
0 ,217 
0 .215 a214 
0.213 
0.211
0 .680
0.676
0.672
0 .667
0.663
0.659
0.466
0.463
0.460
0.457
0.454
0.451
0 3 1 9  
0.317 
0.315 
0.313 
0.311 
0 .309
0.067
0.067
0.0980 .1 4 4
0.143
0 .307
0.305
0.2100 .9 5 7
0.951
0.655 0.448
0.2090.446
0.0670.0970.1420.2070.443 0.3030 .945 0 .647
H O  _  0 .0 6 6
431 0 .066
432_ 0 .065
0.065
0.0970.206 0.1410.440 0 .3 0 1
0.299
0 .9 3 9
0 ,933
0 .927
0.643
0 .0960.1400.2050.4370 .639
0.0950.1390.297 0.2040 .635 0.434
0.1380.2960.4320.921
0.0640 .0940.1380.294 0.2010.4290 .915 0 .627
0 .0640 .0940.1370.2000.2920 .623 0.4260.910
0 .0640.199 0.1360.2900.4240 .904
0.0630.0920.1350.1970.421
0.418
0.2880 .6150 .898
0.0630.0920 .1340.1960.2860 .893
0.0620.133 0.0910.1950.2850.4160 .887 0 .607
0.0620.0910.1320.1940.2830 .603 0.413
0.0620.0900.1320.1920.410 0.2810 .6000 .876
0.0900.2790.4080 .870 0 .596
0.0890 .1300.1900.405 0.2770.5920 .865
0.061
0 .0 6 0
0.0880 .1290.1890.2760.4030 .859 0 .588
0.1280.1880.2740.4000 .5850 .854
0.0600.0870.1280.1860.2720.3980 .849
0.059
0 :059
0.0870.1270.1850.3950.5770 .843
0.0860.1260.1840.2690.3930 .5740.838
0.0590 .0860.1250.1830.2670.3900.5700 .833
0.0580:058
0.058
0 .057
0 .0850 .1240.1820.2650.3880.5660 .827
0 .0850 .1240.2640.3850 .5630 .822
0 .0840.1230.1790.2620.3830 .5590 .817
0 .0840.1220.1780.2600.3800 .5560 .812
0.0570.378 0.2590 .807 0 .552
0 .0560 .0830.1760.2570 .549 0.3760 .802
0 .0 5 6
0 .056
0 .055
0 .0820.1200.1750.2560.373 
0.371 I
0 .5450.797
0.0810.1190.1740.2540 .5420 792
0.0810.1180.1730.2520.3690 .5380.787
0.0550.0800.1180.1720 .535 0.3660.782
0.0550 .0 8 00.1170.2490.3640.777 0 .532
0.079 0 .0 5 4
0 .054
0.170 0.1160.2480.3620.5280.772
0.0790.1680.246 0.1150.3590 .767 0 .525
0.0540.167 0.1150.2450.3570.5220 .762
0.078 0.0530.1660.243 0.1140.3550 .5180 .757
0 .077 0 .0530.165 0.1130.3530 .5150.753
0.077 0 .0530.240 0.164 0.1120 .512 0.3500 .748
0 .0 7 6 0.0520.1630.238 0.1120.3480 .743 0 .509
0 .076 0 .0520.237 0.1620 .738 0 .506 0.346
0 .076 0 .0520.235 0.1100.734 0 .502 0.344
0 .0750.160 0.0510.234 0.1100 .729 0 .499 0.342
0 .0750.232 0.159 0.1090.725 0 .496 0.340
0 .0740.158 0.0510 .720 0 .493 0.337 0.108
0 .074 0.0500.335 0.230 0.157 0.1080 .716 0 .4 9 0
0 .073 0.0500 .487 0.333 0.228 0.156 0.107
0 .0730 .707 0 .4 8 4 0.155 0.0500.331 0.227 0.106
0 .072 0.0490.702 0.481 0.329 0.225 0.154 0.106
0.698 0 .478 0.327 0.224 0.153 0.105 0 .072 0.049
0.693 0 .475 0.325 0.222 0.152 0.0710 .104 0.049
0.323 0.221 0.104 0 .0499,331 0,2-20 0.103 0 .070 0.048
OO
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Part B: Diagnostic Procedures -  PET
Radioactive medicinal product Investigation Route of 
adminis­
Diagnostic
reference
Effective
dose
Dose 
to the
Serial Radio­
nuclide
Chemical
form
tration level (MBq) (mSv) uterus
(mGy)
1 2 3 4 5 6 7 a
6b2i 11C L-methyl-
methionine
Brain tumour 
imaging
IV 400 2 1
6b2ii 11c L-methyl-
methionine
Parathyroid
imaging
IV 400 2 1
7a22i 13N Ammonia Myocardial 
blood flow 
imaging
IV 550 2 1
8a21i 15q Water (bolus) Cerebral blood 
flow imaging
IV 2000 2 1
8a21ii 15q Water (bolus) Myocardial 
blood flow 
imaging
IV 2000 2 1
9a21i 18F FDG Tumour
imaging
IV 400 10 7
9a22ii 18f FDG Myocardial 
imaging *
IV 400 10 7
9a23i 18F Fluoride Bone Imaging IV 250 7 5
1
■i
2 2 8
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CONFIDENTIAL 
Patient Information Sheet 
A comparison of F18 -flnorothvmidine (FLT) PET with routine 
PET in patients with colorectal cancer
Principal Investigators: 
Professor P.J. Ell,
Institute of Nuclear Medicine, 
Mortimer Street,
London WIN 8AA
Other Investigators:
Prof. I. Taylor Department o f  Surgery
Mr. D. L. Francis Department o f  Surgery / Institute o f  Nuclear
Medicine
Dr. D.C. Costa Institute o f N uclear Medicine
If  you have any queries regarding this information sheet, please contact M r D. L. Francis in 
the Department o f  Surgery on 07976 390684.
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CONFIDENTIAL  
Patient Information Sheet
A comparison of F18 -fluorothymidine (FLT) PET with routine 
PET in patients with colorectal cancer
You are invited to take part in a research project. You do not have to take part in this 
study if you do not want to. If you do decide to take part you may withdraw at any time 
without having to give any reason. Your decision whether to take part or not will not 
affect your care and management in any way. All proposals for research using human 
subjects are reviewed by an ethics committee before they can proceed. This proposal was 
reviewed by the joint UCL/UCLH Committees on Ethics of Human Research.
1. This study aims to establish if positron emission tomography (PET) scans using 
an alternative radioactive tracer, FLT, is more accurate than the conventional 
radioactive tracer, FDG for imaging bowel cancer.
2. It has been shown that FDG-PET is an accurate and safe means of imaging 
patients with bowel cancer. This allows the most appropriate treatment to deal 
with an individual patient’s cancer to be chosen. The information, therefore, 
influences the extent o f surgery performed and possibly the use o f other 
treatments such as chemotherapy or radiotherapy.
3. The accuracy of FDG-PET, although extremely good, is not perfect. One method 
of improving this situation is to use an alternative radioactive substance to 
pinpoint the site o f cancer cells in the body. FLT is such an alternative and it can 
be safely substituted for FDG for PET scanning.
Description of the research study:
In addition to a routine FDG-PET scan that patients with bowel cancer undergo at this 
hospital, you will have an FLT-PET scan. PET scans take place in the Institute o f Nuclear 
Medicine at the Middlesex hospital, usually on separate days. The procedure will entail 
you having to fast for a period o f four hours (so that glucose that you consume in your 
diet will not interfere with the FDG-PET scan). Once you are in the Institute of Nuclear 
Medicine you will be given an injection of FDG (chemically similar to glucose, but 
which has been labelled with a radioactive substance) through a cannula (plastic tube) in 
a vein. The radioactivity lasts approximately 90 minutes, therefore you do not have to 
wait for the scan. You will have to lie on a platform that moves you into the scanner. The 
scan itself takes one hour and you will need to lie still with minimum interaction with 
staff, as this interferes with the scan quality. The whole process takes between 2 to 4 
hours. The procedure for the FLT scan is similar to that described above, but you will 
receive an injection of FLT instead of FDG. Most importantly, you will have a cannula 
inserted into an artery and a vein in your arm so that we can take blood (about 50 ml in 
total -  1/6 of the volume of a standard fizzy drinks can) in order to analyse it. Before 
inserting the arterial cannula the blood supply to your hand will be evaluated to assess if 
it is OK for you to take part in the study. We undertake this so that in the highly unlikely
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event that the artery should become damaged or clotted (thrombosed) there would be no 
adverse affects. Local anaesthetic will be used prior to inserting the arterial cannula to 
minimise any pain or discomfort. After removal of the cannula we will press on the artery 
so as to stop it bleeding. This all helps to increase the accuracy o f the scan report we can 
give to the doctors looking after you. It will also help us develop a way o f working out 
the distribution of FLT in the blood so that patients in the future may avoid the blood 
tests. The carmulae will remain in your arm for an hour. If  you proceed to have an 
operation, the surgeon will make a thorough examination and document the findings. A 
tiny fragment of the cancer and surrounding tissue will be taken for examination by one 
o f the doctors involved in the study. Cancers need growth promoting agents as well as a 
blood supply therefore particular attention will be paid to the presence of these factors. 
The main part o f the tissue, which is removed, will be sent for analysis by a pathologist, 
as is the usual practise. A comparison will be made between both types o f PET scan to 
see if  there is in fact any difference in the information gained. Both scan findings will 
then be related to the analysis of the tissue removed.
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CONSENT FORM
STUDY TITLE: A comparison of F-18 fluorothymidine (FLT) PET with routine 
PET in patients with colorectal cancer
PATIENT NAME:
HOSPITAL NUMBER:
WARD/ ADDRESS:
By signing this form I agree that:
1. I have read the patients information sheet and the procedure has been fully 
explained to me.
2. I have had the opportunity to ask questions and I did receive satisfactory answers.
3. I have been given a copy of the information sheet and the consent form to keep.
4. I understand that I am participating in a research study and I understand the risks 
and benefits involved. I freely give my consent to participate in the research study 
outlined in the patient information sheet.
5. I understand that I may withdraw from this research study at any time without 
giving a reason for withdrawing and such a decision would not affect the standard 
of care that I receive in any way.
Signature o f participant................................................................................... Date.......... / ............ / .............
Name of participant (Block Capitals)........................................................................................
Investigator Statement
I have carefully explained to the above named patient the nature o f the research protocol. I hereby certify 
that to the best o f my knowledge the subject signing this form understands the nature, demands, risks and 
benefits involved in participating in this study.
r
Signature o f investigator.................................................. Name o f investigator (Block
Capitals).............................................................
Date................./ ............ / .............
Principal investigator : Prof. P.J. Ell ( tel: 020-7380-9421)
Appendix I 
MIB-1 Immunohistochemistry
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Citrate buffer recipe: 
29.4g sodium citrate 
54mls IM HCL 
10 litres distilled water 
pH to 6.0 with 1M HCL
Appendix J 
Publications arising from Thesis
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Papers
Glucose utilisation and cell proliferation in colorectal cancer
Visvikis D, Francis DL, Costa DC, Mulligan R, Townsend C, Arulampalam
THA, Islam MS, Taylor I, Ell PJ
European Journal Nuclear Medicine 2002 Feb;29(2):280
Potential impact of [^FP’-deoxy-S’-fluorothymidine versus [18F]fluoro-2- 
deoxy-D-glucose in positron emission tomography for colorectal cancer 
D.L. Francis, D. Visvikis, D.C. Costa, T.H.A. Arulampalam, C. Townsend, S.K. 
Luthra, I. Taylor, P,J. Ell
European Journal Nuclear Medicine 2003 Jul;30(7):988-94
In vivo imaging of cellular proliferation in colorectal cancer using Positron 
Emission Tomography
D.L. Francis, A. Freeman, D. Visvikis, D.C. Costa, S.K. Luthra, M. Novelli, I. 
Taylor, P. J. Ell
GUT2003 Nov;52(ll): 1602-6
Comparison of methodologies for the in vivo assessment of 18FLT utilization 
in colorectal cancer
D. Visvikis, D. Francis, R. Mulligan, D.C. Costa, I. Croasdale, S.K. Luthra, I. 
Taylor, P.J. Ell
European Journal Nuclear Medicine 2003 (in press)
Assessment of recurrent colorectal cancer following 5-Fluorouracil 
chemotherapy using both 18FDG and 18FLT PET
D.L. Francis, D. Visvikis, D.C. Costa, I. Croasdale, T. H. Arulampalam, S.K. 
Luthra, I. Taylor, P. J.E11
European Journal Nuclear Medicine 2003 (in press)
FDG-PET for the pre-operative evaluation of colorectal liver metastases 
T.H. Arulampalam, D.L. Francis, D. Visvikis, P.J. Ell, I. Taylor 
European Journal o f  Surgical Oncology 2004 (in press)
Book Chapters
Clinical Molecular Anatomic Imaging
Gustav K. von Schulthess, Lippincott Williams & Wilkins
Chapter 45: PET and PET/CT of Cancers of the Esophagus, Stomach and
Large Intestine.
Daren L Francis, Tan H A Arulampalam, Durval Campos Costa, Peter J Ell.
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Nuclear Medicine in Clinical Diagnosis and Treatment 
Gambhir and Ell, Elsevier 2003 
Chapter 41: Atlas 1: PET and PET/CT.
Buck, G. Gorres, T. Hany, H. Ch. Steinert, K.D.M. Stumpe. G.K. von Schultess,
S. Hughes, D. Francis, D.Costa, P. Ell
Abstracts
Whole Body FDG-PET for Staging Colorectal Liver Metastases 
Francis DL, Arulampalam THA, Costa DC, Loizidou M, Ell PJ, Taylor I.
Br. J. Surg. 2002;89:58
[18F]FDG and [18F]FLT in colorectal carcinoma: preliminary results of a 
comparative study
D. Visvikis, D.L. Francis, D.C. Costa, R  Mulligan, C. Townsend, M.S. Islam, I. 
Taylor.
Nuclear Medicine Communications 2002; 23:386.
Quantitative comparison of 18FDG and 18FLT in colorectal cancer
D. Visvikis, D.L. Francis, D.C. Costa, R  Mulligan, C. Townsend, I.Taylor, P.J. 
Ell.
European Journal o f Nuclear Medicine 2002; 29:S79.
Glucose utilisation (18FDG) versus cellular proliferation (18FLT) using PET 
scanning in patients with colorectal carcinoma
D. Francis, D. Visvikis, D.C. Costa, RS. Mulligan, C. Townsend, S.K. Luthra, I. 
Taylor, P.J. Ell.
European Jouranl o f Surgical Oncology 2002; 28:766.
Evaluating proliferative activity in colorectal cancer using 18F-FLT-PET 
Francis D.L., Visvikis D, Freeman A, Costa DC, Luthra SK, Novelli M, Taylor I, 
Ell PJ.
Nuclear Medicine Communications 2003; 24:458.
Positron Emission Tomography in colorectal cancer: A comparison between 
18FDG and a new tracer 18FLT
DL Francis, D Visvikis, DC Costa, TH Arulampalam, C Townsend, SK Luthra, I 
Taylor, PJ Ell.
British Journal o f Surgery 2003; 90:8.
Quantifying cellular proliferation in colorectal cancer: A comparison 
between Positron Emission Tomography and MIB-1 Immunohistochemistry 
DL Francis, A Freeman, D Visvikis, DC Costa, SK Luthra, M Novelli, I Taylor, 
PJ Ell.
British Journal o f Surgery 2003; 90:78.
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A comparison of 18FDG and 18FLT-PET in quantifying cellular proliferation 
in colorectal cancer
DL Francis, D Visvikis, A Freeman,, DC Costa, SK Luthra, M Novelli, I Taylor, 
PJ Ell
The Journal o f Nuclear Medicine 2003; 44:25
Can Positron Emission Tomography quantify cellular proliferation in 
colorectal cancer? A comparative study using MIB-1 and a new PET tracer 
18FLT.
DL Francis, A Freeman, D Visvikis, DC Costa, SK Luthra, M Novelli, I Taylor 
and PJ Ell.
Colorectal Disease 2003; 5;29
[18F] 3’-deoxy-3-fluorothymidine: A new Positron Emission Tomography 
tracer for imaging colorectal cancer.
DL Francis, D Visvikis, DC Costa, TH Arulampalam,C Townsend, SK Luthra, I 
Taylor and PJ Ell.
Colorectal Disease 2003; 5;76
Moitoring 5-Fluorouracil chemotherapy response in colorectal cancer using 
Positron Emission Tomography
Francis DL, Loizidou M, Visvikis D, De Vos S, Luthra S, Taylor I, Ell PJ 
European Journal o f  Surgical Oncology 2003; 29;789
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